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Human pluripotent stem cell (hPSC)-derived neuronal and glial material 
presents a relatively new opportunity to model human neurophysiology in both 
health, and disease. Validation of regionally-defined hPSC-derived neurones and glia 
cultures thus represents the founding blocks of technology that aims to complement 
existing models. Principally, the relevance of in vitro hPSC-derived material is 
determined by how representative it is of native material, yet at present the 
physiology of these cells remains underexplored. Here, electrophysiology and 
pharmacology are used to functionally assess hPSC-derived excitatory cortical 
neurones (hECNs), motorneurones (MNs) and oligodendrocyte-lineage cells in the 
context of regional-specific properties and maturation. These properties are then 
examined in material derived from hPSCs generated from patients with neurological 
disorders.  
This thesis examines of the properties of GABAARs and strychnine-sensitive glycine 
receptors (GlyRs) in hECNs by assessing their subunit composition, and compares 
these with studies which have made comparable investigations of rodent tissue where 
maturation is associated with a shift in GABAA and GlyR compositions. Using 
pharmacology and RNAseq analysis, GABAAR and GlyRs in hECNs were found to 
possess receptor populations typical of those reported in the immature cortex.  
 hECNs generated from patients harbouring a mutation to the Disrupted-in-
schizophrenia-gene 1 (DISC1), a candidate schizophrenia gene, were then examined. 
Imbalances in the excitation/inhibition balance are suspected in schizophrenia and, in 
this regard, the intrinsic excitability properties alongside expression and composition 
of major neurotransmitter receptors and intracellular chloride concentration were 
assessed. No obvious differences in excitability or functional expression of 
AMPARs, GABAARs or NMDARs were observed between case and control derived 
neurones. Receptor composition and intracellular chloride concentrations were found 
to be predominantly immature-like, however, AMPAR composition and intracellular 
chloride concentration were found to be like that of adult cortical neurones. These 
data are discussed in the context of modelling DISC1-associated pathologies. 
 Thirdly, MNs from hPSCs generated from ALS patients harbouring mutations 
on the C9ORF72 gene were examined. The hypothesis that increased glutamate-
mediated excitoxicity could, in part, be explained by increased expression of Ca
2+
-
permeable AMPARs was examined. The estimated mean single-channel conductance 
of AMPARs was found to be high in MNs derived from ALS patients, reminiscent of 
Ca
2+
-permeable AMPARs and was reversed by gene-editing of the C9ORF72 
mutation.  
 Finally, oligodendrocytes generated from ALS patients harbouring TARDBP 
mutations were examined. Distinctive electrophysiological shifts in 
oligodendrocytes-lineage cell development are reported. A similar AMPAR 
phenotype of elevated Ca
2+
-permeable AMPAR expression was observed in 
oligodendrocytes derived from two patient hPSC lines and was rescued in an 
isogenic, gene-edited line, raising the intriguing possibility of convergence in 
pathophysiologies in the nature of the overlap between cell-type, AMPAR pathology 
and excitotoxicity in ALS disease progression mechanisms. 
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The human brain continuously sends, receives, and processes signals which control 
core aspects of our behaviour – from tasks such as breathing and walking to our 
ability to store and recall memories. Underlying this is a vastly complex network 
of interconnected brain cells with their own properties and behaviours. Human 
brain cells can now be grown in the laboratory from human stem cells – this 
provides a new way to investigate how brain cells function and how they are 
affected by disease. This thesis demonstrates that while this technology has 
limitations, laboratory-grown brain cells can be used to study human development, 
as well as conditions such as motor neurone disease. Initially this thesis confirms 
that these neurones are developing properly and can be used for drug testing on 
human brain tissue. From this, the thesis shows that while studying some 
conditions may require significant developments in the technology itself, highly 
promising results on the mechanisms of motor neurone disease are obtained from 
studying the behaviour of neurones grown from stem cells, taken from patients 
with the condition. This thesis concludes by suggesting that different types of 
mutations that cause motor neurone disease may all share a common mechanism, 
which can be reliably repeated large-scale in human tissue in the laboratory. 
Finally, this thesis shows that genetic engineering of mutant, diseased cells 
corrects the mechanisms which are thought to cause the disease. Thus, this thesis 
describes a single line of evidence as a prototype for advances in genetic 
engineering and drug development using laboratory-grown human brain cells – as 
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 The advent of stem cell technology derived from human sources presents an 
unprecedented opportunity to study human neural development in vitro in both 
health, and disease.  This is highly relevant and useful in that the CNS is responsible 
for cognitive functioning, such as complex language, memory, executive function, 
and motor activity (see Tabar et al. 2014; Livesey et al. 2015; Defelipe. 2011). In 
order to perform these functions, the CNS possesses a highly sophisticated and 
specialised structure. This complexity is manifested anatomically, and 
physiologically by an array of variously interconnected cell types which are 
characterised by differing gene expression, morphology, and functional properties 
(see O’Leary et al. 2007; Stiles et al. 2010; Kiecker et al. 2010; Hamasaki et al. 
2004). As such, any attempts to model either health, or disease must invariably 
reflect this complexity in providing a valid and reliable platform that is 
representative of human development in utero, which is comparable to the body of 
knowledge already obtained from other models of neurodevelopment in health, and 
disease, such as animal models.  
 Critically, there exist a number of highly relevant differences in brain 
development between humans and typical animal models, such as rodents. The 
human brain possesses an enlarged frontal cortex and is gyrencephalic, with many 
deep sulci, gyri, and fissures, and thus has a greater surface area for its volume than 
if it were smooth (Defelipe. 2011). It has been suggested that gyrencephalic features 
and the expansion in the human neocortex are the result of increased cell divisions in 
the outer sub-ventricular zone (OSVZ) during embryonic development, and a 
propensity for transit-amplifying cells to increase the speed of migration from the 
SVZ to the developing cortex (Lui et al. 2011). Additionally, it has been shown that 
white matter structure and cortical projections differ markedly between mouse and 
human (Chesselet et al. 2012), which has strong implications for animal models of 






 Presently, the capacity of human stem-cell derived systems to generate viable, 
functional neurones is well established (Bilican et al. 2014; Livesey et al 2014; 
(Hansen et al. 2011; van den Ameele et al. 2014), and includes experimentation on 
exogenous tissue implantation into host organisms up to, and including, primates 
(Kriks et al. 2011) as an attempted rescue of Parkinson’s disease phenotypes in 
animal models. This technology has, more recently, been pursued in order to 
produce neuronal lineages corresponding to more precise regional specification, or 
cell type, such as cortical excitatory neurones, oligodendrocyte precursors which can 
be later differentiated into mature oligodendrocytes, and cortical motor neurones. 
Typically, these populations are defined by molecular markers as predicted by a 
combination of human, and animal, studies which are used to define an archetype 
against which functional data from the same cells can be tested.  
 This approach provides the foundation for examining pathophysiology in 
native human systems in vitro, in the form of iPSC-derived neuronal tissue taken 
from clinical patients in genetic diseases such as Rett’s syndrome (Farra et al. 2012; 
Andoh-Noda et al. 2015), and Huntingdon’s disease (Kirkeby et al. 2012). The 
pursuit of detailed knowledge of in vitro human systems derived from iPSCs and 
ESCs which allow more precise specification of tissues answers a particular need to 
assure the cellular identity of the tissue explants derived in vitro (see Tabar et al. 
2014), and especially so in disease modelling (see Kriks et al. 2011). This is of great 
relevance when considering both the validity of the in vitro cultures, and the models 
to which they are transplanted in themselves, in how they represent the disease. This 
has had previous consideration in the study of Alzheimer’s disease, where mouse 
and human models have been shown have both strong commonalities and strong 
differences in gene expression patterns (Miller et al. 2009). While this point may 
seem redundant in that it states the obvious, that a mouse is not a human, it invites a 
discussion of precisely what gene expression we ought to expect when engineering 
tissues in vitro, and what a deviation from any norm established in either species 






1.2 Development of the human central nervous system 
 While a vastly complex process, mediated by many factors both genetic and 
environmental, a brief overview of CNS development is necessary in order to 
establish context for any description of in vitro systems which aim to represent 
aspects of this process. 
  Shortly after fertilisation, the developing ball of cells (referred to as the 
blastula) undergoes gastrulation, ultimately yielding 3 layers of cells which are fate-
mapped to a given lineage. Firstly, the endoderm stem cell layer, which gives rise to 
the gut and respiratory system; secondly, the mesoderm layer, which will give rise to 
structures such as the vascular system, muscle, cartilage, and bone; thirdly, the 
ectoderm, which produces both epidermal  (skin, nails, and sweat glands) and neural 
lineages. This subdivision of the ectoderm, the neurectoderm (as opposed to the 
epidermal ectoderm), contains neural progenitor cells (NPCs) from which the CNS 
is derived. From the neurectoderm arises the neural tube, which occurs in humans 
between embryonic day 20 and 27 (see Stiles et al. 2010; Lui et al. 2011). This 
cylindrical structure has a central fluid filled vacuole which is lined with neural 
precursors (NPCs) known as the ventricular zone (VZ). The more caudal regions of 
the VZ give rise to the spinal cord, while the more rostral region becomes the 
telencephalon, and later, the brain, which in totality produces a vast array of cell 
types such as cortical excitatory neurones, interneurons, oligodendrocytes, and 











1.2.1 Cortical development 
 Specification of cortical regions in the developing telencephalon is mediated 
by graded expression of transcription factors, proteins which bind to specific DNA 
sequences and regulate the transcription of DNA to mRNA. Various characteristic 
transcription factors are expressed by progenitor cells in the cortex, including Pax6, 
Gli3, Sp8, Emx2, and Coup-TF1 (O’Leary et al. 2007). Transcription factor 
expression in the developing cortex is predominantly regulated by three major 
telencephalic signalling centres that induce changes in transcription factor 
expression by secreting various chemical messengers: the ventral telencephalon that 
secretes sonic hedgehog (SHH), the anterior neural ridge that secretes fibroblast 
growth factor-8 FGF8, and the cortical hem that secretes WNT and bone 
morphogenetic protein (Marigo et al. 1995; Backman et al. 2005; Hebert et al. 
2003).  Gradients of these chemical messengers define cortical axes in this manner, 
whilst giving rise to regional specification. Subsequently, cortical progenitor cells 
differentiate to neurones and migrate radially out from the telencephalon in a time-









Figure 1.1, Schematic of cortical layers in developing human cortex. Shows subtypes 
of excitatory cortical neurones from upper (Layer I) to lower (Layer VI) cortical layers, and 
associated coritical markers Reelin, TBR1, SATB2, CUX1, CTIP2, and SOX5. Adapted from 
Gemaine et al. 2010. 
 
 
 This process results in cortical layers being formed ‘inside out’ -  the deepest 
cortical layer VI forms first and the upper layer II last, in that layer I, containing 
reelin+ Cajal–Retzius cells, is exempted (Frotscher, 1998). The adult cortex has a 
structure made up of six defined layers (I–VI) of diverse excitatory cortical neuron 
types that can be identified by layer-specific markers, including Reelin (Layer I), 
CUX1 (layer II/III), ROR-β (layer IV), CTIP2 (layer V), SOX5 (layers V and VI) 
and TBR1 (layer VI) (Molyneaux et al. 2007). Additionally, interneurones also 
migrate to the cortical layers, however, they do so via a different migratory 
mechanism. While excitatory cortical neurones typically migrate radially from the 
VZ, interneurons are instead differentiated from NPCs in the ganglionic eminence 
(GE), a temporary structure that exists through embryonic and fetal development in 




a multitude of local guidance cues (Marin and Rubenstein 2001; Huang 
2009;Valiente and Marin 2010).  
1.2.2 Spinal cord development 
 Similar processes of regional specification apply to the spinal cord. Cells are 
initially fated along the anterior–posterior axis by activation of Wingless-type 
MMTV integration site family members (WNTs), and fibroblast growth factors 
(FGFs), respectively. Mesodermal cells surrounding the spinal cord synthesize 
retinoic acid (RA) via the enzyme aldehyde dehydrogenase 1A2 (ALDH1A2). RA 
induces caudal neuronal cell types found in the hindbrain and spinal cord, e.g motor 
neurones, and oligodendrocyte precursors. Retinoic acid signalling decreases 
caudally down the spinal cord, as indicated by both decreased expression of 
ALDH1A2, and increased levels of FGF8, which is highly expressed in more caudal 
regions of the spinal cord. In addition to retinoic acid and FGFs, WNTs are also 
required for the induction of caudal hindbrain and spinal cord identities (Backman et 
al. 2005). Another key molecule is the signalling protein sonic hedgehog (SHH) a 
morphogen which here acts as a ventralising factor (see Marigo et al. 1995; also 
Hebert et al. 2003). Additionally, high SHH concentrations have been shown to 
induce NPC differentiation into ventral spinal lineages, and are critical for MN 
induction (see Qu et al. 2014). In rodents, oligodendrocyte precursors first arise in 
the ventral VZ at approximately E12, though slightly later in development at 
approximately E15, a dorsal VZ source of OPCs also develops. OPCs have been 
shown to migrate into the cortex from both sources, where they are tentatively 
considered equivalent (Richardson et al. 2006). Additionally, the specification of 
oligodendrocyte lineages has also been shown to be initiated by FGFs, SHH, BMP, 








Figure 1.2, Schematic of developing mammalian spinal cord. Illustrates developmental 
stages from pluripotent blastula (1) to maturation (6), and the role of various signalling 
molecules at each stage. The blastula (1) undergoes gastrulation, commencing with the 
archenteron induced by Wnt signalling (2). Subdivision of layers lead to structures such as 
the neural tube (3) regulated by transcription factors such as TGF-β and BMP, among 
others. The neural tube is then caudalised by retinoic acid gradients (4) forming an anterior-
posterior axis to the developing neural tube. Dorsal-ventral axis is then defined by sonic 
hedgehog signalling (5, SHH), resulting in a structure adequate to undergo later, more 















  1.3 Research on CNS patterning and transcription factors inform iPSC                
culture development 
 Previous research into CNS development has subsequently informed the 
generation of increasingly well-specified tissues in vitro. This thesis concerns itself 
with the functional outcomes of the generation of neuronal and oligodendrocytic 
lineages, and as such attempts to generate these various tissues are outlined with 
respect to cell type. 
 
1.3.1 Cortical neurones 
 It has been previously shown that in vitro-derived cortical NPCs (from ESCs 
and iPSCs) spontaneously neuralise and differentiate into neurones (Bilican et al. 
2014; Livesey et al. 2014; Mariani et al. 2012; Shi et al. 2012). Moreover, this 
process can be accelerated by using WNT, and BMP inhibitors, a process known as 
dual-SMAD inhibition (SMA and MAD-related protein inhibition; Chambers et al. 
2009). SMADs represent a family of proteins that mediate cytokine signalling and 
are activated by an endogenous ligand, transforming growth factor-β (TGF-β), 
moreover, isoforms of SMADs also interact with each other in a complex manner. 
Interestingly, differentiation into interneurones can also be induced by SHH, and 
SHH agonists (Germain et al. 2010; Maroof et al. 2013), which is reflective of 
processes in vivo which involve the GE, the developmental source of interneurons in 
the cortex, which also produces SHH.  
 Excitatory cortical neurones produced by the ‘default’ approach (i.e withrawl 
of mitogens post-differentiation) have been shown to be broadly representative of 
their embryonic counterparts by genetic markers, and measures of functional 
maturity as described ion channel subunit expression (Bilican et al.  2014; Livesey et 
al. 2014; Mariani et al. 2012; Shi et al. 2012; James et al. 2014). Here, neurones can 
be differentiated and subsequently maintained for 5 weeks (35 DIV), during which a 
definite neuronal identity is maintained.  
 Additionally, hPSC-derived cortical progenitors typically acquire a caudal 




mouse brains (Espuny-Camacho et al. 2013), and can also be patterned to various 
cortical regions and respond to signalling cues when treated with morphogens 
(Eiraku et al. 2008; Espuny-Camacho et al. 2013; Kadoshima et al. 2013). Cortical 
layer formation is also somewhat reflected in previous study of hECNs, with relative 
expression of markers for each layer varying considerably between different culture 
protocols (see van den Ameele et al. 2014). This suggests that judgements about 
specific sub-populations outside of broadly specified cell type (cortical, excitatory) 
are difficult to make. Transcriptome analyses of in vitro hPSC-derived cultures 
reproduce gene expression profiles in hPSC-derived cortical neurone populations 
that seem equivalent to early native human embryonic cortical development (Stein et 
al. 2014; Pasca et al. 2015).  
 This thesis uses a protocol which generates highly pure (~90%) cortical 
neuronal cultures which can be maintained for 7 weeks in vitro, and display ion 
channel and gene expression patterns broadly typical of immature, embryonic 
cortical neurones, though with several exceptions (AMPARs, see Livesey et al. 


















1.3.2 Lower motor neurones 
 Here, the ‘default’ protocol is supplemented with caudalising factors such as 
RA and SHH activators, yielding caudalised, spinal NPCs (see Chapter 2.2; Figure 
2.1). Previous attempts to generate spinal motor neurones (lower motor neurones; 
LMNs) have met with a degree of success. Neural precursors derived from mouse 
ES cells exposed to retinoic acid and SHH in the presence of knockout serum, which 
is a proprietary, partial purification of albumin from bovine serum, have been 
specified to a motor neurone (MN) fate. This has been found to hold true in human 
ES derived neural precursors (Sances et al. 2016). Human ESCs can be 
differentiated to neural stem cells in the absence of morphogens, treated with RA 
and SHH to induce ventral spinal progenitors, before differentiation into MNs. 
Drawing from these discoveries, most differentiation protocols for human embryonic 
and iPSC-derived LMNs (hPSC-LMNs) share three fundamental steps in induction: 
neuralisation through dual-SMAD inhibition, caudalisation by RA exposure and 
ventralisation through SHH activation by recombinant SHH protein or small-
molecule SHH activators (smSHHs). It has also been shown that WNT signalling 
plays a crucial role, with WNT activators inducing up to 80% Olig2 expression – a 
transcription factor, and marker for MN progenitors (Maury et al. 2015).  
 Currently, protocols which generate highly enriched cultures of MNs from 
iPSCs are available (Selveraj et al. 2016, manuscript in review). Neuronal cultures 
strongly express Islet-1 and choline acetyltransferase, markers of mature MNs (see 
Qu et al. 2014; Sances et al. 2016) at 5 weeks in culture, as well as other neuronal 










1.3.3 OPCs and oligodendrocytes 
 Again, the ‘default’ protocol applied to ESCs/iPSCs is supplemented with 
caudalising factors such as RA, and SHH activators yielding caudalised, spinal 
NPCs (see Chapter 2.2; Figure 2.1) which are subsequently directed to an OPC fate 
by mitogens such as platelet derived growth factor-α, and SHH activator 
purmorphamine. As with MNs, has also been shown that WNT signalling plays a 
crucial role, with WNT activators inducing up to 80% Olig2 expression – a 
transcription factor, and marker for Oligodendrocyte precursors (Maury et al. 2015; 

























1.4 Introduction to ligand-gated ion channels  
 Ligand-gated ion channels (LGICs; also ionotropic receptors), are a group of 
transmembrane ion conducting protein assemblies, positioned at both synaptic, and 
extra-synaptic sites on neuronal membranes which act as gates, opening to allow 








 to pass through the membrane in response to 
the binding of compounds (i.e. ligands) such as neurotransmitters (e.g glutamate).  
To re-iterate, a conformational change in the receptor assembly occurs which allows 
the free movement of ions across the cell membrane. Typically, activation of LGICs 
results in either a membrane depolarization, for an excitatory receptor response, or a 
hyperpolarization, for an inhibitory response, as determined by the ion species 
conducted by the ion channel and the resting membrane potential of the cell in 
question (here, neurones, oligodendrocytes).Typically, LGICs are grouped by amino 
acid sequence similarity, selectivity for certain ligands (e.g GABAA receptors), and 
physiological function – this will be explored in this thesis in the following sections, 

















 1.4.1 Introduction to ionotropic glutamate receptors 
 Glutamate is the principal excitatory neurotransmitter in the adult mammalian 
brain, and activates an array of pre- and post-synaptic receptors of two broad types; 
ionotropic, and metabotropic (see Traynelis et al.  2010). Ionotropic glutamate 
receptors consist of 3 subytpes named for their response to selective ligands; AMPA 
(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, NMDA (N-
methyl D-aspartate) receptors, and kainate (kainic acid) receptors. Altogether, these 
receptors mediate the vast majority of fast excitatory neurotransmission in the adult 




. As a 





ions across the membrane such that the inside of the cell has a potential 
difference of approximately -50 mV to -70 mV relative to the exterior of the cell. 





across the membrane against their electrical and chemical gradients, separating 
charges and thus generating an electrical potential difference. Thus, when an ion 




 is opened, ions flow across the membrane causing 
the potential difference at the membrane to approach 0 mV, as there is now no 
separation of charge, causing neuronal depolarisation, and thus excitation of the 
membrane (for further explanation, see Hille, 2001).   
  Notably in terms of glutamate receptors, NMDA receptors, and certain 
configurations of AMPA receptors are also permeable to Ca
2+
 ions. This has been 
shown to contribute to the roles of these receptors in normal neurodevelopment, 
processes underlying learning and memory, and also in disease states. Metabotropic 
glutamate receptors (mGluRs) do not conduct ions, and instead influence a wide 
array of processes such as synaptic plasticity in the CNS by G-protein signalling 
cascades (see Trzaskowski et al. 2012; Overington et al. 2006) This thesis uses 
electrophysiological and pharmacological methods most amenable to the study of 
AMPA, and NMDA receptors, and as such these will be the focus amongst the 





 1.4.2 AMPA receptor structure and physiological function 
 α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) 
are ligand gated cation channels with a reversal potential of 0mV, which mediate the 
majority of fast excitatory synaptic transmission in the central nervous system (see 
Honore et al. 1982). AMPARs are tetrameric in structure, being composed of four 
subunits, designated GluA1 - GluA4. Most AMPARs are heterotetrameric, 
consisting of symmetric 'dimer of dimers' of GluA2 and either GluA1, GluA3 or 
GluA4 (Traynelis et al. 2010). Dimerisation occurs in the endoplasmic reticulum 
with the interaction of N-terminal domains, which "zips up" the two dimers from the 
ligand-binding domain into the ion pore. AMPARs also play a key role in synaptic 
plasticity, with AMPAR expression being linked to activation of other receptors 
involved in synaptic plasticity such as the NMDAR (Song & Huganir, 2002; Shi et 
al. 1999).  
 The AMPAR's ion selectivity is, in part, governed by the GluA2 subunit. If an 







presence of a GluA2 subunit will almost always render the channel impermeable to 
Ca
2+




(see Kamboj et al. 1995). This is 
determined by post-transcriptional modification by RNA editing of the Q-to-R 
editing site of the GluA2 mRNA. Here, A→I editing alters the uncharged amino 
acid glutamine (Q) to the positively charged arginine (R) in the ion channel pore. 
The positively charged amino acid at this critical point makes it energetically 
unfavourable for Ca
2+
 to enter the cell through the pore, rendering the AMPAR 
impermeable to Ca
2+  












                            
 
Figure 1.3. Schematic representation of AMPA and kainite receptor structure as found 
on the cell surface. Above: Schematic showing AMPA structure as a cross section around 
the central ion pore. Below: Structural representation of the AMPAR. Labels show 
approximate sites of action for commonly used receptor agonists (e.g AMPA), modulators 
(e.g. cyclothiazide), blockers (e.g polyamines, N-acetyl spermine), and antagonists (CNQX).  
Dotted lines indicate cell internal and external as indicated. Adapted from Barr & Burdette. 
(2017) and Traynelis et al. (2010).  
 






 AMPAR subunit composition is highly spatially and temporally regulated. In 
the embryonic cortex, AMPARs are typically GluA2 subunit-lacking, rendering 
them permeable to Ca
2+
. In immature rodent, and human excitatory cortical neurons, 
GluA1/GluA4- containing AMPARs are predominantly expressed, whereas mature 
neurons predominantly express GluA1 and GluA2 subunits (Talos et al. 2006a, 
2006b; Orlandi et al. 2011, see Traynelis et al. 2012). In normal development, the 
GluA2 subunit is predominantly RNA-edited (Q → R), with an edited GluA2 
subunit being strongly suggestive of a postnatal phenotype. Inclusion of at least one 
(Q → R)- edited GluA2 subunit into the AMPAR tetramer confers specific 
biophysical properties such as lower single-channel conductance, insensitivity to 
channel-blocking spermines and Ca
2+
-impermeability (Swanson et al. 1997; 
Traynelis et al.2010). Permeability to Ca
2+
- has been shown to mediate processes 
relating to neuronal excitotoxicity, and, interestingly may relate to possible calcium 
dysregulation in schizophrenia, and negatively impact the development of excitatory 
networks (Berridge. 2012). 
 AMPAR subunits differ significantly at their C-terminal in their amino acid 
sequences. This region enables subunit interactions with many scaffolding proteins. 
While AMPARs all contain scaffolding protein binding domains, which PDZ 
domain they interact with is dependent on subunit composition. Interestingly, 
AMPARs do not directly bind to PSD-95 as they do not share common interaction 
domains. Both, however, interact with PSD-95 via stargazin, a member of the TARP 
family of AMPAR auxiliary subunits which regulate cell-surface AMPAR 
expression. Additionally, AMPAR phosphorylation can regulate channel 
conductance, and localisation. GluA1 has four known phosphorylation sites which 
are phosphorylated by protein kinase C, and from this has been shown to be 
necessary for long-term potentiation (LTP) by affecting delivery of the receptor 
complex to the synapse.  
Developmental and activity-regulated changes in AMPAR expression (and 
composition) are thus instrumental in excitatory synapse formation, stabilization, 
and synaptic plasticity, and thus the development of functional networks. 




and synaptic expression are intimately linked to psychiatric and neurological 
conditions, as well as to cognitive symptoms in neurodegenerative disorders.  
 
1.4.3 AMPA receptor trafficking, expression, and links to disease 
AMPARs are constructed as tetrameric complexes in the endoplasmic 
reticulum (ER), a subcellular structure responsible for protein synthesis, whereupon 
they are trafficked to the golgi apparatus and secreted in vesicles to be trafficked 
along the actin cytoskeleton as mediated by myosin, to synaptic and extrasynaptic 
sites (see Greger et al. 2002; Park et al. 2004; Wang et al. 2008). Dimerization of 
two subunits initially depends on interactions between N-terminal domains, followed 
by the second dimerization step mediated by associations at the ligand-binding and 
membrane domains. Typically, heterodimeric assemblies which preferentially 
incorporate GluA2 are highly typical in adulthood. However, there is considerable 
flexibility in the interface that allows the formation of GluA2-lacking AMPARs in 
both normal development, and also disease states. 
Individual AMPAR subunits have either long or short intracellular C-terminal 
domains that bind to distinct sets of interacting proteins. The main splice isoforms of 
GluA1 and GluA4 have long tails, and GluA2 and GluA3 have short tails. Generally, 
the long-tailed GluA1 and GluA4 subunits dictate the trafficking properties of 
AMPARs when assembled in heteromers with short-tailed subunits and, as GluA4 is 
mainly expressed during early development, GluA1 is by far the most predominant 
long-tailed subunit in mature neurons.  
GluA1 is not edited and, in the absence of GluA2, GluA1 assembles into CP‑
AMPARs that can be rapidly exported from the ER and trafficked to the membrane 
(Greger et al 2002). By contrast, edited GluA2 which accounts for more than 99% of 
all GluA2 in mature neurones  is mostly unassembled and retained within the ER. 
Thus, in studies primarily using exogenous expression of GluA1 or GluA2, Q/R 
editing reduces the formation of GluA2 homotetramers and only allows GluA2 to 
exit from the ER when it is assembled with GluA1. AMPARs that contain both 
GluA1 and GluA2 follow GluA1 trafficking rules and override the ER retention of 




impermeable, Q/R editing also promotes interaction with GluA1 to form 
heterotetrameric channels. This regulated ER exit limits the types and numbers of 
AMPARs that are available for synapses and, by disfavouring GluA2 homotetramer 
formation, maintainsa stable ER pool of edited GluA2, which is then expressed at 
the membrane later in development in the form of GluA2‑containing heteromeric 
AMPARs. 
The TARP family, proteins considered AMPAR auxiliary subunits, also 
influence AMPAR assemblyand trafficking. TARPs act as chaperones that prevent 
the ER exit of incorrectly folded AMPAR proteins. Additionally, TARPs such as 
stargazin (Chen et al. 2000) are involved with ER export of correctly assembled 
receptor complexes. Interestingly, Ca
2+
-permeable AMPARs (CI-AMPARs) and 
Ca
2+
-impermeable AMPARs (CI‑AMPARs) may be differentially trafficked during 
synaptic plasticity. Synaptic retention of AMPARs also likely involves TARPs. 
Owing to incompatible PDZ-binding domains, AMPARs do not directly bind to 
PSD95. Instead, TARPs bind to MAGUKs to stabilize the AMPAR–TARP complex 
at synapses. Additionally, during LTP induction, CaMKII phosphorylates stargazin 
and increases its binding to PSD95. 
 Subunit-dependent and subunitindependentmodes of AMPAR trafficking are 
notnecessarily mutually exclusive. Currently, it is thought that receptors diffuse 
laterally at the membrane, and are captured at synapses during LTP. The 
extrasynaptic receptors themselves are replenished by newly assembled receptors. 
Interestingly, it takes longer for RNA-edited GluA2to actually incorporate into 
AMPARs than other AMPAR subunits (Greger et al. 2002).  
 The faster ER exit of unedited GluA2 facilitates faster forward-trafficking and 
membrane expression of CP‑AMPARs during synapse formation early in 
mammalian development. Later, CNS maturation is associated with RNA editing of 
GluA2, which hinders homodimerization and thus slows ER exit, which then 
increases incorporation of GluA2 into AMPAR heteromers. This is consistent with 
the switch from CP‑AMPARs to CI‑AMPARs during brain development. 
Interestingly,it has recently been shown that GluA2 forward trafficking is also 




interaction with protein interacting with C kinase 1 (PICK1) to facilitate ER exit, 
which may represent a form of synaptically-directed mechanism controlling 
AMPAR trafficking in neurones. 
AMPARs are also suspected to play a role in the neurodegeneration and 
disease progression seen  in amyotrophic lateral sclerosis (ALS). Evidence suggests 
that disease progression in ALS may be caused by glutamate-mediated excitotoxicity 
caused by aberrant expression of CP-AMPARs which takes effect over time as a 
progressive physiological stress (Rothstein & Cleveland, 2001.). Previous work has 
highlighted an intrinsic vulnerability of ALS MNs to glutamate excitotoxicity that is 
mediated by Ca
2+
-permeable AMPARs (Donnelly et al. 2013; Rothstein et al. 1995). 
However, the literature has yet to directly link specific AMPAR structural properties 
that generate Ca
2+
-permeability in ALS MNs to specific mechanisms or genetic 
abnormalities, though several specific genetic mutations are strongly linked to ALS 
(Duncan, 2009; Donnelly et al. 2013; Rothstein et al. 1995; see Cleveland and 
Rothstein. 2001). Crucially, the developmentally regulated AMPAR subunit 
compostion change is seen in stem-cell derived cortical neurones (Livesey et al. 
2014), suggesting the potential for iPSC-derived systems to generate neurones from 
patients harbouring mutations associated with ALS. This, in turn, suggests the 
potential for studying normal AMPAR development and also in exploring potential 
mechanisms of disease progression. Thus, by studying the behaviour of the 
AMPARs expressed be iPSC-MNs with regard to Ca
2+ 
permeability, it is possible 













1.4.4 Pharmacological agents which taget the AMPAR 
There exist an array of compounds which behave variously as agonists, antagonists, 
and modulators at AMPARs. Worthy of note is the key determininant of an AMPA 
receptor – selective activation by AMPA, and conversely recetor inactivation by 
CNQX (see list of abbreviations for full compound names).  
 





Honore et al. (1982); Banke et al. 
(1997); Nakanshi et al. (1990); see 





Nakanshi et al. (1990); see Traynelis 
et al. (2010); Zhang et al. (2006). 
   
NASPM Channel blocker  
(voltage 
dependent) 
Koike et al. (1997); Noh et al. (2005). 
Table 1.1: Pharmacological agents used in this thesis which affect the AMPA 
receptor. This table describes the typical behaviour of agonists AMPA, CNQX, and 
NASPM. Note that typically subunit-selective drugs (indicated by a * prefix) is a brief 
description of the behaviour of a compound in terms of a broad electrophysiological 
response. Greater detail is supplied in later chapters where the compounds are used, and in 









 1.4.5 Introduction to NMDA receptors 
 The N-methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate 
receptor that is selectively activated by N-methyl-D-aspartate (NMDA) in the 
presence of a co-agonist, glycine. The NMDAR has a tetrameric structure potentially 
composed of subunits GluN1, GluN2A-D, and GluN3A-B (Traynelis et al. 2010). In 
the forebrain, most NMDARs are tetrameric formation of two GluN1 subunits and 
two GluN2 subunits, with the crystal structure of the NMDAR showing that GluN1 
and GluN2 subunits are arranged alternately (i.e. 1, 2, 1, 2) in a circular fashion 
around a central ion pore (Lee et al. 2014). GluN1 houses the co-agonist glycine/d-
serine binding site, and GluN2 contains the glutamate binding site, both of which are 
required to have their respective sites occupied by their agonists in order to activate 




, and like the GluA2-lacking 
AMPAR, are also permeable to Ca
2+
. NMDAR-mediated responses are typically 
voltage dependent, in that NMDARs are blocked by extracellular Mg
2+
 at typical 
neuronal resting membrane potentials (approx. -60 mV to -70 mV). This is due to 
NMDARs being impermeable to Mg
2+
, which is drawn to the NMDAR pore by 
negative resting membrane potentials where it blocks the pore, occluding the vast 
majority of ion flow including Ca
2+
. When the membrane local to the NMDAR is 
depolarised, the Mg
2+
 blockade of the NMDAR ceases. Under these circumstances, 






 to flow down their respective 
electrochemical gradients as is energetically favourable.  
 From this, at the synapse the NMDAR can be thought of as a molecular 
coincidence detector in line with the Hebbian principle of synchronised activity 
between a pre- and post-synaptic neurone strengthening the existing connection. 
When a presynaptic neurone depolarises and releases glutamate, the post-synaptic 
neurone is excited, and depolarises in response (typically via AMPARs). Under 
repeated, high-frequency firing, the post-synaptic membrane becomes sufficiently 
depolarised so as to release the Mg
2+
 blockade, causing a post-synaptic rise in 
intracellular Ca
2+
. Many phenomena associated with the NMDAR are thought to 
form the basis for higher cognitive processes predicated on synaptic plasticity such 




NMDARs involvement and learning and memory is fairly well understood. In 
rodents NMDARs are known to play a prominent role in spatial learning, fear 
conditioning, place preference; behavioural tasks which are localised to the frontal 





















                       
 
Figure 1.4. Schematic representation of NMDAR structure as expressed at the cell 
membrane. Above: Schematic showing NMDAR structure as a cross section around the 
central ion pore. Below: Structural representation of the NMDAR. Labels show approximate 
sites of action, and subunit selectivity (determined by presence of subunit noted e.g. 
ifenprodil is a GluN2B-selective inhibitor), for commonly used receptor modulators, blockers, 








 NMDAR subunit expression differs as a function of brain region and 
developmental age [Monyer et al. 1994; Watanabe et al. 1992; see Wyllie et al. 
2013 Sans et al. 2000], and may determine subcellular localization, e.g., in adults, 
NR2A-containing receptors are predominantly expressed at synapses while 
extrasynaptic receptors are predominantly NR2B-containing .Additionally, it has 
been shown that multiple types of NR2 subunit in each complex exist (tri-
heteromeric NR1/NR2X/NR2Y) Further to this, different NMDAR isoforms can be 
expressed at different synapses within the same neuron. 
 NMDAR subunit composition in the forebrain changes from a predominant 
GluN1/GluN2B population in immature neurones to a mixed 
GluN1/GluN2A/GluN2B population  in the second week post-natally (Monyer et al. 
1994; Watanabe et al. 1992; see Wyllie et al. 2013). The noncompetitive negative 
allosteric modulator ifenprodil (Williams, 1993) is a prime example of a wide range 
of compounds (Mony et al. 2009) that display a selectivity for GluN2B-containing 
NMDARs of around 100-fold over other diheteromeric NMDAR assemblies, 
binding at the interface of GluN1 and GluN2B subunit amino-terminal domains 
(Karakas et al. 2011; Williams, 1993; see Traynelis et al. 2010).  
 
1.4.6 NMDA receptor trafficking, expression, and links to disease  
  
 Sequences which regulate trafficking of NMDARs to, and from, the cell 
membrane are found in the C-terminal region of NR1 subunits (e.g. RXR motif. 
PKC phosphorylation sites). Additionally, the HLFY motif on the C terminal of the 
NR2 subunit allows ER exit of NR2-containing NMDAR isoforms. Upon exiting the 
ER, NMDARs are then trafficked by microtubule proteins to the golgi apparatus, 
where they are packaged into mobile vesicles for transport to target sites. In 
immature cortical neurons, prior to synapse formation, NMDARs travel along 
dendrites and go through cycles of exocytosis to (dependent on SNARE protein 
SNAP-23) and endocytosis from dendrite surfaces.  Export from the endoplasmic 
reticulum (ER) and synaptic delivery of NMDARs is also regulated by neuronal 
activity. Retention of GluN2B at synapses requires binding of the C terminus to 




domaincontaining scaffold proteins). Several other kinases, including cyclin-
dependent kinase 5 (CDK5), protein kinase A (PKA), protein kinase C (PKC) and 
SRC tyrosine kinases phosphorylate specific sites of GluN2 subunits, which may 
impact NMDAR assembly and trafficking. GluN2B–CaMKII interaction has major 
implications for synaptic plasticity. This interaction is also critical for proper 
synapse maturation and regulation of AMPAR content during brain development. 
The RAS-guanine-nucleotide-releasin factor 1 (RASGRF1 (REF. 78)) and the 
PSD95–neuronal nitric oxide synthase complex64 are other preferential binding 
partners of GluN2B’s CTD. Their physical association with GluN2B couples 
NMDAR activation to the extracellular signalregulated kinase (ERK; also known as 
MAPK) pathway, and to cyclic AMP-responsive element-binding protein (CREB)-
mediated signalling pathways. 
 Additionally, neuronal activity affects NMDAR synaptic targeting, 
incorporation, and retrieval, of receptors into the endosome–lysosome pathway for 
degradation, and lateral diffusion between synaptic and extrasynaptic sites. It has 
been shown that blocking neuronal activity promotes alternative RNA-splicing of 
the NR1 subunit and increases the rate of forward trafficking of NMDARs to the 
membrane. Conversely, chronic neural stimulation results in subunit-specific 
NMDAR internalization (as well as degradation) through the ubiquitin–proteasome 
system. Further to this, activity-dependent insertion and retrieval of NMDARs 
mediate some forms of LTP and LTD. Thus, they can regulate metaplasticity at 
central synapses, which is interesting in light of this thesis in that studies have 
implicated dysregulation of NMDAR trafficking in several neuropsychiatric 
disorders such as schizophrenia and Alzheimer's disease.  
 There is also a wide array of physiological, behavioural, and clinical literature 
concerning the effects of altered NMDA receptor function in humans, in the form of 
pharmacological blockade of NMDARs, and of extant NMDAR mutations found in 
humans which are associated with clinical pathology. Blockade of the NMDAR in 
humans can result in seizures, and often produces symptoms which approximate 
psychosis, including impaired cognitive ability, memory, and executive function, as 
well as hallucinations, and delusions. It is also known that various rare point 




antagonist ketamine is known to induce both the positive and negative symptoms of 
schizophrenia in humans (Krystal et al. 1994) while genetically reducing NMDAR 
expression in mice induces behaviours reminiscent of schizophrenia (Mohn et al. 
1999).  
 Indeed, previous reports implicate the NMDA receptor (NMDAR) in 
schizophrenia, with NMDAR antagonists producing psychotic-like symptoms and 
NMDAR positive modulators ameliorating this to some degree (Coyle et al. 2012). 
NMDARs has been shown to vary post-mortem in the dorsolateral prefrontal cortex 
in humans with schizophrenia, with an unknown but suggested influence on 
NMDAR subunit stoichiometry (Weickert et al. 2013). NMDAR-mediated 
pathophysiology is also implicated in early developmental processes in 
Schizophrenia (see du Bois & Huang, 2007). The aetiology of schizophrenia is 
highly complex yet nevertheless, there is an overabundance of evidence which 
suggests a strong NMDAR hypofunction component. Currently, a great deal of 
research is aimed at treating NMDAR hypofunction by pharmacologically 
enhancing NMDA function via the glycine binding site (Chang et al. 2014). 
Importantly, NMDAR subunit composition in the forebrain changes from a 
predominant GluN1/GluN2B population in immature neurones to a mixed 
GluN1/GluN2A/GluN2B population in adults (Monyer et al. 1994; Watanabe et al. 















1.4.7 Pharmacological agents which taget the NMDAR 
Agent Effect at AMPAR Reference(s) 
NMDA Agonist 
 
See: Wyllie et al. (2013); 
McKay et al. (2013); Chen et 
al. (2008); Davies & Watkins 
(1982). 
AP5 Antagonist (competetive) 
 
See: Wyllie et al. (2013); 
McKay et al. (2013): Davies & 
Watkins (1982); Evans et al. 
(1982). 
   
*Ifenprodil Channel blocker  
 
See: Wyllie et al. (2013); 
Williams (1993); McKay et al. 
(2013).  
Table 1.2: Pharmacological agents used in this thesis which affect the NMDA 
receptor. This table describes the typical behaviour of agonists NMDA, AP5, and ifenprofil. 
Note that typically subunit-selective drugs (indicated by a * prefix) is a brief description of the 
behaviour of a compound in terms of a broad electrophysiological response. Greater detail 

















1.4.8 Introduction to GABA receptors 
 GABA (γ-amino butryate) receptors are a class of receptors found abundantly 
in the CNS, which principally bind GABA as an agonist, and are subdivided into 
two broad types, the ionotropic GABAA and GABAC receptors, and the metabotropic 
GABABR. Though both types of receptors are known to be heavily expressed in the 
developing cortex of rodents this thesis is concerned with ion channel physiology, 
and as such will focus on the GABAA receptor, as GABAC receptor expression is 
predominantly limited to the retina.  
 
A                               B 
 
Figure 1.5. Schematic representation of GABAAR structure as found on the cell 
surface. A: Schematic representation of GABAAR pentameric structure across the plasma 
membrane. Also shows GABA (α-β) and benzodiazepine (BZ, α-γ) binding sites as a 
product of the respective subunits. B: Labels show potential variability of subunits with the 
subunit stoichiometry typically observed for the GABAAR, with two α-subunits, two β-
subunits, and a fifth additional subunit (typically γ though many others exist) around a 









 The GABAA receptors are members of the Cys loop ligand-gated ion channel 
superfamily which also includes the nicotinic acetylcholine receptors, the glycine 
receptors, and the ionotropic 5-HT3 receptors. GABAARs are ligand-gated anion 
channels that are assembled in a pentameric structure from 21 potential subunits (α1-
6, β1-4, γ1-3, δ, θ, ρ1-3, ε, and π). GABAARs are the principal mediators of fast 
inhibitory neurotransmission in the adult brain, and are important therapeutic targets 
in epilepsy, and anxiety disorder treatments, as well as being directly implicated in 
sedation, and anaesthesia (Reynolds et al. 2003). Subunit composition of GABAAR 
confers characteristic pharmacological properties to the GABAAR (Karim et al. 
2013, Mortensen et al. 2011), and is tightly regulated across time and region (Laurie 
et al. 1992, Fritschy et al. 2005). Across development, GABAARs are highly 
expressed on cortical neurones. During embryonic development the predominant 
isoform of GABAARs expressed on cortical neurones is that of α2/3β2/3γ2, whereas 
postnatally, the most commonly expressed isoform is α1β2/3γ2.  
 GABAARs have been shown to be instrumental in normal neuronal 
development, leading to the description of GABA as a ‘pioneer’ neurotransmitter 
(Ben-Ari et al. 2007). In embryonic development across a wide array of mammalian 
species, GABA-ergic transmission precedes glutamatergic transmission in early 
neuronal networks due to interneurone maturation which occurs at approximately 
E18 in rodents (Ben-Ari et al. 2004; Ben-Ari et al. 2007).  
 Interestingly, the initial activity of GABAARs is depolarising, or shunting in 
nature, which later in development (postnatal day 5-7 in rodents) becomes excitatory 
(Ben-Ari et al. 2004). Cortical excitatory neurones exhibit a characteristic decrease 
in intracellular Cl- across development (see Kaila, et al. 2014). This shift in the 
action of GABA across development has also been confirmed in hECNs using an 
identical protocol to that used to produce hECNs used in this thesis. Intracellular Cl- 
activity (a measure dependent on intracellular [Cl-]) in hECNs falls from around 25 
mM to <7 mM in hECNs (Livesey et al. 2014). This suggests a reliable platform for 
modelling neurodevelopmental conditions associated with impairments in Cl- co-
transporter expression such as Rett syndrome (Tang et al. 2015; Chao et al. 2016), 




1.4.9 GABAAreceptor trafficking, expression, and links to disease  
Like AMPARs, NMDARs, and GlyRs, GABAARs are assembled from their 
component subunits in the endoplasmic reticulum (ER), whereupon they are 
trafficked to the golgi apparatus and secreted in vesicles to be trafficked along 
microtubules and the actin cytoskeleton to target sites. As with other receptors 
previously mentioned, this process plays a critical role in determining the diversity 
of receptor isoforms that are expressed on the membrane. In the case of GABAARs 
exit from the ER is dependent upon proteins reaching “conformation maturity”, with  
misfolded proteins being transferred for degradation in the proteasome. Many 
different subunit combinations are theoretically possible, however it has been shown 
that a limited number of these combinations actually leave the ER and are 
subsequently trafficked to the membrane. Most GABAARs expressed on the surface 
of neurons are composed of 2α, 2β, and 1γ subunit (the γ subunit can be replaced by 
δ, ε or π depending on the neuron type and subcellular localization of the receptor), 
while most homomeric subunits, and αγ and βγ heteromers, are retained in the ER 
and degraded. This is mediated by mechanisms that involve classical ER-resident 
chaperones, such as heavy chain binding protein and calnexin, which facilitate the 
transport of selected subunit compositions. Exactly how this is achieved is not 
known, though it is thought that preferential subunit assembly in the ER occurs.  
Studies on GABAAR subunit-deficient mice demonstrate preferential 
assembly of subunits to form select GABAAR isoforms in vivo. A loss of the δ 
subunit from cerebellar granule cells is seen in α6 knock-out mice. Similarly, there is 
a decrease in α4 subunit expression levels in the anterior cortex of δ subunit-
deficient mice, whereas the levels of α1 subunits remain unchanged, showing that 
the δ subunit preferentially assembles with α4 and α6 subunits. Addiotionally, γ2 
subunit expression also increases, perhaps as a compensatory mechanism, in δ 
subunit-deficient mice, additionally suggesting that γ2 willingly associates with the 
α4 subunit in the absence of the δ subunit. These findings overall suggest that 




ER-associated degradation (ERAD) involves the process protein ubiquitination and 
degradation via the ubiquitin-proteasome system (UPS). GABAAR subunits are 
ubiquitinated in an activity-dependent manner. Long-term inhibition of neuronal 
activity can increase levels of GABAAR ubiquitination within the ER, resulting in 
decreased levels of expression at the plasma membrane, while increasing neuronal 
activity typically results in a decrease in GABAAR ubiquitination and thus an 
increase in cell surface expression. Additionally GABA receptor-associated protein 
(GABARAP) interacts with GABAARs containing γ subunits and binds to 
microtubules as well as to N-ethylmaleimide-sensitive factor (NSF), which is 
implicated in vesicular fusion events.  Another factor, GODZ is enriched in the 
trans-Golgi network, causing accumulation of γ2-containing GABAARs at synapses. 
GODZ presumably acts to control GABAAR trafficking in the secretory pathway and 
the delivery of these receptors to the plasma membrane. Additionally, GABAAR-
interacting factor 1 (GRIF-1) interacts with the β2 subunit of GABAARs. It is a 
member of the TRAK family of coiled-coil domain proteins that have been 
implicated in the trafficking of intracellular vesicles by interacting with kinesin, a 
protein that is implicated in protein trafficking along neuronal processes.  
GABAARs are a key pharmacological target for the treatment of many 
illnesses such as epilepsy, stiff person syndrome, anxiety disorders, and 
schizophrenia. In the case of the latter, one candidate gene that is amenable to study 
in iPSC-derived neuronal material is the DISC1 (1;11)(q42;q14.3) mutation, a 
mutation in the DISC1 gene that is associated with psychotic disorders such as 
schizophrenia and bipolar disorder, as well as recurrent major depression. It is 
suspected that that DISC1 is involved in GABAergic neurotransmission by altering 
microtubule motor protein kinesin 1-mediated GABAAR trafficking in the cortex 
(Twelvetree et al. 2010; Yuen et al. 2012). Interestingly, knockdown of DISC1 
results in a decrease in whole-cell GABAAR expression, as well as at the synapse, 
(Wei et al. 2015). As the DISC1 (1;11)(q42;q14.3) mutation has been associated 
with a lack of DISC1 protein product, it is thus highly possible that GABAAR 
expression in hECNs harbouring the DISC1 (1;11)(q42;q14.3) may be affected, and 





1.4.10 Pharmacological agents which taget the GABAAR 
Activity-dependent GABA, muscimol, bicuculline, picrotoxin, diazepam, gaboxadol, 
Zn
2+
,  propofol, etomidate, salycylidine salycylhydrazide, zolpidem    





See: Karim et al. (2013); (Mortensen et al. 2011). 
Muscimol Agonist 
 
See: Karim et al. (2013); (Mortensen et al. 2011). 
Bicuculline Antagonist  
(competetive) 
Von Blankenfeld & Kettenmann, 
(1991); Avoli (1992); Krishek et al. (1996). 
Picrotoxin Antagonist  
(channel 
blocker) 
Newland & Cull-Candy (1992); Ten Bruggengate 
& Engberg (1971); Krishek et al. (1996). 
   
*Diazepam Potentiator See: Riss et al. (2008); Hunt & Clements-Jewry 
(1981); Li et al. (2013). 
*Gaboxadol Agonist Storustovu & Ebert  (2006) 
Propofol  Hill-Venning et al. (1997); Ruesch et al. (2012). 
*Etomidate Potentiator Hill-Venning et al. (1997). 
*SCS Inhibitor Thompson et al. (2004). 
Zn
2+
 Inhibitor Draguhn et al. (1990). 
*Zolpidem Potentiator Sanna et al. (2002). 
*Furosemide Inhibitor Knoflach et al. (1996); Wafford et al. (1996). 
Table 1.3: Pharmacological agents used in this thesis which affect the GABAA 
receptor. This table describes the typical behaviour of various agonists, antagonists, and 
modulators. Note that typically subunit-selective drugs (indicated by a * prefix) is a brief 
description of the behaviour of a compound in terms of a broad electrophysiological 
response. Greater detail is supplied in later chapters where the compounds are used, and in 





1.4.11 Introduction to glycine receptors 
 The glycine receptor (GlyR) is a member of the pentameric Cys-loop ion 
channel receptor family, selectively activated by glycine and d-serine. These 
receptors mediate inhibitory neurotransmission in the spinal cord, brainstem and 
retina in mammalian species as a postsynaptic receptor, though they are also found 
presynaptically, where they modulate neurotransmitter release. GlyRs are 
pentameric ligand gated ion channels that are highly permeable to Cl
-
 ions, and are 
formed from a total of five subunits (α1–α4, β).  
 Subunit expression in the CNS also typically changes during development, 
with embryonic periods being defined by strong homomeric α2 GlyR expression, 
which undergoes a transient postnatal shift to heteromeric α2β before becoming a 
mix of mainly α1β heteromers and smaller contributions of α1, α3, and α4 homomers 
in the cortex. While the precise function of different subunits remains unclear, β-
subunit associates with gephyrin, and is classically known for mediating inhibitory 
synaptic transmission between interneurons and motor neurons in reflex circuits of 
the spinal cord. Even less is known about the general function of GlyRs in the 
human nervous system beyond their roles in adult neuronal inhibition, and by virtue 
of the 
 Early in development, GlyR predominantly have an α2-homomeric 
configuration, with expression being predominantly in the spinal cord, though also 
in cortical areas. Postnatally, a switch occurs within the first 21 days which includes 
the β-subunit into the receptor complex, and coincides with the expression of α1- and 
α3-subunits at low levels in the brain, and again with typically higher levels in the 
spinal cord.  Interestingly, α2 mRNA has been detected in cortical layer VI in adult 
rats, as well as the β-subunit (Malosio et al. 1991).  This is also reflected at the 
functional level by patch clamp data showing that Cajal-Retzius cells, a Layer I 
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Figure 1.6. Schematic representation of GlyR crystal structure as expressed at the 
membrane. A: Labels show approximate sites of action for competitive antagonist 
strychnine. B: Crystal structure of α3 homomeric GlyR, with ion pore indicated by Cl
-
 label. 
Adapted from Huang et al. (2015) and Lynch (2004). 
 
 Immunocytochemical and electrophysiological evidence also implicates α3β 
GlyRs as critical mediators of glycinergic neurotransmission in nociceptive sensory 
neuronal circuits found in the spinal cord dorsal horn. At present, it is yet to be 
determined why multiple GlyR synaptic subtypes are differentially distributed in 
such a wide variety of tissues with specific expression patterns. The development of 
pharmacological agents that can discriminate strongly between GlyR isoforms is 
very much crucial to the advancement of this aspect of developmental study of 
GlyRs. A critical developmental role for GlyRs is also known, in the migration of 
interneurons in the developing cortex. Additionally, the α1β GlyR is thought to be a 
principal mediator of both spinal pain reflexes, and neuropathic pain. As such, 
studying GlyR expression and subunit composition in ESCs/iPSCs is highly useful, 




normal cortical neuronal development by implantation of exogenous tissues 
derived from ESCs/iPSCs. 
 Assembly of the GlyR complex is perdormed in the ER, whence they are 
trafficked to the golgi apparatus and secreted in vesicles to be trafficked along 
microtubules and the actin cytoskeleton to target sites. Most of the knowledge about 
GlyR signal processing comes from in vitro mutagenesis studies on structure-
function relationships. Recently the structure of α3 and α1 were solved (Du et al. 
2015; Huang et al. 2015). These structures provided deeper insights into the 
mechanisms of signal processing and gating. In GlyRs, the TM3–4 loops interact 
with the scaffold protein gephyrin important for synaptic anchoring or signal 
transduction processes. In addition, the TM3–4 loop is modified by posttranslational 
modifications and binds allosteric modulators that in turn influence functional ion 
channel properties (Ruiz-Gómez et al. 1991; Kirsch & Betz. 1995; Yevenes et al. 
2008; Yevenes & Zeilhofer. 2011).  
 Subdomains of the GlyR TM3–4 loop have been demonstrated to be important 
for receptor trafficking to the cellular membrane and the nucleus (Sadtler et al. 2003; 
Melzer et al. 2010). Although different forms of plasticity at glycinergic synapses 
have been reported, the underlying mechanisms are unclear. For example, increases 
in postsynaptic Ca2+ concentration after high-frequency presynaptic activity are 
thought to affect the rates of insertion and retrieval of GlyRs into and from the 
plasma membrane. This allows modulation of the strength of glycinergic inhibition 
(overview in Legendre 2001). The number of GlyRs at synaptic sites is regulated by 
factors that control exocytotic receptor insertion into the postsynaptic membrane, 
anchoring of the receptors at synaptic sites by binding to the scaffolding protein 
gephyrin, and removal of the GlyR by endocytosis and subsequent proteolysis 








1.4.12 Pharmacological agents which taget the GlyR 
Agent Effect at GlyR Reference(s) 
Glycine Agonist Lynch  (2009); Lynch  (2004); De 
Sant-Jan et al. (2001); Vandenburg et 
al. (1992a) 
Strychnine Antagonist (competetive) Ivic et al. (2003); Rajendra et al. 
(1991). Vandenburg et al. (1992b) 
Picrotoxin Antagonist (channel blocker) Pribilla et al. (1992); Wang et al. 
(2006). 
Table 1.4: Pharmacological agents used in this thesis which affect the glycine 
receptor (GlyR). This table describes the typical behaviour of agonists AMPA, CNQX, and 
NASPM. Note that typically subunit-selective drugs (indicated by a * prefix) is a brief 
description of the behaviour of a compound in terms of a broad electrophysiological 
response. Greater detail is supplied in later chapters where the compounds are used, and in 





















1.4.13 Introduction to Na+-K+-Cl- co-transporters and Cl- channels 
 Cortical excitatory neurones show a decrease in intracellular Cl
-
 across 
development, a process which is critical to normal development and maturation (see 
Kaila, et al. 2014; Ben-Ari et al. 2004). This is mediated by Cl
-
















 gradients across the cell membrane to drive Cl
-
 ions 
into the cell (NKCC1), or out of the cell (KCC2). In normal development, NKCC1 is 
the most strongly expressed Cl
-
 transporter in fetal cortical neurones, however, as 
postnatal development occurs, an isoform of KCC2 (KCC2b, Uvarov et al. 2006, 
Blaesse et al. 2009) Cl
-
 transporter comes to dominate. Thus there is a resultant 
hallmark developmental profile for neuronal tissue; when NKCC1 is dominant in 
early development, intracellular [Cl
-
] is relatively high (approximately 25 mM), with 
the Cl
-
 reversal potential tending to be less negative than the neurones R.M.P. Thus, 
when a GABAAR (or indeed, a GlyR) is opened, the membrane potential depolarises 
to the reversal potential of chloride, occasionally resulting in excitation (Ben-Ari et 
al. 2007).  As KCC2b expression increases dramatically leading to an increase in the 
relative expression of KCC2b with respect to NKCC1 leading to a net extrusion of 
Cl
-
 and a reduced intracellular [Cl
-
] (usually <7 mM in adult excitatory neurones; 
Ben-Ari et al. 2004). The Cl
-
 reversal potential therefore becomes more negative and 
GABAAR (or GlyR) activation results in a net Cl
-
 influx and a hyperpolarising 
response (Blaesse  et al. 2009).  
 Perturbed GABAAR–mediated signalling has been implicated in diseases such 
as Rett syndrome (Chao et al. 2015). Previous studies using iPSC-derived neuronal 
material demonstrated an under-expression of KCC2 causing persistent GABA-ergic 
neuronal excitation, and showed a rescue to an unaffected phenotype (Tang et al. 
2015). Intracellular chloride is also implicated in schizophrenia via dysregulation of 
intracellular chloride transporter activity that is hypothesised to disrupt normal 
development of neuronal networks by altering the overall balance between excitation 
and inhibition (see Kalkman et al. 2011; Arion et al. 2011). The previously observed 
phenotype in Schizophrenia is that NKCC1 expression is aberrantly increased in 
development, resulting in an increase in intracellular [Cl
-
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Figure 1.7. Schematic representing chloride transporter protein activity in cortical 
neurones across development. Adapted from Ben-Ari et al. (2004). A: Schematic of net 
[Cl-] movement across the cell membrane (red arrow) upon GABAAR activation in embryonic 
neurones. B: Schematic of net [Cl-] movement across cell membrane (red arrow) upon 
GABAAR activation in postnatal, and adult neurones. C: Schematic illustrating net [Cl-] 
across development as influenced by transporter proteins KCC2 and NKCC1. Depiction of 
relative expression across development is determined by the size of the circles, and net ion 
flow as a result of transporter activity is shown by weight blue and green arrows. Resultant 
effect of [Cl-] on GABAAR activation (excitation, inhibition) is also shown as an example 





1.5  Clinical presentation of mutations studied within this thesis, and 
potential indicators of ion-channel neuropathology   
1.5.1 DISC1 (1;11)(q42;q14.3) translocation mutation and  associated 
neuropsychiatric conditions 
It is suggested that mutations in DISC1 result in disrupted physiological and 
neuronal function leading to an imbalance in the excitation/inhibition state in the 
pre-frontal cortex that may underlie associated observed disease phenotypes 
(Bradshaw & Porteous. 2012; Lisman. 2012). Previous work has shown that DISC1 
mutations result in altered K
+
-channel expression in rodent cortical neurones (Small 
conductance calcium-activated K
+ 
channels, El-Hassar et al. 2014; KCNQ5, Ozeki 
et al. 2003) and intrinsic neuronal excitability (Gamo et al. 2013) changes in 
neurotransmitter receptor expression and function (Akbarian et al. 1995; Callicot et 
al. 2013; Kim et al. 2012; Wright & Vissel 2012; see Hammond et al. 2010). Indeed, 
many basic functional properties of human cortical neurones harbouring the DISC1 
mutation remain to be described and iPSC technology offers a valuable opportunity 
to address this. Reports also suggest that epistatic interactions affecting genetic risk 
may occur between DISC1 and NDEL1/NDE1 (Hennah et al. 2007), with 
Ser704Cys status altering both risk of schizophrenia detected using the 
NDEL1/NDE1 SNPs, and NDEL1/ NDE1 binding to DISC1 (Burdick et al. 2008). 
An interaction between DISC1 3’UTR SNP rs1411771 and an intronic SNP in the 
gene encoding another DISC1 interactor, CIT, has also been shown to increase the 
risk of developing schizophrenia, and this was validated by fMRI (Nicodemus et al. 
2010). Genetic interaction between DISC1 and PDE4B influences regional brain 
volume (Andreasen et al. 2011), while epistasis between Ser704Cys and FEZ1 is 
reported to act on the risk of developing schizophrenia, and synergistic effects of the 
two proteins on dendritic growth of newborn neurons in the adult mouse 
hippocampus are reported (Kang et al. 2011). Finally, SNPs within DISC1 and the 
gene encoding NKCC1 also interact (Kim et al. 2012). Altogether, these studies 
indicate that pathways involving DISC1 and these associated molecules may be of 






1.5.2 TARDBP mutations, and protein product TDP-43 in ALS  
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor 
neurone disease, and is characterized by the progressive loss of upper and lower 
motor neurons from the spinal cord and motor cortex which leads eventually to 
respiratory failure and subsequently, death. Approximately 7.5%of ALS cases are 
familial, with the remaining 90% being termed “sporadic” in origin. Interestingly, 
despite this, 97 % of patients display a common phenotype in disease-affected 
tissues. Deposits of TAR DNA binding protein (TDP)-43 - interestingly, TDP-43 is 
also the major feature of tau-negative frontotemporal dementia (FTD), which shows 
clinical overlap with ALS. This convergence of genetic and environmental risk 
factors in TDP-43 proteinopathy is hugely informative with regard to investigating 
general disease progression in ALS. Encoded by TARDBP, TDP-43 is a 
ubiquitously expressed DNA-/RNA-binding protein. TDP-43 predominantly resides 
in the nucleus, but is capable of moving into the cytoplams. In the nucleus, TDP-43 
plays a critical role in regulating RNA splicing, as well as affecting mRNA synthesis 
and processing. TDP-43 also regulates the stability of its own mRNA, amounting to 
autoregulation of TDP-43 protein levels. TDP-43 regulates the expression of a great 
many other transcripts, suggesting TDP-43 influences perhaps a multitude of cellular 
and physiological processes. While mostly localised to the nucleus, approximately 
25 % of TDP-43 protein can be found in the cytoplasm, with exit to the nucleus 
being regulated by both activity and stress. TDP-43 also plays a role in synaptic 
plasticity by modulating levels of local protein synthesis in dendrites. TDP-43 is also 
involved in a cytoplasmic stress response —the formation of granular protein 
complexes that scavenge un-needed mRNA molecules. Thus, TDP-43 function 
might be particularly important under conditions of physiological stress, such as 
excitotoxicity. Understanding the functions of endogenous TDP-43 is crucial to 
establishing whether loss of these functions might be key to disease pathogenesis, 
and to developing effective therapeutics.  
TDP-43 protein was identified as a major component of the ubiquitinated 
neuronal cytoplasmic inclusions deposited in cortical neurones in FTD and in spinal 
motor neurons in ALS. TDP-43-positive inclusions have subsequently been shown 




whether sporadic or familial. This transformation is evidenced by the deposition of 
full-length and fragmented TDP-43 protein as detergent-resistant,ubiquitinated and 
hyperphosphorylated aggregates in the cytoplasm, with associated clearing of TDP-
43 from the nucleus. The regional spread of TDP-43 proteinopathy fromspinal and 
cortical motor neurons and glia to other corticalregions can be used to stage ALS 
progression , which suggests that some or all of the features of transformedTDP-43 
protein are linked to pathogenesis.However, a key question in ALS research is which 
of thesefeatures of TDP-43 proteinopathy are required for the developmentof disease 
and thus represent therapeutic targets. Overexpression of wild-type TDP-43 
recapitulatesTDP-43 proteinopathy and disease phenotypes in a range ofanimal 
models, supporting a role for gain of toxicfunction in disease. Initial studies testing a 
loss-of-functionhypothesis used knock-out of TDP-43 from mice, which resultedin 
embryonic lethality This demonstrated TDP-43 to play a vital role in early 
development without necessaril demonstrating that loss of function could be 
degenerative in adulthood.  Interestingly, either overexpression or knockdown of 
TDP-43 selectively in glia or muscle also recapitulates ALS-like phenotypes [40, 
41]. Previous work has highlighted an intrinsic vulnerability of ALS MNs to 
glutamate excitotoxicity that is mediated by Ca
2+
-permeable AMPARs (Donnelly et 
al. 2013; Rothstein et al. 1995). However, the literature has yet to directly link 
specific AMPAR structural properties that generate Ca
2+
-permeability in ALS MNs 















1.5.3 C9ORF72 (G4C2) nucleotide repeat expansion and ALS 
A GGGGCC (G4C2) nucleotide repeat expansion (NRE) in the chromosome 9 
open reading frame 72 (C9ORF72) gene is the most common genetic marker in 
familial amyotrophic lateral sclerosis (ALS) and in frontotemporal dementia 
(FTD)1,2. Additionally, this mutation has also been detected in approximately 12% 
of patients with sporadic ALS. The actual size of the NRE in terms of number of 
G4C2 repeats also varies between clinical patients with ALS and in patients with 
FTD carrying the mutation. While this NRE has been found to contain as many as 
hundreds or thousands of repeats, less than approximately 25 repeats is usually not 
associated with disease. At present, the size of the expansion does not appear to be 
related to disease severity, or age of onset. As this mutation is so commonly detected 
in both ALS and FTD, and also in both familial presentations, and apparent sporadic 
presentations of these disorders, understanding the underlying pathophysiology that 
it causes is possibly of use in both disease management and the development of 
future biomarkers for more representative or subtle physiological models for study, 
and the development of drug therapies.  
C9ORF72 codes for a protein that can be expressed as 2 isoforms termed 
“long”, and “short”. Initially it was suspected that C9orf72 lacked structural 
homology with any known protein, however, recently it has been suggested that 
C9ORF72 protein contains a DENN domain (differentially expressed in normal and 
neoplastic cells), which may allow it to function as a Guanine nucleotide exchange 
factor (GEF). Experiments in animal systems have shown that C9ORF72 highly 
expressed in neurones. Additionally, it appears that the short isoform of C9ORF72 
localizes to the nuclear membrane, whereas the long isoform is predominantly 
located in the cytoplasm. The significance of this distribution is unclear, particularly 









The idea that aberrant C9ORF72 function imparts disease was explored in 
studies of patients with C9 ALS/FTD who exhibited a >50% reduction of C9ORF72 
RNA levels but showed a phenotype similar to patients with C9 ALS/FTD who have 
higher C9ORF72 RNA levels44,45. However, recent work that used mouse models  
that expresses human C9ORF72 containing the (G4C2) NRE provided support for a 
possible C9ORF72 loss of function mechanism. In these studies, several gain of‑
function mechanisms and additional pathological features associated with disease 
were seen, however, the mice showed no neurodegenerative phenotypes, suggesting 
that gain‑of‑function mechanisms alone cannot explain disease pathogenesis. This 
suggests that loss of  C9ORF72 contributes to neurodegeneration. 
 Crucially, there is strong evidence to show that disease progression in ALS is 
likely mediated, in part, by glutamate-mediated excitotoxicity (Rothstein & 
Cleveland, 2001.). Previous work has highlighted an intrinsic vulnerability of ALS 
MNs to glutamate excitotoxicity that is mediated by Ca
2+
-permeable AMPARs 
(Donnelly et al. 2013; Rothstein et al. 1995). However, the literature has yet to 
directly link specific AMPAR structural properties that generate Ca
2+
-permeability 
















1.6 Introduction to the patch-clamp technique 
 The patch-clamp technique pioneered by Sakmann and Neher (Neher & 
Sakmann, 1976) enabled a significant leap forward in electrophysiological study of 
ion channels. Previous methods such as sharp electrode intracellular recording (Ling 
& Gerard, 1949) were used to resolve macroscopic currents in intact neurones, 
however, a limitation of these approaches is an inherently high background noise 
and therefore were not suited to resolving the current passed by single ion channels. 
Thus, a technique was needed to reduce electrical noise in order to resolve activity at 
the level of the single ion channel.  
 Building on the work of Neher and Lux, Neher pressed an electrode tip against 
an isolated skeletal muscle fibre from frog endplate, electrically isolating the patch 
of membrane directly under the electrode (Neher and Lux, 1969). Given that 
background noise is associated with the area of membrane under study, this had the 
practical effect of reducing background noise closer to the pico-Ampere level, a 
more ideal set of conditions for recording microscopic currents. 
 In 1980, Sigworth & Neher established the use of high-resistance sealing of 
the electrode tip with the cell membrane, now commonly known as a Giga-seal 
(Sigworth and Neher, 1980). This had a dual effect which increased the potential 
quality of a recording. Firstly, the tight seal between membrane and a smooth glass 
electrode facilitates mechanically stable recordings, and also further electrically 
isolates the membrane from ion flux typical of lower resistance electrode-membrane 
seals (see Figure. 1.2.). The properties of mechanical stability and electrical isolation 
facilitated the study of ion channels through 3 key mechanisms. Firstly, the ability to 
record currents from the whole cell by breaking the seal such that the whole 
membrane is electrically continuous with the electrode (“whole-cell patch-clamp”, 
see Figure. 1.2) enabled the examination of synaptic currents as well as bath-applied 
agonist-mediated ion channel activity and high-resolution recording of action 
potentials. Secondly, mechanical excision of the sealed patch of membrane in the 
“inside out” or “inside in” configurations (Figure. 1.2) enabled the study of single 
ion channels housed in the membrane patch. This was of great relevance as the 




structure-function studies, in that agonists and modulators could be applied to either 
the inside or outside of an excised membrane patch.   
 Thirdly, because of its high spatial and temporal resolution as a result of 
mechanical and electrical stability, the patch-clamp technique can be used to study 
the activity of transporters and metabotropic receptors on ionic balances using 
adaptations such as perforated patching. Here, a pore-forming antibiotic is added to 
the solution inside the electrode. Upon contact with the cell membrane, a Giga-seal 
is established. Slowly, the antibiotic polymerises into ring-like structures in the cell 
membrane, allowing ion conductivity with minimal dialysis of intracellular ions or 
























1.7 Experimental aims  
 Thus far, it is argued that human ESC/iPSC-derived neuronal, and 
oligodendroglial  material is sufficiently well developed as a technology to produce 
stable, replicable, and comparable platforms from which to study human 
development in both health, and disease. The scope of this thesis is to describe the 
extent to which iPSC technology can recapitulate certain aspects of development, 
and to observe any phenotypes imparted by mutations associated with neurological 
disease. 
 
1.7.1 Characterising GABAARs and GlyRs expressed on hECNs 
 As has been previously described, human embryonic cortical neurones derived 
from ESC/iPSC sources recapitulate many fundamental functional aspects of 
neurodevelopment as observed in animal models such as progressive lowering of 
intracellular [Cl
-
], decreased AMPAR Ca
2+
 -permeability, and maturation of action 
potential parameters, little is known about the subunit composition of GABAARs 
and GlyRs. Given the prominent role that GABA signalling plays in development, 
and recent suggestions that GlyRs may play a role in illness, such as inflammatory 
pain, and movement disorders, this thesis will address the question of which 
GABAAR isoform(s) are expressed by hECNs. This represents an advance that may 
inform the utility of hECNs as a human in vitro model of GABAAR, and GlyR 










  1.7.2 Investigating potential ion channel and Cl- co-transporter   
function in hECNs harbouring the DISC1 (1;11)(q42;q14.3) mutation 
 Thus far, it has been suggested that the DISC1 (1;11)(q42;q14.3) mutation 
may result in ion channel pathologies which are highly amenable to 
electrophysiological study, in the form of altered AMPAR, NMDAR, and GABAAR 
expression, and composition. It has also been suggested that this mutation may affect 
Cl
-
 -transporter protein expression in hECNs, as has been observed in animal 
models. This may be relevant to the study of the inhibitory-excitatory balance during 
network formation in neurodevelopmental hypotheses of psychotic disorders 
associated with the DISC1 (1:11)(q42;114.3) mutation, such as schizophrenia.  
 Additionally, previous work suggests that the DISC1 (1;11)(q42;q14.3) 
mutation may also produce subtle, yet general developmental deficits in maturation 


















1.7.3 General development, and possible AMPAR pathology in an                      
iPSC-MN model of ALS 
Crucially, there is strong evidence to show that disease progression in ALS is likely 
mediated, in part, by glutamate-mediated excitotoxicity (Rothstein & Cleveland, 
2001.). Previous work has highlighted an intrinsic vulnerability of ALS MNs to 
glutamate excitotoxicity that is mediated by Ca
2+
-permeable AMPARs (Donnelly et 
al. 2013; Rothstein et al. 1995). However, the literature has yet to directly link 
specific AMPAR structural properties that generate Ca
2+
-permeability in ALS MNs  
 
 
1.7.4 General development, and possible AMPAR pathology in an                      
iPSC-OPC/OL model of ALS 
Previous work has suggested an intrinsic vulnerability of OPCs and OLs to 
glutamate excitotoxicity that is mediated by Ca
2+
-permeable AMPARs in a manner 
similar to that as described in MNs (see Donnelly et al. 2013; Rothstein et al. 1995). 
However, the literature has yet to directly link specific AMPAR structural properties 
that generate Ca
2+



































2.1 Generation of induced pluripotent stem cells (iPSCs) and 
specification of cellular identities from iPSCs and embryonic stem cells 
(ESCs). 
2.1.1 Sources of ESCs and iPSCs 
 ESCs were obtained from WiCell (Madison, WI) with full ethical/IRB 
approval of the University of Edinburgh. Hereafter, H9 ESC derived material will be 
described as ‘ES’ in figures and text.  
 The technology of iPSC reprogramming is based on the use of Yamanaka 
factors, a set of transcription factors which are highly expressed in ESCs and which 
induce pluripotency in mouse and human somatic cells (Liu et al. 2008). Briefly, 
iPSCs were generated from grafted adult upper arm dermis by reprogramming 
fibroblasts to pluripotency using retroviral vectors expressing coding sequences of 
genes constituting Yamanaka factors OCT4 and SOX2 (‘core’ factors), c-MYC 
(upregulates metabolism), KLF4 (enhances effects of core factors), and additional 
factors hTERT and SV40 large T (see Liu et al. 2008). In the case of iPSCs, written 
informed consent was obtained from each individual participant. iPSC generation 
and derivation to regionally specific material was performed by the Chandran 
laboratory. iPSCs used in this Thesis: 
 
2.1.2 Control iPSC lines 
 The iPSC control line was derived from fibroblasts taken from a 56-yr old 
normal male, hereafter designated as ‘Control.’ For DISC1 experiments, control cell 
lines DR3 and GS8 not harbouring the (1;11)(q42;q14.3) translocation were derived 
from disease-unaffected relatives of diagnosed psychiatric patients. Hereafter, line 
DR3 and GS8 will be respectively described as ‘DISCControl-1’ and ‘DISCControl-2’. 
Where data are pooled, lines will be referred to in graphs and text as ‘Control’, with 








2.1.3 Case iPSC lines 
 Two mutant lines were generated from MND patients harbouring the 
C9ORF72 (G4C2) repeat expansion and will be referred to as “C9-1” and “C9-2” in 
the text. A third line derived from C9-2 which has the G4C2 repeats excised by 
Cas9/CRISPR is known as “∆C9-2”. Gene editing on line C9-2 was conducted by 
Dr. Bhuvaneish Selveraj using the CRISPR/Cas9 genome engineering system 
detailed in Ran & Hsu (2013).  Briefly, hexanucleuotide repeats in C9ORF72 mutant 
lines were excised using an RNA-guided nuclease (Cas9) targeted to the sequence of 
the hexanucleotide repeats.  
 Three separate lines expressing mutated forms of TDP-43 were also generated. 
Firstly, one derived from a patient harbouring the M337V mutation, referred to as 
“TDP-1”, and two others harbouring the G298S mutation derived from two different 
patients,  referred to in the text as “TDP-2”, and “TDP-3”. A third line, derived from 
TDP-3, with the G298S point mutation corrected using Cas9/CRISPR by Dr. 
Bhuvaneish Selveraj, is referred to as “∆TDP-3”.  
Patient-derived DISC1 iPSC lines were taken from individuals with a diagnosed 
psychiatric disorder (MW and MR) who’s genomes harbour the (1;11)(q42;q14.3) 
translocation mutation in the DISC1 gene, and are referred to in the text as 
‘DISCCase-1’ (derived from MW) and ‘DISCCase-2’ (derived from MR). Where data 
are pooled, lines will be referred to in graphs and text as ‘Case’, with ‘N’ denoting 














2.2 In vitro ESC/iPSC-derived material generation  
2.2.1 Human excitatory cortical neurone (hECN) generation 
 The following protocol was employed previously in Bilican et al. (2014), 
Livesey et al. (2014) and is summarised in Figure. 2.1. ESCs/iPSCs were maintained 
on irradiated mouse CF-1 embryonic fibroblasts supplemented with Advanced 
DMEM/F12 (A-DMEM/F12), L-glutamine (1 mM), Knockout Serum Replacement 
(20%, PeproTech), FGF2 (10 ng/ml, Sigma), 2-mercaptoethanol (100 mM, Sigma) 
and 1% penicillin/streptomycin (P/S, 1%, Sigma). ESCs/iPSCs were neuralised in 
suspension in chemically defined medium as described in Stacpoole et al. (2011). 
The media was changed to Base media (A-DMEM/F12 (BD Biosciences), P/S (1%), 
Glutamax (1%, BD Biosciences), N2 (1%), B27 (0.4%), FGF-2 (2.5 ng/ml, Sigma) 
upon observation of radially oriented structures in neurospheres (10–21 days) and, 
after 7 days, plated on Laminin (Sigma) coated tissue culture plates (Nunc). Neural 
rosettes were mechanically isolated and subsequently dissociated with Accutase 
(Sigma).  20-40k cells were then plated onto one Laminin-coated well of a 96-well 
plate (Nunc) in proliferation media (Base media, B27 (0.1%), FGF2 (10 ng/ml), and 
EGF (10 ng/ml). Anterior neuronal precursors (aNPCs) were grown to high density 
before passaging 1:2 with Accutase (Sigma) on laminin (Sigma) coated plates until 
passage 5–6 and maintained on 1:100 Reduced-growth factor Matrigel (BD 











Figure. 2.1, Schematic describing generation of material. Cortical neurones were 
neuralised using the default method of neurogenesis involving minimal chemical 
conditioning. The NPCs generated stained for telencephaelic marker FOXG1. aNPCs were 
maintained in 3% O2, plated down and FGF2 removed for differentiation. For both OLs and 
MNs, iPSC were neutralised using Dual SMAD inhibition and caudalised with RA to give 
spinal cord NPCs positive for OLIG2. For MNs, NPCs were induced by the addition of 
Purmorphamine and BDNF/GDNF. For OPCs/OLs, lineages were established by the 
addition of SAG, Purmorphamine, PDGFα, and T3. Terminal differentiation into OLs was 
achieved by mitogen withdrawl. Immunohistochemical stainings used with permission, taken 
from Bilican et al. (2012), Bilican et al. (2014), Livesey et al. (2014) and provided by 




 For the generation of neuronal cultures, aNPCs (see Figure. 2.1) were plated at 
20-25k (for ESC-derived aNPCs) or 100-120k (iPSC-derived aNPCs) in default 
media  A-DMEM/F12, Invitrogen), containing P/S (1%, Sigma), Glutamax (0.5%, 
Sigma), N2 (0.5%, Sigma), B27 (0.2%), Heparin (2 µg/mL, Sigma) on poly-D-
lysine (Sigma), laminin (Sigma), fibronectin (Sigma), coated coverslips for 
differentiation in 3% O2, and fed twice weekly. For hECNs (see Figure. 1.1), default 
media was supplemented with forskolin (10 µM, Tocris) from DIV 14-21. From 
DIV 21 onwards forskolin was removed. Cells were stored in default media 
thereafter containing BDNF (20 ng/mlSigma) GDNF (20 ng/ml, Sigma) from DIV 
21. For studies examining [Cl
-
]i, BDNF and GDNF were omitted and included IGF-
1 (20 µg/ml, PeproTech) from week 4.  
 
2.2.2 Human lower motor neurone generation  
 A summary of the protocol is given in Figure 1. For differentiation into motor 
neurons, iPSCs were initially neuralised to a caudal identity using proliferation 
media supplemented with with  Retinoic Acid (RA, 0.3mM, Sigma), then plated 
down on poly-D-lysine (Sigma), laminin (Sigma)- and fibronectin (Sigma)-coated 
coverslips in Neurobasal, RA (0.1 mM), Purmorphamine (2 mM Calbiochem), N2 
(1%), P/S (1%), Glutamax (1%), bFGF (5 ng/ml) for 7–10 days to promote 
generation of precursors. Motor neuron precursors were re-plated and media was 
switched to Neurobasal, N2 (0.5%, Sigma), B27 (0.2%, Sigma), P/S (1%, Sigma), 
Glutamax (0.5%, Invitrogen), BDNF (10 ng/ml, Sigma), GDNF (10 ng/ml, Sigma). 










2.2.3 Human OPC/OL generation  
 A summary of the protocol is given in Figure 1. For the generation of 
oligodendrocytes and OPCs, derivation of spinal cord neural precursors (NPCs), was 
performed as described in
 
Bilican et al. (2012). NPCs were cultured in suspension as 
neurospheres in Advanced DMEM/F12 (Invitrogen) supplemented with: GlutaMAX 
(0.5%, Invitrogen), FGF-2 (20 ng/ml PeproTech), N-2 (1%, Invitrogen), B27 (1%, 
Invitrogen), P/S (1%, Invitrogen), PDGFα (20 ng/ml, PeproTech), puromorphamine 
(1 µM,Calbiochem), SAG (1 µM, Calbiochem), T3 (60 ng/ml, Sigma), and IGF-1 
(10 ng/ml, PeproTech), for 6-12 weeks. Neurospheres were dissociated with papain 
and plated Matrigel (BD Biosciences), Fibronectin (Sigma), Laminin (Sigma) coated 
coverslips. Terminal differentiation of oligodendrocytes was achieved by mitogen 
withdrawal (except for T3 and IGF-1).  
2.3 Electrophysiology 
2.3.1 Introduction to the patch-clamp technique 
  The patch clamp technique (Sigworth and Neher, 1980) is a high-resolution 
electrophysiological recording technique capable of observing minute current, or 
voltage changes, in the cell under recording. Because of its high spatial and temporal 
resolution as a result of mechanical and electrical stability, the patch-clamp 
technique can be used to study the activity of ion channels and the biophysical 
behaviour of cell membranes in a variety of configurations (see Figure. 1.2) as well 
as transporters and metabotropic receptors on ionic balances using adaptations such 
as perforated patching (Figure. 1.2). Here, a pore-forming antibiotic is added to the 
solution inside the electrode. Upon contact with the cell membrane, a Giga-seal is 
established. Slowly, the antibiotic polymerises into ring-like structures in the cell 
membrane, allowing ion conductivity with minimal dialysis of intracellular ions or 
proteins into the pipette solution (Kyrozis and Reichling, 1995). Recordings 
described in this thesis utilise either the whole-cell configuration, or the perforated 





Figure 2.2, Patch-Clamp Configurations. Schematic showing the various methods of 
establishing different patch-clamp configurations. Initially, the “Cell-attached” configuration is 
achieved by application of negative pressure (mild suction) to produce a Giga-seal. In the 
presence of a perforation agent added to the patch pipette (here, Gramicidin), waiting 
results in the perforated configuration. Electrode withdrawal from the cell-attached 
configuration results in an inside-out patch, whereas an acute-application of sharp suction 




Mechanical electrode withdrawal from the whole-cell configuration results in the outside-out 
configuration. 
2.3.2 Patch electrodes 
 Electrodes were made from thick-walled borosilicate glass of 1.5 mm outer 
diameter and 0.86 mm inner diameter with filament (Harvard Apparatus). Electrodes 
were pulled on a Narishige PP-830 two-stage pipette puller (Narishige, Japan), and 
when were filled with an internal recording solution (see 2.3.3) had final resistances 
of 4 – 7 MΩ. . 
 
2.3.3 Patch-clamp recording 
 The whole-cell patch-clamp technique was used to record currents from 
ESC/iPSC-derived material using an Axon Multiclamp 700B amplifier (Molecular 
Devices, Sunnyvale, CA).  Patch electrodes were filled with internal recording 
solutions as described in the text, with the following compositions (amounts in mM): 
 
Potassium Gluconate Internal Solution (K-Gluconate internal):  
K-gluconate 155, MgCl2 2, Na-HEPES 10, Mg2-ATP 2, Na-PiCreatine 10, and Na3-
GTP 0.3, pH 7.3 at 300 mOsm. The use of K-gluc asssocited with a liquid junction 
potential (LJP) of +14 mV (LJPcalc; Barry, 1994).), which was corrected post hoc. 
All reported voltage data is corrected for LJP.  
 
Potassium Chloride Internal Solution (KCl internal):  
KCl 145, MgCl2 1, CaCl2 0.1, EGTA 1, Na-HEPES 10, pH 7.3 at 300 mOsm. (LJP = 
+4.3 mV). 
 
Caesium Chloride Internal Solution (CsCl internal): 
CsCl 140, EGTA 1.1, CaCl2 0.1, MgCl2 1, Na-HEPES 10, Mg2-ATP 2, pH 7.3 at 





 Glass coverslips containing ESC/iPSC-derived cultures were placed in the 
recording chamber and superfused with an external solution composed of (in mM) 
NaCl 152, KCl 2.8, glucose 10, CaCl2 2, HEPES 10, pH 7.3 (320–330 mOsm) using 
a gravity-fed perfusion system at room temperature (20-23°C), and, where indicated, 
a higher temperature of 30-33
o
C, with a flow rate of approximately 4 ml.min
-1
 in all 
cases.  Series resistance (Rs) was generally less than 25 MΩ in the case of whole-cell 
recordings, with an absolute cut off Rs of 30 MΩ. Recordings were discarded if 
change in Rs  exceeded 10%.  
 In the case of perforated patch-clamp recording to examine [Cl]i, a KCl 
internal solution was supplemented with gramicidin (75-100 µg mL
-1





 ions, but not Cl
-
 (Tajima et al. 1996).  Therefore, the use of 
Gramicidin does not affect intracellular [Cl
-
]. Perforation was monitored by the 
increase in size of capacitive transients which reflect Rs. Here, Rs was typically 
below 30 MΩ with an absolute cut off Rs of 40 MΩ. Rs was compensated to 80% in 
















2.3.4 Application of pharmacological agents  
 In the case of assessing agonist and antagonist potency, and current 
modulation (potentiation or inhibition), three applications of a given concentration 
of agonist that gave equivalent current amplitudes within 15% of the initial 
amplitude were obtained to establish a stable current response prior to the 
experimental pharmacological assay.  Similarly, a control concentration of agonist 
was applied at the end of the assay to ensure recording stability.  Recordings were 
only accepted as valid if the amplitude of the final control response was within 15% 
of the initial controls.  Selective agonists, antagonists and allosteric modulators were 
purchased either from Tocris Bioscience (Bristol, UK) or Abcam (Cambridge, UK).  
 Pharmacological agents were applied using a bath-exchange system which 
utilised a gravity feed with multiple possible aCSF sources (“barrels”) containing an 
appropriate concentration of experimental agents. These barrels are switched as 
required to deliver various agents, with the liquid aCSF contents of the bath being 
replaced within approximately 5 - 10 seconds of onset. With the exception of non-
stationary fluctuation analysis experiments (which require slow onset of agonist as 
described in Chapter 2.4.2), onset time was minimised as much as possible with no 










2.4 Data analysis and statistics 
 Whole-cell patch-clamp, recordings were low-pass filtered at 2 kHz, digitized 
at 10 kHz via a BNC-2090A (National Instruments, Texas, USA) interface and 
recorded to computer using the WinEDR V2.7.6 Electrophysiology Data Recorder 
(J. Dempster, University of Strathclyde, UK 
(www.strath.ac.uk/departments/physpharm). Data are presented as mean ± standard 
error of the mean (s.e.m).  The number of experimental replicates is denoted as ‘n,’ 
while ‘N’ represents number of de novo preparations of batches form which ‘n’ is 
obtained.  Statistical analysis was conducted using Student’s t-test as multiple 
comparisons across large data sets was not necessary. This form of t-test is 
considered standard format for peer review, including material contained Chapter 3, 
published as James et al. (2014), and Chapter 6, contributing to Livesey et al. 
(2015).  Where results are described by asterisks (*), * indicates p=<0.05, ** 
indicates p=<0.01. *** indicates p=<0.001  
 The rationale for using individual cells as ‘n’, and number of experimental 
replicates as ‘N’ was to establish that so-called “batch to batch” variation did not 
underlie any putative cellular phenotype observed in stem-cell derived neuronal 
material grown in vitro, or rather, to account for this effect if noticed in order to 
interpret the effects of any experimental intervention. For example, if a cellular 
phenotype for a mutation which may impact general neuronal development was 
being studied, and one “batch” of hECNs typically displayed a slower maturational 
profile, then an artefactual phenotype would result. This effect is then presumed to 
be comparable between hECNs with and without the mutation when taking into 














2.4.1 Agonist and antagonist concentration response curves 
 Agonist concentration-response curves were fitted individually for each cell 
using the Hill equation: 
 






where I is the current response to agonist concentration [A], nH is the Hill 
coefficient, Imax is the maximum current and EC50 is the concentration of agonist that 
produces a half-maximal response. Each data point was normalized to the fitted 
maximum of the dose-response curve, then pooled, averaged and re-fitted again with 
the same equation with the maximum and minimum for each curve being 
constrained to asymptote to 1 and 0, respectively (Frizelle et al. 2006) . 
Concentrations of antagonists required to inhibit agonist-evoked responses by 50% 
(IC50) were determined by fitting inhibition curves with the equation: 
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where nH is the Hill coefficient, I[B]0 is the predicted current in the absence of 
antagonist and [B] is the concentration of the antagonist. Data points were again 








2.4.2 Non stationary fluctuation analysis 
 Non-stationary fluctuation analysis (Colquhoun, 1979; Dempster, 1993) was 
conducted on slow-rising whole-cell currents evoked by AMPA (10 µM) in the 
presence of cyclothiazide (10 µM) at a holding potential of –84 mV. Current 
recordings were split to generate AC- and DC- characteristics. To generate the AC-
characteristic, currents were amplified 10 times to that of the DC current and low-
pass filtered using a Butterworth filter (1 – 1200 Hz).  The resultant variance in 
current evoked by AMPA was plotted against a simultaneously acquired DC 
component of the whole-cell current in order to yield a linear relationship. The 
resulting slope gave the estimated unitary single-channel current amplitude that was 








 Given the AMPAR is a non-selective cation channel (Jonas, 1993) and we 
established its Erev to be close to 0 mV, then the AMPAR single-channel 












2.4.3 Rectification Indices 
 Ion channel rectification is the property of preferential movement of charge 
across the cell membrane at equal, but opposite driving forces. This is described in 
terms of “inward” and “outward” rectification or an Ohmic relationship where no 
rectification is present. A rectification index (RI) can be used to describe these 
properties and is given as the outward conductance divided by the inward 
conductance. Thus, with no rectification, the index is 1. When values are less than or 
greater than 1, this indicates inward and outward rectification, respectively. RIs were 
calculated from the following equation: 
 
) = /(16 − .)/(124 − .) 
 
where I is current amplitude, and, Erev indicates the reversal potential of currents 
under study.  
 
2.4.4 The Nernst equation and estimation of [Cl-]i 








Where EGABA represents the experimentally established GABAAR-mediated reversal 
potentials (corrected for LJP post hoc), R is the universal gas constant, T is the 
temperature in Kelvin, z is the valence of the ion species in question (for chloride, -
1), and F is the Faraday constant. [Cl
-




 activity was 




2.5 Imaging and identification of cell types 
 Identification of oligodendrocyte precursors, and oligodendrocytes, was 
conducted via fluorescence microscopy on live iPSC-derived OPC/OL cultures in 
vitro, while simultaneously conducting electrophysiological experiments on said live 
tissue cultures. This process allows selective staining of cell types expressing 
PDGDFRα, a marker for OPCs, and O4, the canonical mature OL marker that 
strongly assiociates with myelin basic protein (MBP) expression – itself a marker of 
mature oligodendrocytes. A full characterisation of the protocol and methods used to 
establish the expression of these markers in iPSC- derived OPC/OLs can be found in 
Livesey et al. 2015. In experiments outlined within this thesis, the robust expression 
of this marker in these OPC/OL cultures facilitatesd quick and clear identification of 



















2.5.1 Identification of iPSC-derived Oligodendrocytes and OPCs 
 In order to distinguish and identify OPCs and OLs, plated cultures were 
incubated in a 4-well culture plate (Nunc) with a PDGFRα primary antibody (Cell 
Signalling, 1:300), or in the case of oligodendrocytes, an O4 (R&D Systems, 
1:1000) for 1h in default media. Cells were then washed by emptying 75% of media 
in each well, refilling each well with default media (500 µL) a total of 4 times. 
Cultures were subsequently incubated with a secondary antibody at 1:1000 dilution, 
conjugated to a fluorophore (Alexa Fluor 470, Molecular Probes Inc.) against anti-
O4 primary Ab, Alexa Fluor 588, (Molecular Probes Inc) for anti-PDGFRα primary 
Ab) for 45 minutes after which each culture plate was washed with default media by 
replacement a further 5 times. Cells were then left to equilibrate in an incubator for a 
further hour and imaged live at the rig where electrophysiological experiments were 
conducted as described.  
 Live imaging was conducted using an Olympus IX51 Inverted microscope 
(Olympus, Shuinjuku, Japan) fitted with CoolLED pE100 (CoolLED, UK) 
fluorophore excitation light sources. Glass coverslips in the recording chamber were 
observed through a phase-contrast array and lit with an Olympus TL4 brightfield 
















2.5.2 Antibodies described in this thesis 
Table 2.1 
Antibody Host Company 
BRN2  Goat polyclonal Santa Cruz 
CTIP2 Rat monoclonal Abcam 
CUX1 Mouse monoclonal Abnova 
EGFR1 Mouse monoclonal BD biosciences 
FOXG1 Rabbit polyclonal  Abcam 
GAD65/67 Rabbit polyclonal Millipore 
HB9 Mouse monoclonal DHSB 
HOXB4 Mouse monoclonal DHSB 
MAP2 Mouse monoclonal Sigma 
NESTIN Mouse monoclonal Millipore 
OLIG2 Rabbit polyclonal Millipore 
OTX2 Goat polyclonal R&D Systems 
PAX6 Mouse monoclonal DHSB 
PSD-95 Mouse monoclonal Neuromab 
PSD-95 Rabbit polyclonal Cell Signaling 
REELIN Mouse monoclonal Novus 
SATB2 Mouse monoclonal Abcam 
Sox1 Rabbit polyclonal Millipore 
O4 Mouse monoclonal R&D Systems 
PDGFRα Goat polyclonal Cell Signalling 
VGLUT1 Mouse monoclonal Neuromab 







2.6 Full list of abbreviations used in this thesis 
Table 2.2 For reference this list is presented in alphabetical order.  
aCSF  Artificial cerebro-spinal fluid 
AD  Alzheimer’s disease 
A-DMEM  Advanced Dulbecco’s Modified Eagle’s Medium 
AHP  After-hyperpolarisation 
ALDH1A2  Aldehyde dehydrogenase 1A2 
ALS  Amyotrophic Lateral Sclerosis 
AMPA  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
aNPC  Anterior neural precursor cell 
AP  Action potential 
AP5  (2R)-amino-5-phosphonovaleric acid; (2R)-amino-5-
phosphonopentanoate 
Bic  Bicuculline 
BMP  Bone morphogenic protein 
BNC  Bayonet Neill–Concelman 
C9ORF72  Chromosome 9, open reading frame 72 
Ca2+  Calcium 
CamKII  Calcium-calmodulin kinase 2 
Cas9  CRISPR associated protein 9 
CCD  Charge-coupled device 
ChAT  Choline acetyltransferase 
c-MYC  Myelocytomatosis viral oncogene c-variant 
CNQX  6 -cyano-7-nitroquinoxaline-2,3-dione 
CNS  Central nervous system 
CRISPR  Clustered regularly interspaced short palindromic repeats 
CSF  Cerebro-spinal fluid 
CTIP2  Chicken ovalbumin upstream promoter transcription factor-
interacting protein 2 




DISC1  Disrupted in schizophrenia-1 (gene product). 
DISC1  Disrupted in schizophrenia-1 (gene). 
DIV  Days in vitro 
DMEM  Dulbecco’s modified Eagle’s medium 
DNA  Deoxyribonucleic acid 
DZ  Diazepam 
EGTA  Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic 
acid 
ESC  Embryonic stem cell 
Etom  Etomidate 
FEZ1  Fasciculation And Elongation Protein Zeta 1 
FGF  Fibroblast growth factor 
FGF-2  Fibroblast growth factor 2 
FGF-8  Fibroblast growth factor 8 
fMRI  Functional magnetic resonance imaging 
FOXG1  Forkhead box G1 
FTD  Fronto-temporal dementia 
Furo  Furosemide 
GABA  Gamma-amino butyric acid 
GE  Ganglionic eminence 
GEF  Guanine nucleotide exchange factor 
GFAP  Glial fibrillary acidic protein 
Gly  Glycine 
GPCR  G-protein coupled receptors 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HP  Holding potential 
hPSC  Human pluripotent stem cell 
hTERT  Human telomerase reverse transcriptase 
K+  Potassium 




LGE  Lateral ganglionic  eminence 
LGIC  Ligand-gated ion channel 
LTD  Long-term depression 
LTP  Long-term potentiation 
Mg2+  Magnesium 
MGE  Medial ganglionic eminence 
MN  Motor neurone 
MRI  Magnetic resonance imaging 
mRNA  Messenger RNA 
Mus  Muscimol 
Na+  Sodium 
NASPM  N-acetyl spermine 
NDE1  NudE Neurodevelopment Protein 1 
NDEL1  NudE Neurodevelopment Protein 1 Like 1 
NKCC1  Na+/K+/Cl- co-transporter protein 1 
NMDA  N-methyl D-aspartate 
NPC  Neural precursor cell 
NRE  Nuclear repeat expansion 
O4  Oligodendrocyte marker 4 
OCT4  Octamer-binding transcription factor 4 
OL  Oligodendrocyte 
Olig2  Oligodendrocyte transcription factor 2 
OPC  Oligodendrocyte precursor cell 
PDE4B  Phosphodiesterase 4B 
PDGFRα  Platelet derived growth factor receptor alpha 
PFC  Pre-frontal cortex 
PKC Protein kinase C 
Prop  Propofol 
PTX  Picrotoxin 




RI  Rectification index 
RMP  Resting membrane potential 
RNA  Ribonucleic acid 
ROR-β  Retinoic acid-related orphan receptor beta 
SATB2  Special amino terminal-rich sequence-binding protein 2 
SC  Spinal cord 
SCS  Salicylidine Salycylhydrazide 
SHH  Sonic Hedgehog 
SMAD  SMA and MAD-related protein 
SNP  single nucleotide polymorphism 
SOD-1  Superoxide dismutase 1 
SOX2  Sex determining region Y box 2 
SOX5  Sex determining region Y box 2 
STX  Strychnine 
SVZ  Sub-ventricular zone 
TARDBP  TAR DNA-binding protein (gene). 
TBR1  T-box brain 1 
TDP-43  TAR DNA-binding protein 43 kDa. 
TGF-β  Transforming growth factor beta 
TTX  Tetrodotoxin 
UTR  Untranslated region 
Val  Valproic acid 
VGLUT1  Vesicular glutamate transporter 1 
VNa Voltage-sensitive Na+ channel 
VZ  Ventricular zone 
WNT  Wingless-Int1 intracellular protein signalling pathway 
Zn2+  Zinc 





Characterisation of ionotropic GABA receptors 
























3.1 Motivation for study 
 Technological advances in the field of stem-cell biology have yielded the 
ability to generate human excitatory cortical neurones (hECNs) from pluripotent 
stemcells (hPSCs), giving the potential to study human-specific physiology and 
disease in vitro. Previous reports describe a protocol that generates cultures of 
predominantly hECNs by 4 weeks of differentiation from anterior neural precursors 
(which, incidentally can be derived from various stem cell lines; Bilican et al. 2014). 
The translational impact of this technology is ultimately determined by the ability of 
hECNs to display properties that reflect neurones in their native environment (Yang 
et al. 2011; Sandoe & Eggan, 2013). Indeed, we have previously identified that 
hECNs are a useful model to study the maturation of AMPAR composition and the 
reduction in intracellular Cl− concentration that is observed in native neuronal 
development (Livesey et al. 2014). The present study characterises the likely subunit 
composition of GABAAR and GlyRs expressed b hECNs and illustrates that their 
subunit composition are likely to be similar to those that have been described for 
inhibitory ionotropic receptors expressed in immature rodent cortex. Methods In 
vitro hECN preparation A detailed description of the derivation of hECNs can be 
found in Bilican et al. (2014). Briefly, hECNs were differentiated from anterior 
neural precursors that were derived from the H9 human embryonic stem cell line 
(WiCell), which was obtained under ethical approval of the University of Edinburgh. 
Experiments were carried out on cells that had been differentiated and maintained in 
culture for 28–42 days in vitro (DIV), or 49–56 DIV. At these time points, around 
70% of cells were neuronal (β3-tubulin+), with little contamination from neural 
precursor cells (nestin+), astrocytes (GFAP+) or GABA-ergic (GAD65/67+) 
interneurons (Bilican et al. 2014; Livesey et al. 2014). Neurones were consistent 
with an excitatory (VGLUT1+) identity that also exhibited properties of neurones of 







3.1.1 Characterisation of hECNs 
 Previous work characterising hECNs derived from ESCs has shown hECN 
cultures at DIV 49-56 are 86.7%  ± 3.6% β-3 Tubulin
+
, and less than 10% GFAP
+
, 
indicating cultures highly enriched for neurons with nominal presence (<10%) of 
astrocytes and interneurones (Bilican et al. 2014; Livesey et al. 2014). Neurites in 
hECNs were heavily enriched for VGLUT1, with nominal GAD-65/67 staining 
(3.5% ± 0.4%), indicating a predominant composition of excitatory neurones. 
Additionally, hECNs were shown to express cortical-layer markers CTIP2, BRN2, 
Reelin, CUX1, and SATB2 at 49-56 DIV (Figure. 3.1 B-F).  
 
3.1.2 Motivation for studying GABAARs and GlyRs in hECNs 
 GABAARs are the principal mediators of fast inhibitory neurotransmission in 
the adult brain, and are important therapeutic targets in the treatment of epilepsy and 
anxiety disorders, as well as being directly implicated in anaesthesia and sedation 
(Reynolds et al. 2003). GABAARs are pentameric, ligand-gated anion channels that 
are assembled from 21 potential subunits (α1-6, β1-4, γ1-3, δ, θ, ρ1-3, ε, and π).  Subunit 
expression is tightly regulated both spatially and developmentally (Laurie et al. 
1992, Fritschy et al. 2005), and further to this, GABAAR subunit composition 
imparts distinctive pharmacological properties to the GABAAR complex (Karim et 
al. 2013, Mortensen et al. 2011). Identification of the GABAAR isoform/s expressed 
by hECNs would provide indications of the relative maturity of hECNs, and inform 
their potential to model normal development and disease. Additionally, this type of 
study may elucidate potential for hECNs to function as an in vitro drug discovery 
system. All material studied in this section (unless described otherwise) were 







Figure 3.1. Initial immunohistochemical characterisation of hECNs by the Chandran 
Lab. A: Reelin stain (green) in Week 5 hECNs. B: β-3 Tubulin (green) and CTIP2 (red) 
stains. C: BRN2 stain (green). D: CUX1 stain (red). E: SATB2 stain (red). F: Expression of 
cortical markers by %age of cells expressing a given marker. H9hESCs are referred to in 
this thesis as hECNs. Images taken with permission from Bilican et al. (2014) and Livesey et 
al. (2014).Panels A – E show images acquired using confocal fluorescence microscopy. All 

















3.1.3 Determination of typical GABAAR agonist and antagonist potency 
 To initially examine the composition of GABAARs expressed on hECNs (28-
42 DIV), concentration-response experiments using GABA and the GABAAR 
agonist muscimol were conducted, given that the potency of agonists at GABAARs 
has been shown to vary a great deal between isoforms (Mortensen et al. 2011; Karim 
et al. 2013).  Previously, hECNs were found to robustly respond to GABA 
applications at this time point (Livesey et al. 2014). Upon establishing stable control 
responses to GABA (100 µM), or muscimol (300 µM), increasing concentrations of 
agonist were applied sequentially (see Figure. 3.2A) to generate dose-response 
curves.  Mean EC50 values for GABA- and muscimol-activated currents were found 
to be 278 ± 11 µM (n = 12, N = 2) and 182 ± 10 µM (n = 6, N = 2), respectively 
(Figure. 3.2B, example traces shown in 4A), where coloured lines are graphical 
indications of EC50.  GABA (EC50)-evoked current responses were blocked by 
GABAAR antagonists bicuculline (100 nM to 30 µM, n = 5, N = 2) and picrotoxin 
(300 nM to 100 µM, n = 4, N = 2) in a dose-dependent manner giving respective 
IC50 values of 2.7 ± 0.2 µM and 5.1 ± 0.2 µM (Figure. 3.3B, with example traces in 
3.3A).  
 The observed low potency of GABA was then confirmed not to be a 
consequence of the specific culture conditions that we employed.  GABA potency 
was not influenced by the culture of hECNs in atmospheric O2 concentrations 48 
hours prior to recording (222 ± 13 µM, n = 3, N = 1), the absence of brain-derived 
neurotrophic factor and glial cell-derived neurotrophic factor media supplements 
(222 ± 36 µM, n = 5, N = 2), or maintaining hECNs for extended (49-56 DIV) 
culture periods (204 ± 17 µM, n = 5, N = 2).   
 It has been shown previously that relatively low GABA potency occurs at 
several receptor isoforms (Karim et al. (2013); Mortensen et al. (2011). In order to 
establish a more precise description of the subunit composition GABAARs on 
hECNs, further pharmacological investigation was conducted. 






     
  B 
                      
Figure 3.2. Assessment of agonist potency at GABAARs expressed by hECNs. A: 
Example whole-cell voltage-clamp traces from data set in 4B showing 3 initial control 
amplitudes of agonist followed by sequentially applied experimental concentrations (as 
indicated), and final control application of agonist. B: Concentration-response curve for 
bath-applied agonists GABA and muscimol. Dashed lines indicate mean EC50 for GABA 
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Figure 3.3. Assessment of antagonist potency at GABAARs expressed on hECNs. A: 
Example whole-cell voltage-clamp  traces from data set shown in 4B showing 3 initial control 
amplitudes of agonist followed by experimental concentrations (as indicated). Multiple end 
controls demonstrate wash-out of antagonist and thus return to uninhibited EC50 response. 
B: Concentration-response curve showing inhibition of responses (GABA EC50) by 
antagonists bicuculline (IC50 2.7 ± 0.2 µM; n = 5, N = 2) and picrotoxin (IC50 5.1 ± 0.2 µM; n 




3.2 Subunit-selective pharmacological identification of GABAAR 
composition.  
3.2.1 Assays for γ- and δ-subunit inclusion 
 A series of pharmacological assays to survey the presence of γ- and/or δ-
subunit containing GABAARs were performed.  Applications of the γ-selective 
allosteric potentiator diazepam (30 nM and 3 µM, see Figure. 3.4A for traces) to 
GABA (EC10)-mediated currents potentiated the control GABA response by 10 ± 6 
% (p = 0.1 vs. control) and 46 ± 10 % (p = 0.001 vs. control, Welch’s t-test, n = 17, 
N = 3), respectively, showing inclusion of the γ-subunit (Figure. 3.4B).  Further to 
this, the potent δ-containing GABAAR-selective agonist gaboxadol (3 µM and 300 
µM; (Storustovu & Ebert. 2006) elicited only nominal currents (6.0 ± 2.3% and 14.6 
± 3.7%, respectively) compared to the maximum response that could be elicited by 
GABA (GMAX, 3 mM; Figure. 3.4C, example traces in 6A) confirming the absence or 
nominal expression of a population of GABAARs that contain δ subunits. 
Additionally, the currents elicited by gaboxadol (300 µM; 9.7 ± 4.1 %, n = 4, N = 1) 
upon 49-56 DIV hECNs were equivalent to the previous (p= 0.65, student’s t-test) 
indicating the GABAAR population did not begin to express a δ-containing receptor 
population  when maintained in culture to extended time periods.  
 Applications of Zn
2+ 
(10 µM and 300 µM; n = 7, N = 2), which selectively 
inhibits GABAARs composed of α- and β- subunits alone (Draguhn et al. 1990), did 
not significantly inhibit GABA (EC50)-evoked currents (Figure. 3.5B, traces in 
3.5A). Thus the collective data obtained using diazepam, gaboxadol, and Zn
2+
 
indicate the major presence of γ-subunit-containing GABAARs.  
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Figure 3.4. Modulatory effects of diazepam, and activation by gaboxadol of GABAARs 
expressed on hECNs. A: Example whole-cell voltage-clamp  traces detailing responses of 
γ-subunit selective positive allosteric modulator diazepam co-applied with GABA (above), 
and direct activation by δ-subunit selective agonist gaboxadol (below). Coloured bars 
indicate application of pharmacological agents. B: Mean potentiaton of GABAAR responses 
by co application of diazepam and GABA (n = 17, N = 3). C: Mean direct activation of 
GABAARs by δ-selective gaboxadol (n = 6 - 7, N = 1) as a percentage of maximal GABA-
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Figure 3.5. Modulation of  GABAARs  by Zn2
+
. A: Example whole-cell voltage-clamp trace 
showing control applications of GABA (EC50), and responses to GABA (EC50) co-applied 
with Zn
2+
 at concentrations and times indicated by coloured bars. B: Graph showing mean 
modulation of GABAARs by Zn
2+
 as a percentage response vs control GABA applications (n 








3.2.2 Assaying β-subunit inclusion and identity 
 The presence of β-subunits in hECN GABAARs was confirmed by 
potentiation of GABAAR-elicited current by the intravenous anaesthetic propofol (n 
= 8, N = 3; 10 µM. Sanna et al. 1995; Hill-Venning et al. 1997) of GABA (EC30)-
evoked currents which resulted in robust potentiation of the control current 
responses by 144 % ± 29 % (Figure. 3.6C, traces in 3.6A; p = 0.005 vs control, 
paired t-test.  Furthermore, direct activation of GABAARs was observed when 
propofol (100 µM) was applied on its own (n = 8, N = 3; 98 ± 21 % relative to 
control, Figure. 3.6B, traces in 3.6A). This behaviour is typical of native GABAARs 
incorporaing a β-subunit (Hill-Venning et al. 1997, Ruesch et al. 2012).  
 Next, the β-subunit identity was examined, the GABAARs being of known 
variants β1, β2, and β3. The intravenous anaesthetic etomidate (3 µM) which is 
selective for β2/3-subunit containing GABAARs (Hill-Venning et al. 1997) also 
potentiated GABA (EC30)-evoked currents by 75 ± 20 % ( n = 6, N = 2; Figure. 
3.6B; p = 0.006 vs control, paired t-test) while application on its own and at a higher 
concentration (300 µM) directly activated GABAARs (n = 6, N = 2; 116 ± 23 % 
relative to GABA (EC30)-evoked control; Figure. 3.6C,traces in 3.6A). Direct 
activation of GABAARs containing a β2/3-subunit by etomidate is a typical property 
of those GABAAR isoforms (Ruesch et al. 2012; Hill-Venning et al. 1997). 
Altogether, these data indicate that GABAARs expressed by hECNs are 
predominantly a β2/3-containing isoform.  Conversely, the absence of β1-containing 
GABAARs was demonstrated by the use of the selective inhibitor of β1-containing 
GABAARs, SCS (Salycylidine salycylhydrazide; Thompson et al. 2004). SCS failed 
to antagonise GABA (EC30)-evoked currents (n = 8, N = 3; Figure. 3.6C, traces in 
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Figure 3.6, Modulation and activation of hECN GABAARs by β-subunit selective 
agents. A: Example whole-cell voltage-clamp traces showing control applications of GABA, 
and subsequent modulation by co-applied GABAAR positive modulators: broadly β-selective 
propofol, β2/3-selective etomidate, and β1-selective negative modulator SCS. B: Direct 
GABAAR activation (relative to controls shown in 8A) by propofol (n = 8, N = 2), and 
etomidate (n = 6, N = 1). C: GABAAR-mediated current is potentiated by propofol (n = 8, N = 




3.2.3 Assaying α-subunit identity 
 As illustrated above GABA-evoked currents are potentiated by diazepam 
which confirms the GABAAR population expressed by hECNs contain α1-, α2-, α3-, 
or α5-containing GABAARs (Olsen & Sieghart. 2009), where a conserved histidine 
residue not present in α4- and α6-subunits confers insensitivity to benzodiazepines 
(Wafford et al. 2004).  To rule out the possibility of the expression of α4- and α6-
subunits, GABA (EC30)-elicited currents were shown to be insensitive to the α4/α6-
subunit containing GABAAR inhibitor furosemide (100 µM; Figure. 3.7B, traces in 
3.7A; (Knoflach et al. 1996; Wafford et al. 1996).   
 The observed low GABA and muscimol potencies (Figure. 3.2B) argues 
against the expression of α4-, α6-, and also, α5-subunits, which typically display 
comparatively high GABA potency (Karim et al. 2013; Mortensen et al. 2011).  To 
identfiy the α subunit subtype we then examined the actions of zolpidem (50 nM and 
500 nM), which exhibits selectivity for α1-containing GABAARs with lesser potency 
at α2- and α3-containing GABAARs and negligible activity at α5-containing 
GABAARs (Sanna et al. 2002).  Co-application of zolpidem to GABA (EC10)-
evoked currents resulted in only a mild potentiation of control currents (Figure. 
3.7B, traces in 3.7A; 50 nM: 46 ± 10 %, p = 0.003 vs control; 500 nM: 70 ± 10 %, p 
= 0.002 vs control; paired t-tests) indicating the GABAAR population expressed by 



















      
Figure 3.7. Modulation of GABAARs by zolpidem, and furosemide. A: Example whole-
cell voltage-clamp traces showing GABAAR current elicited by  control applications of GABA 
(at concentrations indicated), and the same concentration of GABA co-applied with a 
modulator at the concentrtations and times indicated. B: Mean percentage modulation of 
GABAAR currents by the modulators furosemide (n = 6, N = 1; 100 µM), and zolpidem          





 Further to the above measures, RNA sequencing and analysis on GABAAR 
subunits at 35 DIV was conducted by J. Qiu and O. Dando of the Hardingham, and 
Kind labs respectively. Figure. 3.8 shows the relative mRNA expression levels of 
GABAAR subunits (normalised to expression of the β3 subunit). These sequencing 
data are in strong agreement with the established pharmacology of GABAARs 






























Figure 3.8. Graph showing RNA sequencing of hECNs for GABAAR subunit 
expression levels. Analysis conducted by O. Dando, using data supplied on hECNs by G. 












3.3 Characterisation of ionotropic, strychnine-sensitive glycine 
receptors (GlyRs) expressed by hECNs 
 GlyRs are a pentameric ligand-gated ion channel assembled from 5 possible 
subunits (α1-4, β), and are highly expressed in cortical development (Lynch et al. 
2009). During embryonic development, the α2 homomeric isoform dominates, with 
the α1β isoform being expressed predominantly in adulthood. Recent discoveries 
concerning GlyRs in the CNS suggest their role in embryonic cortical development 
may be more extensive than previously understood, with indications they may play a 
role in neurodevelopmental disorders such as Schizophrenia and Autistic Spectrum 
Disorders, as well as some forms of temporal lobe epilepsy (Avila et al. 2013a). 
3.3.1 Assessment of agonist potency at GlyRs expressed by hECNs 
 Similar to GABA, hECNs at DIV 35 exhibited robust responses to 
applications of glycine. The potency of glycine at hECN GlyRs was assessed by 
conducting concentration-response experiments similar to previous descriptions; 
initially, 3 control responses were elicited by glycine (300 µM),  ascending 
concentrations of glycine were applied (3 µM – 3 mM), and a final control 
application of glycine to end the recording. Fitted curves to mean normalised 
responses to glycine yielded an EC50 of 167 ± 20 µM (Figure. 3.9B, traces shown in 
3.9A). 
  Glycine-evoked (500 µM) currents were blocked fully by strychnine in a 
concentration-dependent manner with an IC50 of 630 ± 59 nM (n = 5, N = 2; 
Figure. 3.10B, traces in 3.10A). Note that an increased agonist concentration (EC85), 
rather than the typical EC50, was used to elicit suitable current responses to measure 
antagonist effects. The composition of the expressed GlyRs was probed using 
picrotoxin, which exhibits selectivity for homomeric over heteromeric GlyR forms, 
as the inclusion of the β subunit into the GlyR results in a reduction in sensitivity to 
picrotoxin (Pribilla et al. 1992; Wang et al. 2006; Lynch, 2009). Inhibition of GlyRs 
by picrotoxin (Figure. 3.10B, traces in 3.10A) gave an IC50 of 197 ± 22 µM (n = 5, 




that the majority of these receptors are heteromeric assemblies of α and β subunits. 
Interestingly, while the observed EC50 for glycine at the GlyR is roughly on the 
order of previous reports (approx. 100 µM – 300 µM; See De Sant-Jan et al. 2001), 
though the IC50 values for picrotoxin, and strychnine, were higher than expected. 
Typical values are on the order of 10 µM – 100 µM for picrotoxin (see Mangin et al. 
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Figure 3.9. Assessment of agonist potency at GlyRs expressed on hECNs. A: Example 
whole-cell voltage-clamp traces showing 3 initial control amplitudes of agonist followed by 
experimental concentrations (at time and concentration shown) and final control application 
of agonist to indicate comparable access resistance to the start of the recording. B: 
Concentration-response curve for applied agonist glycine. Dashed lines indicate EC50 value 
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Figure 3.10. Assessment of antagonist potency at GlyRs expressed on hECNs. A: 
Example whole-cell voltage-clamp traces showing 3 initial control amplitudes of agonist 
followed by experimental concentrations (at times and concentrations indicated). B: mean 
inhibition curves (dashed lines) for GlyR antagonists picrotoxin (IC50 = 197 ± 22 µM; n = 5, 
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Figure 3.11. mRNA sequencing of hECNs for GlyR subunit expression levels. Analysis 
conducted by O. Dando, using data supplied on hECNs by G. Hardingham. mRNA 
expression levels are normalised to α2 expression. 
 
 Additional GlyR characterisation was performed with RNA-seq analysis of 
GlyR subunit mRNA transcripts in hECNs at 35 DIV as described previously. Both 
α2 and β subunits were highly expressed at the mRNA level, whilst α1 and α3 
subunits were nominally or weakly expressed, respectively, relative to α2 subunit 
expression (Figure. 3.11). α4 subunit mRNA was not detected as expected given its 
status as a pseudogene in humans (Lynch, 2009). Collectively, these data suggest a 










3.4 Discussion on characterisation of GABAARs and GlyRs in hECNs 
 Changes in GABAAR subunit composition across development have been 
observed previously in other work, such that a characteristic isoform is expressed 
almost exclusively in cortical regions during embryonic development (Laurie et al. 
1997, Fritschy et al. 2005). This isoform is composed of α2/3β3γ2 subunits, and has 
a typical response profile to pharmacological assay. Collectively, the above results 
demonstrate that this isoform predominates in GABAAR populations on hECNs. In 
light of relative abundances for GABAAR subunit mRNA expression in hECNs, a 
low potency for GABA suggests α2/3 expression, responses to diazepam indicate the 
presence of a γ2-subunit, and responses to etomidate indicate the expression of the 
β3 subunit. Notably, the use of agents which select for GABAAR subunits atypical in 
embryonic development yielded nominal responses. These findings on responses are 
supported at the transcript level by an mRNA screen indicating low relative mRNA 
expression levels for these subunits (e.g δ-subunit or β1).  
 Interestingly, due to the method of drug delivery, by exchanging the bath 
aCSF to another aCSF source containing pharmacological agents, it is possible that 
some α1 –subunit expression occurs and that the bath exchange time is sufficiently 
slow to activate and de-sensitise the α1 –subunit containing GABAARs, as α1 –
subunit containing GABAARs typically show extremely rapid desensitisation 
(Bianchi & MacDonald. 2002). Under ideal conditions the extracellular fluid in the 
bath is encouraged to flow across the cellular material under study, providing as 
rapid an exchange time between extracellular fluid without a pharmacological agent 
present, and that of an extracellular fluid with an agent which produces the effect 
that the experiment aims to measure. Typically in whole-cell recordings from cell 
culture, this effect is produced using a rapid flow rate which hECNs do not tolerate 








 As a result, flow rate was maximised and allowed an onset time of less than 5 
seconds in all recordings. While RNA sequencing shows that the presence of α1-
subunits is likely to be relatively low, it cannot be discounted that a population of 
desensitised α1 –subunit containing receptors may be present but unobserved. Given 
that zolpidem did potentiate responses somewhat more than expected, the possibility 
of α1 at the GABAAR as a small sub-population of receptors seems more likely.  
 Assays of the GlyR isoform expressed on hECNs demonstrated robust GlyR 
responses with sensitivity to strychnine, a defining characteristic of GlyRs on 
cortical neurones. The observed potency of picrotoxin shows inclusion of the β-
subunit into the GlyR complex, a finding more typical of maturity, however, relative 
mRNA expression levels for the typical counterpart of the β-subunit, the α1- subunit, 
were unexpectedly low. Instead, it is apparent that GlyRs expressed on hECNs are 
composed of α2β. Previous work (Okabe et al. 2014) has shown this isoform to be 
transiently expressed in cortical tissue during early postnatal development, however, 
which suggests a developmental identity for GlyRs expressed on hECNs, though 
little is known as to the precise role of α2β (Lynch. 2009).  
 Additionally, it is worthy of note that the methods used to apply 
pharmacological agents vary in terms of the speed at which an agent is delivered to 
the receptor. Crucial, however, in interpreting the results of these experiments is the 
idea that the “typical” adult GABAAR isoform of α1β2/3γ2 readily desensitises on a 
much shorter timescale than the typical onset time. Thus, the experimental results 
may not reflect the true complement of possible α1- containing GABAARs, however, 
given the relative lack of potentiation by zolpidem at high concentrations, and 
relatively low mRNA transcript levels for α1 GABAAR subunits, a significant 










 Also, RNA-sequencing, while undeniably a powerful tool for examining a 
plethora of physiological processes, also must be taken with some caveat in that the 
detection of an mRNA signal (termed “reads”) is established by mapping the 
detected amino acid sequences of mRNA to known sequences from mapping to 
known sequences expressed by human cells. Thus, it does not measure the protein 
product, as proteins can be altered or degraded in a variety of ways before functional 
assembly into a protein isoform is performed. As such, RNA sequencing speaks to 
the potential for a predicted protein product to be formed (in this context GABAARs 
and GlyRs). This being said, the RNA-sequencing data suggests high expression of 
receptor isoforms that are supported strongly by the attendant pharmacology.   
 
3.4.1 Modelling the role of GABAARs in development and disease using 
hECNs 
 GABAARs have been shown to be instrumental in normal neuronal 
development, leading to the description of GABA as a ‘pioneer’ neurotransmitter 
(Ben-Ari et al. 2007). In embryonic development across a wide array of mammalian 
species, GABA-ergic transmission precedes glutamatergic transmission in early 
neuronal networks due to rapid interneurone maturation, occurring as early as E18 in 
rodents (Ben-Ari et al. 2004; Ben-Ari et al. 2007).  
 Interestingly, the initial activity of GABAARs is depolarising, or shunting in 
nature, which later in development (postnatal day 5-7 in rodents) becomes excitatory 
(Ben-Ari et al. 2004). Cortical excitatory neurones exhibit a characteristic decrease 
in intracellular Cl- across development (see Kaila, et al. 2014). This is achieved by 
the activity of Cl- transporter proteins, Na+-K+-Cl- co-transporter 1 (NKCC1) and 
K+-Cl- co-transporter 2 (KCC2). These transporters utilise Na+ and K+ gradients 
across the cell membrane to drive Cl- ions into the cell (NKCC1), or out of the cell 
(KCC2). In normal development, NKCC1 is the dominant Cl- transporter in 
embryonic cortical neurones yet as postnatal maturation progresses, an isoform of 




predominantly expressed. Post-natally, GABAAR activation causes a net influx of 
Cl- ions, leading to a more negative membrane potential, whereas in early 
development, the elevated intracellular [Cl-] causes the reversal potential of the 
GABAAR to shift to a value close to, or above that of the RMP (Ben-Ari et al. 
2004). 
 This shift in the action of GABA across development has also been confirmed 
in hECNs using an identical protocol to that used to produce hECNs used in this 
thesis. Intracellular Cl- activity (a measure dependent on intracellular [Cl-]) in 
hECNs falls from around 25 mM to <7 mM in hECNs (Livesey et al. 2014). This 
suggests a reliable platform for modelling neurodevelopmental conditions associated 
with impairments in Cl- co-transporter expression such as Rett syndrome (Tang et 
al. 2015; Chao et al. 2016), and psychotic disorders (Kalkman et al. 2011; Arion et 
al. 2011). 
 Interestingly, hECNs do not show any change in receptor subunit expression. 
Typically, α2/3 expression in early development switches to a predominantly α1 –
containing isoform post-natally (Laurie et al. 1992; Fritschy  et al. 1994), which 
does not occur in hECNs in culture at 5 weeks, or for longer periods (7 weeks). 
Given that the intracellular [Cl-] at these later time-points describes a mature-like 
identity, the GABAAR subunit switch does not occur, indicating incomplete 












3.4.2 Modelling the role of GlyRs in development and disease using 
hECNs 
 The GlyR, like the GABAAR, is an anion channel, conducting primarily Cl- 
ions. As a result, the previous description for Cl- -transporter proteins also applies 
(see above, Chapter 3.4.1). Typically in early development, GlyRs activation results 
in excitation or shunting which becomes an inhibitory action at P5-7.  
 The established GlyR isoform expressed on hECNs at 5 weeks in culture is 
that of α2β, an isoform that typically dominates, albeit transiently in the early 
postnatal period in rodents (Okabe et al. 2004). While it is suggested (Lynch, 2009) 
that the α2β receptor is not essential for neuronal functioning from studies in 
knockout mice, it remains to be seen as to the potential developmental function of 
this specific receptor isoform. It has been shown that the α2β GlyR co-localises with 
gephryin (Haverkamp et al. 2004), a synaptic protein that localises GlyRs and 
GABAARs to synapses (Essrich et al. 1998; Giesemann et al. 2003). As such, this 
receptor isoform may serve a more subtle developmental function, though the tools 






































4.1 Motivations for study 
 A mutation in the Disrupted in schizophrenia 1 (DISC1) gene was originally 
identified from a Scottish family that co-segregated with schizophrenia, bipolar 
disorder and major depression (Millar et al. 2000; Millar et al. 2005). The mutation 
is a balanced translocation at the (1;11)(q42;q14.3) locus and yields a truncated 
DISC1 protein (A schematic of the truncated DISC1 protein is given in Figure. 4.1.). 
Other mutations are also known to be associated with psychiatric disorders and 
autism (Thomson et al. 2013). DISC1 is expressed widely in the adult and 
developing brain including the cortex and hippocampus, and in both excitatory and 
inhibitory neurones (Schurov et al. 2004). Furthermore, the DISC1 protein is widely 
intrinsically expressed within both inhibitory and excitatory neurones, particularly at 
or near the synapse, and participates in cellular proliferation, migration, neurite 
outgrowth and cell-to-cell adhesion, and other processes that regulate neural 
development via many potential signalling pathways (Bradshaw & Porteous. 2012). 
Much of this research has been performed upon rodent models and knowledge of 
DISC1 in normal human neuronal function and disease is lacking. Thus, following 
on from findings in animal models and elsewhere, hECNs derived from patients 
harbouring this mutation presents a unique opportunity to examine human tissue for 
previously observed pathophysiology associated with this DISC1 mutation.  
 Association studies have shown a link between genetic variations of DISC1 
and specific endophenotypes that are commonly associated with schizophrenia, 
depression, and bipolar disorder (Brandon & Sawa. 2011; Callicott et al. 2005; 
Cannon et al. 2005; Carless et al. 2011; Prata et al. 2008). During early 
development, DISC1 affects cellular proliferation via glycogen synthase kinase 3-
regulated WNT activity and post-differentiation neuronal migration by interacting 
with microtubules and the centrosome (Ishizuka et al. 2011; Kamiya et al. 2005; 
Mao et al. 2009). Additionally, inn the adult brain, DISC1 regulates neurogenesis 







Figure. 4.1. Schematic representation of the DISC1 protein. Of note is the dotted line 
indicating the (1;11)(q42;q14.3) breakpoint at which the DISC1 protein is truncated. The 
schematic highlights the DISC1 interaction sites of selected proteins that are involved in 
neuronal physiological processes. In this regard, the DISC1 truncated protein loses 
interaction sites for NDEL1 and FEZ1 Splice variants are not included in this schematic. 
(adapted from Newburn et al. 2011). 
 
 It is hypothesised that mutations in DISC1 result from a marked decrease of 
DISC1 protein product, and result in disrupted physiological neuronal function 
leading to an imbalance in the excitation/inhibition state in the pre-frontal cortex that 
may underlie the observed disease phenotypes (Bradshaw & Porteous. 2012; 
Lisman. 2012). Previous work has shown that DISC1 mutations result in altered K
+
-
channel expression in rodent cortical neurones as mediated by PDE4, which binds to 
the PDEZ domain labelled in Fig. 4.1 (Small conductance calcium-activated K
+ 
channels, El-Hassar et al. 2014; KCNQ5, Ozeki et al. 2003) and intrinsic neuronal 
excitability (Gamo et al. 2013) changes in neurotransmitter receptor expression and 
function (Akbarian et al. 1995; Callicot et al. 2013; Kim et al. 2012; Wright & 
Vissel 2012; see Hammond et al. 2010). Note also the GSK3β interaction site, which 
has been shown to affect gene transcription and cell proliferation. If mis-folded or 
under-produced DISC1 protein were to impact this, it may also affect the broader 
maturation of neuronal processes such as changes in ion channel complement. 
 Additionally, the excitatory post-synaptic density is heavily enriched for 
DISC1 (Kirkpatrick et al. 2006), where it has been shown to regulate dendritic spine 




AMPA receptor synaptic trafficking via the 7-Rac1-PAK pathway (see Hayashi-
Kagaki et al. 2010). DISC1 also regulates the maintenance of synapses by 
interacting with NCK-interacting protein kinase (Wang et al. 2011) and exerts an 
important effect on NMDA receptor expression and function through a mechanism 
depending on the transcription factor cAMP response element binding protein (Wei 
et al. 2014). 
 Crucially, many basic functional properties of human cortical neurones 
harbouring the DISC1 mutation remain to be described and iSPC technology offers a 
valuable opportunity to address this. Experiments in this chapter were conducted in 
order to explore the functional properties of two lines of hECNs each separately 
derived from iPSCs obtained from clinically-defined patients carrying the DISC1 
mutation (1;11)(q42;q14.3) with respect to two lines of equivalently derived hECNs 
from healthy (familial) patients. Work was carried out to confirm that these hECNs 
indeed harboured the mutation and minimally expressed the truncated or fully 
expressed a normal DISC1 protein, respectively (performed in the laboratories of 
Professor S .Chandran and Dr. K.  Millar, both University of Edinburgh). Data sets 
for control- and mutant DISC1- case derived hECNs (hereafter referred to as 
‘Control’ and ‘Case’, respectively), were pooled together as there was no statistical 
difference between data sets in Case or Control lines, for presentation of data 














4.2 Passive properties of DISC1 patient iPSC-derived hECNs. 
 Initial electrophysiological characterisation of hECNs derived from DISC1 
iPSCs was conducted at 7, 21, and 35 DIV time points (Figure.4.1) in order to 
observe potential alterations in development in Case lines with respect to control 
lines. Typical patterns of maturation investigated in terms of the intrinsic properties 
of hECNs between DIV 7 and DIV 35 indicated that there was no notable difference 
between Case and Control hECNs.  Input resistance measurements decreased 
(Figure. 4.1A), though not significantly (Student’s t-test; Control p=0.56 and Case 
p=0.13). The mean resting membrane potential (RMP) in each line became more 
hyperpolarised with time (Figure. 4.1B), though again not significantly (Student’s t-
test; Control p=0.65 and Case p=0.22). From 7 DIV to 35 DIV, whole-cell 
capacitance significantly increased (Student’s t-test; Control p=0.0002 and Case 
p=0.0002) in both Control and Case to similar levels (Figure. 4.1C). These data are 
consistent with a maturing neuronal profile, but no significant differences were 
found between Case and Control at any time point studied (Student’s t-test, 
minimum p=0.15 for each parameter studied). Importantly, the mean values of 
passive properties obtained at all time points are not what are expected of adult 
cortical neurones (Moody & Bosma. 2005); input resistance measurements are 10-
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Figure. 4.2, Passive membrane properties of DISC1-iPSC-derived neurones at 7, 21 
and 35 DIV as established using whole-cell patch-clamp. For all panels, Control; n= 14-
21, N=2, Case; n= 10-20, N=2. A: Mean input resistances of Control and Case hECNs. 
Input resistance was established from the mean passive membrane current amplitude 
generated from thirteen sequential -50 mV pulses. B: Mean resting membrane potential 
(RMP) of Control and Case hECNs. C: Mean whole-cell capacitance of Control and Case 












4.3 Firing properties of mutant DISC1 Case and control iPSC-derived 
hECNs. 
 In order to examine the potential for more subtle, yet general, developmental 
pathology, both DISC1 Control and Case hECNs were examined with regard to their 
firing properties. Initial study in this area was focused on categorising the firing 
behaviour of neurones at 7, 21, and 35 DIV.  Neurones were held at -70 mV (-84 
mV) in the current-clamp configuration (see Methods) and depolarised by 
incremental current pulses of 10 pA of 500 ms duration. Responses were assigned to 
one of four categories describing action potentials (A.P.) detailed in Figure. 4.3A; 
“no response”, “failed initialisation”, “single” and “burst”. “No response” indicates 
the lack of any response beyond the passive membrane response. “Failed 
initialisation” describes the mutual presence of two essential characteristics: a spike 
without a characteristic afterhyperpolarisation (A.H.P.), and of below 20 mV 
amplitude. A “single” A.P. categorisation was applied when a spike exceeded 20 
mV and possessed an A.H.P. which undershot the plateau phase of the voltage 
response. Categorisation of a “Burst” was described as the firing of more than one 
A.P. in response to a rheobasic current injection. The results of this study are 
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Figure. 4.3, Characterisation of firing properties in DISC1 iPSC-derived neurones 
using whoce-cell patch-clamp. A: Example traces illustrating action potential categories 
(signified by labels accordingly), which indicates functional development of action potentials 
in DISC1-hECNs. B: Graph showing development of DISC1-hECNs by proportional change 
in percentage responses of each AP category in Control (n= 15-17, N=1-2) and Case (n= 7-






 Resultant data gathered from Case and Control showed a progressive increase 
in the proportion of cells which fired at least 1 A.P. in response to a rheobase current 
injection, with almost all neurones firing at least 1 A.P at 35 DIV (Fig 4.3B); by 35 
DIV, 87% of Control neurones (n=15, N=1) fired at least 1 A.P. while 89% of Case 
neurones did the same (n=9, N=1). No notable difference was observed across the 
general firing properties of the Case and Control hECNs. Theis observed pattern of 
results is similar to developmental timelines previously detailed in studies of hECNs 
derived from other human pluripotent stem cells (Bilican et al. 2014).. 
 Further to this, parameters of the A.P. were also measured, namely, amplitude 
(Figure. 4.4), threshold for A.P. generation (Figure. 4.5), half-width (Figure. 4.6; the 
width of an action potential at half of its peak amplitude, in ms), and size of after-
hyperpolarisation (A.H.P; Figure. 4.7.). These measures were taken from either 
single A.P.s, or in the case of burst firing, the first A.P. of the barrage elicited by the 
rheobase. Collectively, these results show no statistical difference (minimum 
p=0.21) between Case and Control in any A.P. parameter observed. In terms of the 
development of neural properties in vitro, here between DIV 7 and DIV 35, A.P.s in 
both Case and Control became faster with a reduced half-width (Control, p=0.37; 
Case, p=0.06. Student’s t-test), and an increase in amplitude (Control, p=0.05; Case, 
p=0.04; Students t-test). No significant development was observed for A.P. threshold 
(Control, p=0.30; Case, p=0.84. Students t-test) and A.H.P (Control, p=0.09; Case, 







































Figure. 4.4, Development of action potential amplitude in Case and Control hECNs 
across time in culture: Whole-cell current-clamp A.P amplitude was determined from the 
threshold potential to the maximum voltage deflection. From DIV 7 to DIV 35, mean 
amplitude of A.P.s increased progressively (Control, n= 7-19, N=1-2, p=0.05; Case, n= 3-13, 




































Figure. 4.5, Development of action potential threshold in Case and Control hECNs. 
Threshold was established in whole-cell current-clamp by pulsed rheobasic current input as 
described in Chapter 2: Methods & Materials. From DIV7 to DIV35, mean A.P. threshold did 









































Figure. 4.6, Change in action Potential half-width across development in Case and 
Control DISC1-hECNs. Values established by whole-cell current-clamp using APs elicited 
by pulse rheobasic current injection as described in Chapter 2: Methods & Materials). From 
DIV7 to DIV35, mean A.P. half-width did not change significantly (Control, n= 7-19, N=1-2, 











































Figure. 4.7, Action potential after-hyperpolarisation (AHP) in Case and Control DISC1-
hECNs: The after-hyperpolatisation (AHP) value was measured from the peak of the rising 
phase of the AP to its peak hyperpolarisation in whole-cell current-clamp (See Chapter 2: 
Methods & Materials). From DIV7 to DIV35, mean A.P. threshold did not change 


















4.4.1 Characterisation of neurotransmitter receptors expressed by 
Control and mutant DISC1 Case hECNs  
 A key feature of cortical excitatory neurones’ development is response to 
neurotransmitters such as GABA and glutamate, a property that has since been 
replicated in hECNs (Bilican et al. 2014). To that end, responses to GABA, AMPA, 
and NMDA were examined, along with a basic characterisation of GABAAR, 
AMPAR, and NMDAR subunit composition. Collectively, these types of receptors 
are the primary mediators of neurotransmitter-mediated excitation and inhibition, 
with a balance between the two being suspected to be disrupted in schizophrenia 
(Gamo et al. 2013), which may have correspondent neuropathology reflected in the 
behaviour of these receptors.   
4.4.2 Characterisation of GABAAR-mediated responses, and GABAAR 
subunit composition. 
 Recently, DISC1 has been shown to be involved in the regulation of GABAAR 
trafficking in cortical pyramidal neurones (Wei et al. 2015). GABAARs are 
assembled in the endoplasmic reticulum, and are then trafficked to the Golgi 
network. They are then transported along microtubules on dendrites and inserted into 
extra-synaptic sites, where they diffuse laterally into synapses (see Wei et al. 2015). 
It is suspected that that DISC1 exerts a critical effect on GABAergic inhibitory 
transmission by regulating microtubule motor protein kinesin 1-mediated GABAAR 
trafficking in the cortex (Twelvetree et al. 2010; Yuen et al. 2012). Crucially, 
knockdown of DISC1 results in a decrease in whole-cell GABAAR expression, as 
well as at the synapse, while overexpression results in an increase in whole-cell 
GABAAR expression, and also at the synapse (Wei et al. 2015). As the DISC1 
(1;11)(q42;q14.3) mutation has been associated with a lack of DISC1 protein 
product, it is thus highly possible that GABAAR expression in hECNs harbouring the 





 Furthermore, previous studies demonstrate the involvement of the α2 and α3 
GABAAR subunits in cognition in schizophrenia, with positive allosteric modulators 
selective for these subunits improving markers of cognition that are shown to be 
affected in schizophrenia (Lewis et al. 2005, also see Rudolph & Mohler. 2014). 
Given this and that previous work has indicated that hECNs show substantial 
GABAAR expression, which are likely composed of α2/3β2/3γ2 (see Chapter 3.2.1; 
James et al. 2014), initial experiments examined the current density of GABA (300 
µM) responses at 35 DIV in Case and Control hECNs (Fig, 4.8 A,B). Responses to 
GABA, at a cell holding potential of 0 mV (-14 mV) were blocked by GABAAR 
antagonist, bicuculline (not shown). The current densities of GABAAR-mediated 
responses did not significantly differ between Case and Control lines (p=0.57), with 
all cells responding to GABA.  
 A decreased level of γ2 subunit mRNA has been observed in the frontal cortex 
in schizophrenia (Akbarian et al. 1995b; Huntsman et al. 1998), with little effect on 
γ1- and γ3- subunit expression (Ishikawa et al. 2004a). Potential alterations in 
expression of other subunits were examined by the effects of diazepam (γ-subunit 
selective) on GABA-mediated currents and responses to gaboxadol (δ-subunit 
selective). Diazepam (30 nM) mildly potentiated currents in both Control and Case 
hECNs, with strong potentiation achieved at a higher diazepam concentration (3 
µM) in both Control and Case hECNs (no statistical difference observed, p=0.62, 
Student’s t-test; Figure. 4.8C). Gaboxadol (3 µM) elicited nominal current relative to 
currents elicited by a saturating concentration of GABA (3 mM), while a higher 
concentration of gaboxadol (300 µM) showed little further activation in both Case 
and Control lines. No statistical difference was observed between Case and Contol 
(p=0.51, Student’s t-test; Figure. 4.8D). Collectively, these data suggest that 
GABAARs are not expressed differently in terms of total expression or composition 
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Figure. 4.8, GABAAR mediated responses in Case and Control hECNs at 35 DIV. A: 
Trace showing a whole-cell voltage-clamp (0 mV; -14 mV LJP corrected) current response 
to bath applied GABA (300 µM). B: Mean whole-cell GABAAR current densities (pA.pF) 
elicited by GABA (300 µM) are not significantly different between Case and Control hECNs 
(Control, n= 6-8, N=1-2; Case, n= 5-8, N=1-2). C: Mean potentiation of whole-cell GABAAR- 
mediated responses by diazepam (30 nM and 3 µM) in Case and Control DISC1-hECNs 
(Control, n= 3, N=1; Case, n= 3, N=1). D: Mean responses to δ-subunit selective GABAAR 














4.4.3 Examination of intracellular Chloride [Cl-] concentration 
 
 Cortical excitatory neurones exhibit a typical decrease in intracellular Cl
-
 
across development, a process which has been shown to be critical to normal 
development and maturation (see Kaila, et al. 2014). This is achieved by the use of 
Cl
-















 gradients across the cell 
membrane to drive Cl
-
 ions into the cell (NKCC1), or out of the cell (KCC2). In 
normal development, NKCC1 is the dominant Cl
-
 transporter in fetal cortical 
neurones, however, as postnatal maturation progresses, an isoform of KCC2 
(KCC2b, Uvarov et al. 2006, Blaesse et al. 2009) Cl
-
 transporter rapidly dominates.  
This results in a hallmark developmental profile for neuronal tissue; when NKCC1 is 
dominant in early development, intracellular [Cl
-
] is known to be relatively high 
(approximately 25 mM), with the Cl
-
 reversal potential tending to be less negative 
than the neurones R.M.P. Thus, when a GABAAR is opened, the membrane potential 
depolarises to the reversal potential of chloride, sometimes resulting in excitation 
(Ben-Ari et al. 2007).  With development KCC2b expression increases dramatically 
leading to an increase in the relative expression of KCC2b with respect to NKCC1 
leading to a net extrusion of Cl
-
 and a reduced intracellular [Cl
-
] (approximately 5-10 
mM in adult excitatory neurones). The Cl
-
 reversal potential therefore becomes more 
negative and GABAAR (or GlyR) activation results in a net Cl
-
 influx and a 
hyperpolarising response (Blaesse  et al. 2009). 
 Importantly, perturbed GABAAR–mediated signalling has been implicated in 
diseases such as Rett syndrome. Previous studies using iPSC-derived neuronal 
material demonstrated an under-expression of KCC2 causing persistent GABA-ergic 
neuronal excitation, and showed a rescue to an unaffected phenotype (Tang et al. 
2015). Intracellular chloride is also implicated in schizophrenia via dysregulation of 
intracellular chloride transporter activity that may disrupt normal development of 
neuronal networks by altering the overall balance between excitation and inhibition 
(Kalkman et al. 2011; Arion et al. 2011). The previously observed phenotype in 
Schizophrenia is that NKCC1 expression is aberrantly increased in development, 
resulting in an increase in intracellular [Cl
-




previous findings about Cl
-
 transporters in hECNs (Livesey et al. 2014), showing 
that intracellular [Cl
-
] decreases across development to a ‘mature-like’ state, it is 
thus plausible to examine the intracellular [Cl
-
] in Case and Control hECNs for any 
Cl
-
 transporter-related pathophysiology. Notably, to obtain this reduction in 
intracellular [Cl
-
] hECNs were maintained in media lacking neurotrophic factors 
(BDNF and GDNF), which are known to the influence intracellular [Cl
-
], and 
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Figure. 4.9. Using perforated patch-clamp technique to elicit GABAAR responses, and 
assaying intracellular [Cl-] activity in Case and Control DISC1-hECNs at 7, 35 and 49 
DIV. Significance; *** indicates p=<0.001. A: The holding potential at which GABA 
application ceased to evoke a response was determined to be the reversal potential at the 
GABAAR (GABA Erev). GABA Erev was then used to calculate intracellular [CI
-
] using the 
Goldman-Hodgkin-Katz equation, and subsequently to adjusted to give apparent 
thermodynamic activity. B: Trace showing current-clamp recordings of GABA responses 
from Case at 7 and 49 DIV..C: Mean GABA reversal potentials (GABA Erev) in Control and 
Case lines (Control, n= 3-6, N=1-2; Case, n= 3-6, N=1-2). D: Intracellular Cl
-
 activity (mM) in 





































































 Here, the perforated patch-clamp technique using gramicidin (75 – 100 µg.ml) 
in the patch pipette solution was used to measure intracellular [Cl
-
] in hECNs (see 
Methods 2.3.3). Gramicidin has an ability to perforate the cell membrane and 




) but not Cl
-
, 
therefore this technique allows electrical access to the intracellular compartment of 
the cell whilst maintaining intracellular [Cl
-
] (Owens et al. 1996). GABAAR-
mediated responses were elicited with applications of GABA (300 µM) and the 
holding potential was adjusted until no current was passed upon GABA application, 
indicating no net flow of Cl
-
 in or out of the cell and the reversal potential for Cl
- 
at 
the GABAAR. Fig 4.9A shows GABA applications at varying holding potentials and 
the respective current response, while Figure. 4.9B shows current-clamp recordings 
from a Case hECN at 7 and 49 DIV showing the shift in the nature of membrane 
potential responses to GABA application over time.  
 Figure. 4.9C shows mean GABAAR reversal potentials in DISC1 Case and 
Control hECNs. In line with native excitatory cortical maturation, increasingly 
negative reversal potentials for the GABAAR was observed between 7 DIV and 49 
DIV in Control (-49.1 mV ± 1 mV, n=3, N=1, to -58.6 mV ± 0.8 mV n=6, N=2; 
p=<0.0005) and Case (-49.2 mV ± 1 mV, n=3, N=1, to -57.6 mV ± 0.8 mV, n=6, 
N=2; p=<0.0003), in line with previously published work on hECNs (Livesey et al. 
2014) and others concerning Cl
-
 transporter maturation (Uvarov et al. 2006, Blaesse 
et al. 2009), with no statistical differences being observed between Case and Control 
lines (minimum p=0.51, Student’s t-test). These reversal potential values were 
entered into the Nernst equation to yield intracellular [Cl
-
]. Note that Cl
- 
concentrations were then corrected for thermodynamic activity in line with the 
Guggenheim convention (Activity factor 0.77, Kielland, 1937).  
 Briefly, the Guggenheim convention describes the behaviour of ions in 
solution as thermodynamic activity as determined by concentration, as opposed to 
purely concentration alone. An intuitive description would be to say that as the 
concentration of ions in a solution increases, past a point those ions will begin to 
occlude each other, reducing their actual activity i.e. thermodynamic activity, which 
determines the physiological phenomenon being observed. This is useful because the 




and when interpreting our assumed concentration, we must then apply the idea that 
the ionic concentration that is determined by the Nernst equation must be amended 
in terms of the thermodynamic activity of the ion species under consideration.  
 Figure. 4.9D shows intracellular Cl
-
 activity in mutant DISC1 Case and 
Control hECNs. A typical reduction in intracellular Cl
-
 activity was observed 
between DIV 7 and DIV 49 in both Control (19 ± 0.7 mM, n = 3, N = 1, to 13 ± 0.6 
mM, n = 6, N = 2; p=<0.0005, Students t-test) and Case (21 ± 0.8 mM, n = 3, N = 1, 
to 14 ± 0.5 mM, n = 6, N = 2; p=<0.0003, Students t-test). These results show no 
statistical difference in intracellular Cl
-
 activities between Control and Case at any 


























4.4.4 Characterisation of NMDA receptors. 
 Previous reports implicate the NMDA receptor (NMDAR) in schizophrenia, 
with NMDAR antagonists producing psychotic-like symptoms and NMDAR 
positive modulators ameliorating this to some degree (Coyle et al. 2012). Further to 
this, it has been shown that knock-down of DISC1 increased NMDAR-mediated 
currents in rodent cortical cultures (Wei et al. 2014). The expression of NMDARs 
was therefore intially examined in Case and Control hECNs. Whole-cell currents in 
35 DIV hECNs were elicited using NMDA (100 µM; in the presence of glycine, 50 
µM, Figure. 4.10A) and current densities calculated. Figure. 4.10B shows mean 
current densities at 35 DIV for both Case and Control hECNs and significant 
differences were observed in current density between Case and Control lines 
(p=0.86, Student’s t-test). All cells responded to NMDA and were blocked by 
NMDAR antagonist APV (not shown).  
 NMDAR subunit mRNA for various NMDARs has been shown to vary post-
mortem in the dorsolateral prefrontal cortex in humans with schizophrenia, with an 
unknown but suggested influence on NMDAR subunit stoichiometry (Weickert et 
al. 2013). NMDAR-mediated pathophysiology is also implicated in early 
developmental processes in Schizophrenia (see du Bois & Huang, 2007). 
Furthermore, Wei et al. (2014) determine that a DISC1 knock-out-mediated 
reduction in NMDAR expression in rodent cortical neurones is accompanied with an 
alteration in GluN2A subunit expression.  Importantly, NMDAR subunit 
composition in the forebrain changes from a predominant GluN1/GluN2B 
population in immature neurones to a mixed GluN1/GluN2A/GluN2B population in 
adults (Monyer et al. 1994; Watanabe et al. 1992; see Wyllie et al. 2013). To 
establish the possibility of NMDAR subunit changes in Case and Control hECNs the 
GluN2B subunit-selective NMDAR antagonist ifenprodil (3 µM) was used. 
Ifenprodil (3 µM) strongly blocked NMDAR-mediated currents (Figure. 4.10C) in 
both Control and Case hECNs, respectively, to 76.1% ± 3.3%, (n = 3, N = 1), and 
72.2%, (n = 3, N = 1; p=0.50, Student’s t-test). This data is compatible with data 
from ‘pure’ recombinantly expressed GluN1/GluN2B NMDARs (Kew et al. 1996), 
indicating the predominant expression of GluN2B subunit-containing NMDARs on 




































































Figure. 4.10. NMDAR-mediated responses in Case and Control hECNs. A: Trace 
showing whole-cell voltage clamp response to NMDA (100 µM, in the presence of glycine, 
50 uM) and block by ifenprodil (3 µM) as indicated by coloured bars. B: Mean NMDAR (100 
µM) current density (pA.pF; n = 3, N = 1). C: Mean block of NMDAR- mediated responses 











4.4.5 Characterisation of AMPA receptors 
 Previous work has suggested possible AMPA receptor (AMPAR) 
pathophysiology in Schizophrenia in general, primarily through expression, mRNA 
editing, and trafficking of different AMPAR subunits (Akbarian et al. 1995; Wright 
& Vissel 2012; see Hammond et al. 2010) and DISC1 (Hayashi-Takagi et al. 2010) 
specifically, thus highlighting the potential for studying altered AMPAR expression 
and composition in mutant DISC1 Case hECNs with respect to Control hECNs.                                                    
Initially, to characterise the functional expression of AMPARs on 35 DIV Case and 
Control hECNs, whole-cell currents were elicited using AMPA (100 µM; Figure. 
4.11A) and current densities were determined, using a whole-cell voltage-clamp 
holding potential of -60 mV (-74 mV). Figure. 4.11B shows the mean current 
densities at 35 DIV and no significant differences in current density were observed 
between Case and Control (Figure. 4.11B; p=0.54, Student’s t-test) .with all cells 













































Figure. 4.11. AMPAR mediated responses in Control and Case hECNs. A: Trace 
showing whole-cell response to AMPA (100 µM) at a holding potential of -74 mV. B: No 
difference in the mean AMPAR current density (pA.pF). Control, n=8, N=2; Case, n=5, N=2;. 
 
  
 The composition of the AMPARs expressed upon Case and Control hECNs 
was then investigated. The AMPAR has a tetrameric structure, potentially composed 
of 4 subunits (GluA1-4), with developmentally regulated subunit composition. In 
immature rodent, and human excitatory cortical neurons, GluA1/GluA4- containing 
AMPARs predominate, whereas mature neurons have an increased expression of 
GluA1 and GluA2 subunits (Talos et al. 2006a, 2006b; Orlandi et al. 2011, see 
Traynelis et al. 2012). In normal development, the GluA2 subunit is predominantly 
RNA-edited (Q → R), with an edited GluA2 subunit being strongly suggestive of a 
postnatal phenotype (Brill & Huguenard. 2008). Inclusion of at least one edited 
GluA2 subunit into the AMPAR tetramer imparts distinct biophysical properties 
including a lower single-channel conductance, insensitivity to channel-blocking 
spermines and Ca
2+
-impermeability (Swanson et al. 1997; Traynelis et al.2012). 
This has been shown to regulate Ca
2+
-mediated processes relating to neuronal 
excitotoxicity, and, interestingly may relate to possible calcium dysregulation in 
schizophrenia, and may contribute to the aberrant development of excitatory 
networks (Berridge. 2012). Thus, an age-dependent phenotype may exist in mutant 




AMPAR isoforms as evidenced by their AMPAR complement. Additional 
experiments were thus conducted to establish the likely AMPAR isoform expressed 
on Case and Control hECNs. 
 Alterations in AMPAR single-channel conductances are amenable to 
biophysical investigation using electrophysiological techniques. An estimate of the 
mean AMPAR single-channel conductance in hECNs at 35 DIV was made using 
non-stationary noise analysis. In the first, two simultaneous whole-cell voltage-
clamp recordings were made in each experiment, where the described AMPAR-
evoked responses in both Case and Control hECNs were made in AC and DC 
current formats (see Figure. 4.12A,B). For these experiments the extracellular 
recording solution was supplemented with cyclothiazide (20 µM), an AMPAR-
selective positive modulator that prevents AMPAR desensitization (Cowen et al. 
1998) to elicit larger responses. The resultant plot of AC-current variance against 
DC-current amplitude yielded a straight-line plot (example in 4.12C) from which the 
estimated AMPAR single-channel current amplitude was determined and single-
channel conductance calculated (Shown in Figure. 14.3D). Mean estimated single-
channel conductances for Case (2.3 ± 0.6 pS; n = 6, N = 1) and Control (2.3 ± 0.6 
pS; n = 4, N = 1) hECNs were identical (p=0.97, Student’s t-test).  This data 
indicates Case and Control hECNs display low AMPAR conductances typical of 
AMPARs that are edited GluA2 subunit-containing (Figure. 4.12D; Swanson et al. 
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Figure. 4.12, Non-stationary noise analysis of AMPAR-mediated currents in Case and 
Control hECNs at 35 DIV. A: Traces from a Case hECN showing a slowly-rising and 
decaying whole-cell (-60 mv; -74 mV LJP corrected) response to AMPA (50 µM); the upper 
trace shows the AC current recording and the lower shows the DC current recording. B: As 
in ‘A’ but for Case hECNs. C: Example current-variance plot. The relationship yields a linear 
relationship to which a straight line was fitted. The slope of the plot gave the estimated 
AMPAR single-channel current. D: Mean estimated AMPAR single-channel conductances of 











 Next, in order to confirm the presence of edited GluA2 AMPAR subunits, 
experiments were conducted to assess the sensitivity of AMPAR-mediated currents 
to the channel blocker 1-naphthyl acetyl spermine (NASPM, 3 µM; Koike et al. 
1997), which is selective for AMPARs that lack the edited GluA2 subunit. To 
examine NASPM block of AMPAR-mediated currents, I-V relationships in the 
presence and absence of extracellular applied NASPM were obtained (Figure. 4.13A 
and Figure. 4.13B). No receptor block was observed at negative or positive holding 
potentials in both Case and Control hECNs. This observed behaviour was quantified 
using ‘rectification index’ (RI; see Methods for details); a ratio of the conductances 
at a positive holding potential (+60 mV) and a negative holding potential (-100 mV). 
Rectification indices were calculated in the presence and absence of NASPM 
(Figure. 4.13C). Between Case (n = 3, N = 1) and Control (n = 3, N = 1), no 
significant differences were observed in the presence or absence of NASPM (p>0.1 
in all cases; Student’s t-test).  These data confirm the predominant AMPAR 
composition contains the edited GluA2 subunit in both the Case and Control hECNs 
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Figure. 4.13. NASPM sensitivity to AMPAR-mediated responses in Case and Control 
hECNs. A: Control hECN: leak subtracted I-V plot generated from an AMPAR-mediated 
steady-state response which was ramped from -100 mV to +60 mV for 1 s. B: As in ‘A’, but 
for Case hECNs. C: Mean rectification indices for AMPAR-mediated I-V plots obtained from 












 This study examines the functional properties of hECNs generated from 
patient-derived iPSCs harbouring a mutation to the DISC1 gene (1;11)(q42;q14.3) 
that is strongly associated with psychiatric disorders including schizophrenia. Such 
disorders are associated with an imbalance in the relationship of cortical cellular 
excitation to inhibition that are thought to underpin some of the psychiatric 
phenotypes (Akbarian et al. 1995; Bradshaw & Porteous. 2012; Gamo et al. 2013; 
Lisman. 2012; Callicot et al. 2013; Kim et al. 2012; Schurov et al. 2004; Wright & 
Vissel 2012; see Hammond et al. 2010). In essence, the properties examined with 
this study did not reveal any mutant DISC1-associated phenotypes with respect to 
control. 
4.5.1 Intrinsic excitability 
 Initially the intrinsic passive and firing properties of Case and Control hECNs 
were investigated across multiple time points in order to detect any potential 
developmental difference in excitability. The data in broad agreement with a 
developing neuronal phenotype (increasing whole-cell capacitance, increase in 
ability to fire and increase in amplitude and speed of action potentials) across all 
lines examined. The fact that no difference was found is consistent with a study 
where hippocampal CA1 neurones from a transgenic mouse expressing the 
equivalent truncated DISC1 protein also did not show any difference in the passive 
or intrinsic properties (Randall et al. 2014). Importantly, the properties of hECNs 
examined even at 35DIV are consistent with an immature neuronal profile; 
hyperpolarized RMP, high input resistance and low whole-cell capacitance, and are 
consistent with in vitro pluripotent stem cell derived neurones in general (see Kim et 
al. 2011; Pak et al. 2015; Scheglovitov et al. 2013). It maybe therefore plausible that 
in vitro hECNs may not have reached a sufficient level of maturity for excitability 
phenotypes to emerge. Moreover, hECN culture composition may not be sufficiently 
representative to the possibility that specific neurones of the cortex may exhibit 




nominal proportions of interneurones for which there is an important role in 
schizophrenia (Lewis et al. 2005). 
4.5.2 Neurotransmitter receptor expression and composition 
 The properties of major neurotransmitter receptors, AMPARs, GABAARs and 
NMDARs, were then investigated. The expression of GABAARs upon Case and 
Control hECNs was found to be statistically equivalent indicating that mutant DISC1 
does not influence GABAAR expression in hECNs. This is in agreement with a 
recent study examining mutant DISC1 protein in rodent cortical neurones which 
expressed equivalent levels of GABAARs versus controls despite knock down and 
over expression of the full DISC1 protein having opposing effects upon GABAAR 
expression (Wei et al. 2015). The previous results chapter determined that the 
composition of GABAARs was representative of the major immature GABAAR 
expressed in the immature cortex. Selected pharmacological analyses demonstrated 
that it is unlikely that GABAAR composition in Case and Control hECNs was 
different. Similarly, the NMDAR receptor expression in Case hECNs was not 
different from Control hECNs and the composition was pharmacologically 
determined using ifenprodil to be representative of a predominantly immature 
NMDAR cortical profile, i.e., GluN1/GluN2B-containing. Recently, Wen et al. 
(2014) report a modest increase in the GluN2B mRNA level, but not GluN1 protein 
levels, in hECNs derived from mutant DISC1 patients. Data presented here suggests 
that this disparity does not manifest at the functional level.  
 The finding that GABAAR and NMDAR compositions are consistent with 
immature neuronal profiles clearly restricts conclusions to the subunits expressed. 
Mutant DISC1 patients have a late juvenile/young adult symptomatic onset 
(Thomson et al. 2013) and maturation of cortical GABAAR and NMDAR 
composition is expected to have taken place. For example, the findings that mutant 
DISC1 affects GluN2A NMDAR subunit expression (Wei et al. 2013) and 
potentially reduces functional NMDAR expression to slow NMDAR maturation in 
the mouse barrel cortex (Greenhill et al. 2015) cannot be feasibly interrogated in this 




this study and that it is absolutely required if the field is to interpret findings from 
stem cell-derived neuron technology for disease-modelling studies.  
 AMPAR expression was observed to be equivalent between Case and Control 
hECNs at 35 DIV indicating that mutant DISC1 has no apparent effect. AMPAR 
composition was then determined using non-stationary fluctuation analysis and the 
sensitivity of AMPAR-mediated currents to NASPM. This data was directly 
equivalent to that of rodent cortical neurones that had undergone a period of post 
natal development in which edited GluA2 is upregulated (Brill and Hugenuard. 
2008) and also recombinantly expressed AMPARs containing edited GluA2 subunts. 
(Swanson et al. 1997). Both strategies clearly converged on the predominant 
AMPAR composition at 35 DIV as being edited GluA2-containing for both Case 
and Control hECNs. Contrary to the GABAAR and NMDAR, AMPAR expressed on 
hECNs have a composition that is expected of neurone that has undergone a period 
of maturation (Orlandi et al. 2011; Talos et al. 2006). A rapid upregulation of GluA2 
AMPAR subunit transcripts has also been reported in other similar systems (Stein et 
al. 2014; van de Leemput et al. 2014). Wen et al. (2014) recently reported an 
increase in the mRNA level of GluA2 in hECNs generated from mutant DISC1 
patient-derived iPSCs over control and isogenic, gene-corrected mutant DISC1 
hECNs, though data obtained in this study indicates this transcriptional difference 
may not translate to a functional difference. It appears that the functional 
upregulation of the GluA2 subunit is much faster than expected from what is 
expected in vivo (Orlandi et al. 2011; Talos et al. 2006). Of note, Whitney et al. 
(2008) report that the GluA2 is rapidly edited and functionally upregulated within 4 
weeks in in vitro neurones differentiated from human cortical progenitors. This 
suggests that the upregulation of the edited GluA2 subunit is a potential result of the 







4.5.3 Intracellular [Cl-] 
 Previous studies of GABAAR-mediated signalling has shown a developmental 
a change in the intracellular chloride concentration occurs as mediated by changes in 
expression levels of Cl
-
 transporter proteins NKCC1 and KCC2 (Blaesse et al. 
2009). Here, the perforated patch-clamp technique was used to determine the 
reversal potential of the GABAAR in DISC1 iPSC-hECNs in light of the possibility 
of Cl
- 
transporter dysfunction or dysregulation as previously described for the DISC1 
(1;11)(q42;q14.3) mutation (Kalkman et al. 2011; Arion et al. 2011). Here, the data 
show an equivalent reduction in the GABAAR reversal potential and related 
intracellular Cl
-
 reported for other hECNs derived from other lines (Livesey et al. 
2014), though no significant difference in the reduction in intracellular [Cl
-
] between 





 are under complex homeostatic regulation (Blaesse et al. 2009). 
It is therefore quite possible that in vitro maintenance conditions may surmount any 
potential difference or signalling factor/s may not be present in the Case and Control 
hECN cultures.  
 It is particularly unusual that there is a reduction in intracellular [Cl
-
] occurs 
over the period of 7 weeks as it is expected to mature in the human brain throughout 
the embryonic period and is reported to persist up to two years after birth in parts of 
the cortex (Bayatti et al. 2008; see Blaesse et al. 2009). It is therefore intriguing that 
a population of human sub-plate neurones (Pax-6
+
) highly express KCC2 from 16 
post-conception weeks and hECNs in this study are derived from Pax-6
+
 neural 
progenitors (Bilican et al. 2014; see Methods and Chapter 2). Given that previous 
study of intracellular chloride in iPSC-derived material in other diseases (Rett 
syndrome, Tang et al. 2015) has demonstrated that the cultures can fundamentally 
replicate this pathology, and that a similar pattern of maturation is observed as 
elsewhere concerning intracellular [Cl
-
] in normal, unaffected development (Livesey 
et al. 2014; Tang et al. 2015), it is concluded that DISC1-iPSCs demonstrate no 
effect of the DISC1 mutation (1;11)(q42;q14.3) on intracellular [Cl
-





4.5.4 What about synaptic properties? 
 Very subtle phenotypic differences in some of the functional properties 
described above maybe resolved with extensive further experimentation, however 
together these data suggests that principle differences in neuronal dysfunction 
caused by the mutation in DISC1 are to be found at the synaptic or circuit level. 
 DISC1 is particularly enriched in post-synaptic density fractions and in 
dendritic spines (Carlisle et al. 2011; Clapcote et al. 2007; Hayashi-Takagi et al. 
2010; Kirkpatrick et al. 2006). Moreover, analysis of the DISC1 protein-protein 
interactions highlights that DISC1 interacts with a number proteins with known roles 
in synaptic function (Camargo et al. 2007). Studies examining mutant DISC1 on 
synaptic properties in rodent models are not widespread and indicate alteration in the 
frequency in excitatory post-synaptic events compared to controls in cortical layer 
II/III pyramidal neurones due to an impairment in pre-synatptic glutamate release 
(Holley et al. 2013; Maher & LoTurco. 2012). Moreover, conditionally-induced 
mutant DISC1-associated deficits in synaptic plasticity in the mouse barrel cortex 
during a critical developmental window has prolonged effects on functional synaptic 
plasticity into adulthood (Greenhill et al.2015).  
 A major road block to studying synaptic properties in neurones derived from 
pluripotent stem cells is that the cultures do not commonly generate robust synaptic 
activity (Bardy et al. 2015). Indeed, cultures employed in this study were no 
exception to this. To circumvent this issue, numerous groups are now employing 
various strategies including co-culture of human stem cell-derived neurones with 
rodent astrocytes to promote functional synaptogenesis (Johnson et al. 2007; Kim et 
al. 2011; Pak et al. 2015; Shcheglovitov et al. 2013). Recently, Wen et al. (2014) 
employed this strategy to examine synaptic properties of hECNs generated from 
mutant DISC1 patients and, also, isogenic-corrected mutant DISC1 lines to similarly 
demonstrate a reduced post-synaptic synaptic event frequency due to impairments in 
neurotransmitter release. Additionally, Brennand et al. (2011), also showed a 
difference in frequency of spontaneous excitatory post-synaptic currents between in 




patients. It remains pertinent to note that potential synaptic plasticity deficits in 
human mutant DISC1 neurones remain unreported. 
 In conclusion, this study highlights that mutant DISC1 (1;11)(q42;q14.3) 
hECNs do not exhibit changes in intrinsic excitability, expression/composition of 
neurotransmitter receptors and maturation of intracellular [Cl
-
] compared to healthy 
controls. Emerging evidence suggests that more definitive neuronal dysfunction 
associated with mutant DISC1 manifests at the synaptic level. A secondary, but 
nonetheless important, outcome of this study is the appropriateness of stem cell-
derived neurones to model specific aspects of mutant DISC1 pathophysiology and 
also other adult-onset neurological diseases. These data and other groups show that 
human pluritpotent stem cell technology requires to be further developed beyond 
‘standard’ cultures in order to generate more relevant, native-like material.  
 Previous studies of GABAAR-mediated signalling has shown a developmental 
a change in the intracellular chloride concentration occurs as mediated by changes in 
expression levels of Cl
-
 transporter proteins NKCC1 and KCC2 (Blaesse et al. 
2009). Here, the perforated patch-clamp technique was used to determine the 
reversal potential of the GABAAR in DISC1 iPSC-hECNs in light of the possibility 
of Cl
- 
transporter dysfunction or dysregulation as previously described for the DISC1 
(1;11)(q42;q14.3) mutation (Kalkman et al. 2011; Arion et al. 2011). Here, the data 
show an equivalent reduction in the GABAAR reversal potential and related 
intracellular Cl
-
 reported for other hECNs derived from other lines (Livesey et al. 
2014), though no significant difference in the reduction in intracellular [Cl
-
] between 





 are under complex homeostatic regulation (Blaesse et al. 2009). 
It is therefore quite possible that in vitro maintenance conditions may surmount any 
potential difference or signalling factor/s may not be present in the Case and Control 
hECN cultures.  
 It is particularly unusual that there is a reduction in intracellular [Cl
-
] occurs 
over the period of 7 weeks as it is expected to mature in the human brain throughout 
the embryonic period and is reported to persist up to two years after birth in parts of 
the cortex (Bayatti et al. 2008; see Blaesse et al. 2009). It is therefore intriguing that 
a population of human sub-plate neurones (Pax-6
+




post-conception weeks and hECNs in this study are derived from Pax-6
+
 neural 
progenitors (Bilican et al. 2014; see Methods and Chapter 2). Given that previous 
study of intracellular chloride in iPSC-derived material in other diseases (Rett 
syndrome, Tang et al. 2015) has demonstrated that the cultures can fundamentally 
replicate this pathology, and that a similar pattern of maturation is observed as 
elsewhere concerning intracellular [Cl
-
] in normal, unaffected development (Livesey 
et al. 2014; Tang et al. 2015), it is concluded that DISC1-iPSCs demonstrate no 
effect of the DISC1 mutation (1;11)(q42;q14.3) on intracellular [Cl
-
] levels in 
development. 
 Very subtle phenotypic differences in some of the functional properties 
described above maybe resolved with extensive further experimentation, however 
together these data suggests that principle differences in neuronal dysfunction 
caused by the mutation in DISC1 are to be found at the synaptic or circuit level. 
 DISC1 is particularly enriched in post-synaptic density fractions and in 
dendritic spines (Carlisle et al. 2011; Clapcote et al. 2007; Hayashi-Takagi et al. 
2010; Kirkpatrick et al. 2006). Moreover, analysis of the DISC1 protein-protein 
interactions highlights that DISC1 interacts with a number proteins with known roles 
in synaptic function (Camargo et al. 2007). Studies examining mutant DISC1 on 
synaptic properties in rodent models are not widespread and indicate alteration in the 
frequency in excitatory post-synaptic events compared to controls in cortical layer 
II/III pyramidal neurones due to an impairment in pre-synatptic glutamate release 
(Holley et al. 2013; Maher & LoTurco. 2012). Moreover, conditionally-induced 
mutant DISC1-associated deficits in synaptic plasticity in the mouse barrel cortex 
during a critical developmental window has prolonged effects on functional synaptic 
plasticity into adulthood (Greenhill et al.2015).  
 A major road block to studying synaptic properties in neurones derived from 
pluripotent stem cells is that the cultures do not commonly generate robust synaptic 
activity (Bardy et al. 2015). Indeed, cultures employed in this study were no 
exception to this. To circumvent this issue, numerous groups are now employing 
various strategies including co-culture of human stem cell-derived neurones with 
rodent astrocytes to promote functional synaptogenesis (Johnson et al. 2007; Kim et 




employed this strategy to examine synaptic properties of hECNs generated from 
mutant DISC1 patients and, also, isogenic-corrected mutant DISC1 lines to similarly 
demonstrate a reduced post-synaptic synaptic event frequency due to impairments in 
neurotransmitter release. Additionally, Brennand et al. (2011), also showed a 
difference in frequency of spontaneous excitatory post-synaptic currents between in 
vitro neurones derived from clinically, but not genetically, defined schizophrenia 
patients. It remains pertinent to note that potential synaptic plasticity deficits in 
human mutant DISC1 neurones remain unreported. 
 In conclusion, this study highlights that mutant DISC1 (1;11)(q42;q14.3) 
hECNs do not exhibit changes in intrinsic excitability, expression/composition of 
neurotransmitter receptors and maturation of intracellular [Cl
-
] compared to healthy 
controls. Emerging evidence suggests that more definitive neuronal dysfunction 
associated with mutant DISC1 manifests at the synaptic level. A secondary, but 
nonetheless important, outcome of this study is the appropriateness of stem cell-
derived neurones to model specific aspects of mutant DISC1 pathophysiology and 
also other adult-onset neurological diseases. These data and other groups show that 
human pluritpotent stem cell technology requires to be further developed beyond 

















Characterisation of motor neurones harbouring the 



























5.1 Motivations for study 
 Experiments in this chapter were conducted in order to explore the potential 
utility of lower motor neurones (LMNs) derived from iPSCs (iPSC-MNs) carrying 
the C9ORF72 hexanucleotide repeat expansion mutation in modelling 
pathophysiology associated with amyotrophic lateral sclerosis (ALS). The C9ORF72 
gene is located on the short arm of chromosome 9 (open reading frame 72; see Mori 
et al. 2013). Normally, approximately 30 repeat expansions of GGGGCC (G4C2) are 
found, however, in the case of the hexanucleotide repeat expansion mutation, this 
number can be on the order of hundreds (Donnelly et al. 2013; DeJesus-Hernandez 
et al. 2011; see Figure. 5.1). As of 2012, the hexanucleotide repeat expansion 
mutation is the most common mutation in familial ALS (approx. 40% of cases; Zu et 
al. 2011), and is also associated with sporadic cases (approx. 8-10%; DeJesus-
Hernandez et al. 2011), and interestingly, is linked to frontotemporal dementia 
(FTD), accounting for 10% of sporadic FTD cases (Khan et al. 2012; Majounie et al. 
2012). It has been shown that significant overlap exists between these conditions, 
with as many as 50% of ALS patients displaying cognitive impairment, while 
approximately 50% of patients with FTD also suffer MN impairment (See Ferrari et 
al. 2011). Thus there is an imminent need to understand the role that the G4C2 repeat 





Figure. 5.1. Schematic of C9ORF72 including G4C2 repeat expansion. Above: 
C9ORF72 gene schematic indicating region subject to repeat expansion of “ggggcc”. Below: 






 Crucially, there is strong evidence to show that disease progression in ALS is 
likely mediated, in part, by glutamate-mediated excitotoxicity (Rothstein & 
Cleveland, 2001.). Previous work has highlighted an intrinsic vulnerability of ALS 
MNs to glutamate excitotoxicity that is mediated by Ca
2+
-permeable AMPARs 
(Donnelly et al. 2013; Rothstein et al. 1995). However, the literature has yet to 
directly link specific AMPAR structural properties that generate Ca
2+
-permeability 
in ALS MNs to genetic abnormalities (Duncan, 2009).  
 To address this, MNs from patients harbouring the C9ORF72 G4C2 repeat 
expansion, and unaffected controls were generated using a previously described 
protocol (Maury et al. 2015; Selvaraj et al. manuscript in review; see Methods). For 
all lines examined, cultures contained >95% cells that stained for neuronal marker, 
Tau
+
, at week 3 (see Figure 5.2). These cells lines generated between 40-60% of 
neurones that stained for Islet1/2, a marker for MNs, at 1 week, with cultures also 
being heavily enriched for neuronal marker Tau, and displaying RNA foci, a key 
feature of ALS pathology in vivo that are enriched for G4C2 repeats (Figure 5.2). 
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Figure. 5.2 Initial characterisation of MNs, and confirmation of RNA foci. Adapted with 
permission from Selveraj et al. (manuscript in review). All  A: MN culture co-stained for 
DAPI, MN marker Islet 1/2, and neuronal marker Tau. Scale bar, 50 µm. B: Graph showing 
percentage of neurones in culture at week 3 which express Islet 1/2. C: Co-stain showing 
DAPI, Neuronal marker MAP2, and RNA foci containing G4C2 repeats. Scale bar, 5 µm. D: 





 In this chapter, iPSC-MNs derived from a patient without the C9ORF72 
(G4C2) mutations will be referred to as “Control”. Cell lines derived from two 
different patients, both harbouring the C9ORF72 (G4C2) are referred to as C9-1, and 
C9-2, respectively (see Methods). iPSC-MNs derived from C9-2 with the C9ORF72 
(G4C2) hexanucleotide repeats excised using Cas9/CRISPR (see Ran et al. 2013) are 
referred to as ∆C9-2. This powerful approach allows the examination of 2 sets of 
material with an identical genetic background with the exception of the mutation that 
has been excised/corrected. In this regard, relative changes in the ‘corrected line’ to 
the paired patient line are therefore more likely to be as a result of the mutation 
rather than genetic variation that is associated with independently derived lines. In 
this case, this tool allows potential corrected phenotypes to be directly associated 

























5.2 Passive properties of iPSC-MNs. 
 Initial electrophysiological characterisation of iPSC-MNs was conducted at 1, 
3, and 5 week time points (Figure.5.2) in order to observe potential alterations in 
development in C9-1, and C9-2 with respect to Control, and ∆C9-2. Typical patterns 
of maturation investigated in terms of the intrinsic properties of iPSC-MNs between 
week 1 and week 5 indicated that there was no notable difference between any iPSC-
MN line at any specific time point.   
 From week 1 to week 5, mean input resistance measurements broadly 
decreased (Figure. 5.3A; all p=<0.05, Student’s t-test). The mean resting membrane 
potential (RMP) in each line became more hyperpolarised with time (Figure. 5.3B; 
all p=<0.05, Student’s t-test;). Additionally, whole-cell capacitance significantly 
increased (Student’s t-test; all p=<0.05) in all lines to similar levels (Figure. 5.3C). 
These data are consistent with a maturing MN profile; importantly, the mean values 
of passive properties obtained at all time points are not what are expected of adult 
MNs (Oswald et al. 2013); input resistance measurements are somewhat higher, 
whole-cell capacitance values are slightly lower, and RMP values are more 
hyperpolarised.  
 While the maturation of some properties did not reach statistical significance 
between week 1 and week 5, general trends toward the same endpoint are as 
described, in that by week 5, all iPSC-MNs surveyed showed no statistical 
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Figure. 5.3. Passive membrane properties of iPSC-MNs. For all panels, control iPSC-MN 
n = 6 - 14, N = 1-3, and C9ORF72 (G4C2), n = 7 - 15, N = 1 - 3. X-axis labels denote weeks 
in culture. A: Mean input resistances of control, and C9ORF72 (G4C2) iPSC-MNs. Input 
resistance was established from the mean passive membrane current amplitude generated 
from thirteen sequential -50 mV pulses. B: Mean resting membrane potential (RMP) of 
control, and C9ORF72 (G4C2) iPSC-MNs. C: Mean whole-cell capacitance of control, and 












5.3 Characterisation of the AMPAR on iPSC-MNs 
 Previous reports strongly implicate the AMPAR in ALS via a mechanism of 
“slow” excitotoxicity as mediated by Ca
2+
-permeable AMPARs (Donnelly et al. 
2013; Rothstein et al. 1995). Crucial to this hypothesis is the finding that MNs are 
inherently more susceptible to glutamate-mediated excitotoxicity. This is mediated 
by three key processes; a) a reduced ability to clear excess glutamate at the synapse, 
leading to increased  AMPAR activation; b) Increased expression of Ca
2+
-permeable 
AMPARs leading to increased/toxic Ca
2+




 Previous chapters have explored the utility of examining the AMPAR 
estimated mean single-channel conductance (γ) as a potential indicator of some 
broad developmental neuropathology in DISC1 iPSC-hECNs. Here, the AMPAR 
Ca
2+
 -permeability is of particular relevance with regard to the above concerning 
aberrant Ca
2+
 entry into the cell in ALS. Thus, it seems plausible that iPSC-MNs 
harbouring the C9ORF72 (G4C2) repeat expansion mutation may show altered 
apparent Ca
2+
 -permeability at the AMPAR, using previously detailed methods of 
non-stationary noise analysis (See Methods; Chapter 3) and subunit selective 
pharmacology (See AMPAR characterisation in Chapter 3). To re-iterate, the 
AMPAR has a tetrameric structure, potentially composed of 4 subunits (GluA1-4), 
with developmentally regulated subunit composition. In early development, 
AMPARs are typically assembled without the RNA edited (Q → R) GluA2 subunit, 
and are typically Ca
2+
 -permeable. Inclusion of the edited form of GluA2 renders the 
AMPAR impermeable to Ca
2+ 
(see Swanson et al. 1997), which is an isoform of the 
AMPAR associated with mature MNs, typically representing a postnatal phenotype 
(Talos et al. 2006a, 2006b; Orlandi et al. 2011, see Traynelis et al. 2012).    
 The estimated mean single-channel conductance (γ) at the AMPAR increases 
markedly with the property of Ca
2+
 -permeability (Swanson et al. 1997; see 
Traynelis et al. 2012). Thus pervasive expression of Ca
2+
 -permeable AMPARs by 
altered subunit composition or inefficient RNA editing is prospectively detectable in 
iPSC-MNs, and as a result may shed light on the viability of iPSC-MNs to model 





5.3.1 Establishing responses to AMPA in iPSC-MNs. 
 Initial experiments in characterising AMPARs expressed by iPSC-MNs 
confirmed reliable AMPAR expression, with all MNs studied responding to AMPA 
(Figure. 5.4A; n=20, N=4) Of note is the use of cyclothiazide (10 µM), an AMPAR-
selective positive modulator that prevents AMPAR desensitization (Cowen et al. 
1998), which reliably potentiated AMPAR-mediated currents by 531% - 808%, 
(n=20, N=4; Fig 4.2). Additionally this response was blocked by CNQX (20 µM, 
n=20, N=4).  
 




























Figure. 5.4. Potentiation of AMPAR current by cyclothiazide. A: Mean potentiation of 
AMPA-mediated current by cyclothiazide (n=4-6, N=1). B: Example trace of recording from 
MN (Control) at -70 mV (-84 mV) showing application AMPA (blue bar), cyclothiazide (green 






5.3.2 Characterising C9ORF72 (G4C2) effects on AMPAR estimated 
mean single-channel conductance (γ). 
 As previously described (Materials and methods; see Chapter 4), non-
stationary noise analysis was used to estimate the mean AMPAR single-channel 
conductance (γ) in iPSC-MNs from week 1 to week 5. As before, two simultaneous 
whole-cell voltage-clamp recordings were made in each experiment, where the 
described AMPAR-evoked responses were made in AC and DC current formats (see 
Figure. 5.4B). For these experiments the extracellular recording solution was 
supplemented with cyclothiazide (10 µM). The resultant plot of AC-current variance 
against DC-current amplitude yielded a straight-line plot (example in 5.4C) from 
which the estimated AMPAR single-channel current amplitude was determined and 
single-channel conductance calculated (Shown in Figure. 5.5D).  
 At 5 weeks, Control and isogenic control line ∆C9-2 showed markedly 
similar, low mean estimated channel single-channel AMPAR conductance (2.4 pS ± 
0.5 pS; n = 6, N = 1, and 2.3 pS ± 0.2 pS; n = 12, N = 3; p=0.71 vs Control, 
Student’s t-test, respectively), whereas in sharp contrast, both C9ORF72 (G4C2) -
harbouring lines, C9-1 and C9-2 showed pervasively elevated conductances (Figure 
5.5D; 4.5 pS ± 0.5 pS; n=12, N=3; p=0.012 vs Control, Student’s t-test, and 5.1 pS ± 
0.7 pS; n = 12, N = 3; p=0.010 vs Control, Student’s t-test, respectively), thus 
demonstrating that the C9ORF72 (G4C2) mutation disrupts normal AMPAR 
development, maintaining an AMPAR conductance highly suggestive of Ca
2+
 -
permeability, that of an AMPAR isoform relatively lacking the RNA edited (Q → R) 
GluA2 subunit. 
 Further to this, from week 1 – week 5, a significant reduction was observed in 
estimated mean AMPAR single channel conductance in both the Control line (5.4D; 
n = 6 - 11, N = 1 - 2; p=0.0074, Student’s t-test) and the Cas9/CRISPR edited line 
∆C9-2 (Figure. 5.4D; n = 8 - 17, N = 1 - 2; p=0.00039 Student’s t-test), as would be 
expected of a typical AMPAR maturation profile (see Swanson et al. 1997; 
Traynelis et al. 2012). This maturation, the progressive lowering of AMPAR-γ 
between week 1 and week 5 did not occur in lines harbouring the C9ORF72 (G4C2) 
repeat expansion mutation, namely C9-2 (Figure. 5.5A; n = 9 - 18, N = 2 - 4; 




Student’s t-test). These results again clearly demonstrate that the C9ORF72 (G4C2) 
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Figure. 5.5, Non-stationary noise analysis using whole-cell voltage-clamp, of AMPAR-
mediated currents in C9ORF72 (G4C2), and control iPSC-MNs at week 5. A: Traces from 
a week 5, Control iPSC- MN showing a slowly-rising and decaying  whole-cell response to 
AMPA (10 µM) at a membrane holding potential of -60 mV (-74 mV); the upper trace shows 
the AC current recording and the lower shows the DC current recording. B: As in ‘A’ but for 
week 5, C9-2 iPSC-MN. C: Example current-variance plot from week 5, Control iPSC-MN 
(black) and C9-2 iPSC-MN (red). The relationship yields a linear relationship to which a 
straight line was fitted. The slope of the plot gave the estimated AMPAR single-channel 
current. D: Mean estimated AMPAR single-channel conductance of AMPARs expressed on 




5.3.3 Characterising the effect of the C9ORF72 (G4C2) mutation on 
AMPAR blockade by NASPM. 
 Next, in order to confirm the observed persistent expression of Ca
2+
 -
permeable AMPARs, experiments were conducted to assess the sensitivity of 
AMPAR-mediated currents to the channel blocker 1-naphthyl acetyl spermine 
(NASPM, 3 µM; Koike et al. 1997), which is selective for AMPARs that lack the 
Ca
2+
 -impermeable, RNA-edited GluA2 subunit (for traces, see Fig 5.6A, B).  
At 5 weeks, Control, and isogenic control line ∆C9-2 showed low NASPM block 
(Fig 5.6C; 16.6% ± 2.2%; n=7, N=2, and 23.2% ± 2.1%; n=8, N=3, respectively; 
p=0.54 vs Control, Student’s t-test), indicating predominant expression of  the RNA 
edited (Q → R) GluA2 subunit, whereas in sharp contrast, both C9ORF72 (G4C2) -
harbouring lines, C9-2 and C9-1 showed consistently higher levels of NASPM 
blockade (Fig 5.5C; 38.6% ± 6.9%; n=9, N=3; p=0.0009 vs Control, Student’s t-test, 
and 44.3% ± 4.1%; n=9, N=2; p=0.0004 vs Control, Student’s t-test, respectively), 
thus demonstrating that the C9ORF72 (G4C2) mutation disrupts normal AMPAR 
development, maintaining an AMPAR conductance highly suggestive of Ca
2+
 -































































Figure. 5.6. Whole-cell voltage clamp NASPM blockade of AMPAR-mediated currents 
in iPSC-MNs. A: Traces from a week 5, Control iPSC-MN showing application of AMPA and 
NASPM (NAS) at a membrane holding potential of -60 mV (-74 mV). B: As in ‘A’ but for C9-
2 iPSC-MN. C: Graph showing NASPM block across all iPSC-MN lines from week 1 to week 









 Further to this, from week 1 – week 5, a notable decrease was observed in 
mean NASPM block in both the Control line (Figure. 5.5C; n=6-7, N=1-2; 
p=0.0009, Student’s t-test) and the Cas9/CRISPR edited line C9-2 (Figure. 5.5C; 
n=8-17, N=1-2; p=0.0004 Student’s t-test), as would be expected of a typical 
AMPAR maturation profile (see Swanson et al. 1997; Traynelis et al. 2012). This 
progressive increase in AMPAR blockade by NASPM between week 1 and week 5 
did not occur in lines harbouring the C9ORF72 (G4C2) repeat expansion mutation, 
namely C9-2 (Figure. 5.5C; n=9-18, N=2-4; p=0.0074, Student’s t-test) and C9-1 
(Figure. 5.5C; n = 7 - 12, N = 1 - 3; p=0.0074, Student’s t-test). These results again 
clearly demonstrate that the C9ORF72 (G4C2) mutation perturbs AMPAR 
maturation in iPSC-MNs, causing a relatively increased expression Ca
2+
 -permeable, 
non- RNA edited (Q → R) GluA2 subunit -containing AMPARs. 
5.4 Discussion 
 Here, the whole-cell patch-clamp technique was used in order to investigate 
the appealing prospect that iPSC-MNs may replicate previous findings in ALS 
research from other systems concerning increases in intracellular Ca
2+
, and 
subsequent excitotoxicity mediated by aberrant, predominant expression of Ca
2+
-
permeable AMPARs (Donnelly et al. 2013; Rothstein et al. 1995; see Cleveland and 
Rothstein. 2001). Initial experiments surveying the development of passive 
membrane properties revealed no statistically significant effect of either the 
C9ORF72 (G4C2) mutation or the use of CRISPR/Cas9 to excise the G4C2 repeats, 
demonstrating the validity of comparing a highly developmentally regulated system 
such as AMPAR Ca
2+
 -permeability between different lines and isogenic controls.  
While occasional trends could arguably be observed in selected passive properties, 
no wide-ranging differences were seen, with all lines following highly similar 
developmental trajectories toward lower input resistances, increased capacitances, 
and more negative resting membrane potentials.  Of particular note, the novelty and 
utility of a native human in vitro system for modelling ALS-related AMPAR 




5.4.1 Aberrant Ca2+ -permeable AMPAR expression  
 Here, findings using non-stationary noise analysis, and subunit-selective 
pharmacology show that multiple iPSC-MN lines harbouring the C9ORF72 (G4C2) 
mutation do indeed show aberrant and persistent expression of Ca
2+
 -permeable 
AMPARs, a compelling finding that supports a large body of previous work 
(Donnelly et al. 2013; Rothstein et al. 1995), and invites further study of the iPSC-
MNs capacity to model “slow” excitotoxicity in ALS as mediated by AMPARs (see 
Selvaraj et al. 2016, manuscript in review). Notably, the observed AMPAR 
conductance measurements for C9ORF72 (G4C2) were in line with previously 
reported values in recombinant and animal systems which predominantly express 
Ca
2+
-permeable AMPARs, typically in early development (Talos et al. 2006a, 
2006b; Orlandi et al. 2011, see Traynelis et al. 2012). This is evidenced by the mean 
single-channel conductance (γ) established using non-stationary noise analysis. 
Early in development, Ca
2+ 
-permeable AMPARs predominate, and are composed of 
receptor isoforms which do not contain an RNA-edited (Q → R) GluA2 subunit. 
Those AMPARs which do contain an RNA (Q → R) GluA2 subunit are typically 
expressed post-natally and are relatively Ca
2+
-impermeable, while in ALS, this high 
Ca
2+
-permeability persists and is, as described elsewhere (Donnelly et al. 2013; 
Rothstein et al. 1995), a compelling candidate for further examination as to the 
neuronal mechanisms affected in ALS in systems such as stem cell technologies, in 
that here it would appear that these systems are capable of modelling this 
phenomenon to refine targets for therapeutic intervention.  
 While it initially might seem plausible (if somewhat unlikely, given the stable 
nature of AMPAR responses) that other subunits might “fill in” an altogether-absent 
GluA2 in C9ORF72 (G4C2), leading to another mechanism of sustained Ca
2+
-
permeability, the data does show that some AMPAR mean single channel 
conductance measurements are in the range expected of an edited GluA2 subunit. 
This interpretation, even at its most cautious, suggests at the least a problem with 
concerning a long-term reduction in expression of (Q → R) edited GluA2 subunits 
and thus increased Ca
2+




quantitative expression by fluorescence might provide a definitive insight as to what 
is likely to be expressed at the membrane in light of the results in this thesis. 
5.4.2 CRISPR/Cas9 and isogenic controls 
 Secondly, the amenability of iPSC-MNs to CRISPR/Cas9 gene editing was 
employed to produce isogenic controls also derived from patient lines and lacking a 
pathological number of G4C2 repeats. This was shown to rescue the observed 
persistent Ca
2+
 -permeable AMPAR expression found in the presence of C9ORF72 
(G4C2), which clearly implicates C9ORF72 (G4C2) in ALS-related AMPAR 
pathology. Additionally, demonstrating the utility of gene-editing suites to directly 
remedy a disease phenotype is confluent with the goals of gene therapy; while not 
presently implemented large-scale, initial rigorous validation of genetically 
engineered iPSC-derived tissue in the modelling of disease represents robust 
groundwork in a promising emergent health technology. 
5.4.3 What of other iPSC-MNs, and MNs in ALS in general? 
 A recent report also in iPSC-MNs (Selvaraj et al. 2016) demonstrates a direct 
link between aberrant Ca2+- permeable AMPAR expression in C9ORF72 (G4C2) 
iPSC-MNs and MN vulnerability to excitotoxicity. Given additional previous reports 
of MN vulnerability to excitotoxicity via AMPAR pathology, it can be said that 
iPSC-MNs do represent an amenable system to the study of ALS, particularly in the 
case of C9ORF72 (G4C2). Of particular note is the use of CRISPR/Cas 9 gene 
editing tools to generate an isogenic control line, which consistently displayed a 
control-like phenotype. Notably this resulted in AMPAR measurements being highly 
similar to control values (Selvaraj et al. 2016), again in agreement with the results 
presented in this chapter of this thesis. Such ‘rescue’ of the AMPAR phenotype 
clearly demonstrates the utility of the CRISPR/Cas 9 gene editing system in 
modelling disease using iPSC-MN cultures, and further compounds the findings 
comparing C9ORF72  (G4C2) with non-isogenic control lines (i.e those who do not 





Characterisation of OPCs and oligodendrocytes 





























6.1 Motivations for study 
 OLs and OPCs are highly relevant in the study of human brain development in 
general, in that they constitute approximately 5% of total cells in the adult human, 
and also rodent cortex (Ongur et al. 1998; Stark et al. 2004; for rodents see Irintchev 
et al. 2005; Jakovcevski et al. 2009) and are heavily implicated in a great number of 
crucial developmental processes involving the myelination of virtually all neurones 
in the CNS, a process in which a single OL enhances action potential conductance 
along the axons of multiple target neurones and is crucial for neuronal network 
function in mammals. Typically, a pool of self-regenerating OPCs is maintained in 
the sub-ventricular zone (SVZ) in both the developing, and adult human brain, 
however, in later development a population arising from the dorsal spinal cord also 
begins to myelinate the spinal cord, accounting for some 10-15% of the mature OL 
content there. It has been shown that across development and maturity, OPCs 
regenerate via a balance between proliferation, the replication of an OPC, and 
differentiation into mature OLs. This marks a process which leads from the 
predominant expression of OPC marker PDGFRα, to that of OL marker O4. 
Notably, no overlap in marker expression (PDGFRα/O4) within a single cell is 
typically observed in the maturation of OPCs to OLs, indicating a highly reliable 
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Figure. 6.1. iPSC-OPCs/OLs express key cell identity markers PDGFRα, and O4, 
respectively, with nominal overlapping expression. Aadapted with permission, from 
Livesey et al. (2015): A: Co-stain showing separate PDGFRα and O4 expression in OPCs 
and OLs. B: Graph showing co expression of OPC identity marker PDGFRα, and OL marker 
MBP, relative to their co-expression with O4, an OL marker.        
 
 The generation of functional, viable Oligodendrocytes (OLs) and 
Oligodendrocyte precursor cells (OPCs) from iPSCs, represents a stable platform to 
model normal human development in both health, and diseases implicating  ion 
channel dysfunction, such as in ALS (Livesey et al. 2015). Importantly, ALS is 
characterised by excessive demyelination of axons by OLs, and neurodegeneration, 
with approximately 5-10% of cases being associated with a known mutation. One 
prominent mutation that has been studied in iPSC-derived neuronal material is the 
TARDP mutation TDP-43 (G298S). Mutations in the TARDP gene account for 2-6% 
of familial ALS cases, and presents hallmark ALS pathologies in vitro and in vivo in 
rodents and iPSC-derived material, of nuclear foci of mutant RNA, and 
susceptibility to neurodegeneration (Thomsen et al. 2014). Additionally, these 
typical pathologies have been replicated in iPSC-MN cultures, demonstrating their 















 channels, and ligand-gated ion channels such as 
the AMPAR are definitive of OPC maturation into OLs, a finding recently replicated 
in iPSC-OPC/OLs. This thesis has previously observed a tissue-specific maturational 
defect in MNs harbouring an ALS mutation which does not affect OPC/OLs, 
however, previous study has shown that OPC/OLs are affected in their own right, 
and that demyelination and neurodegeneration in ALS may be caused in part by OL-
mediated effects. Thus, it may be the case that different ALS mutations cause tissue-
specific impairments that converge on the known ALS phenotypes, and that these 
pathologies may be convergent on some common mechanism such as that suggested 
by slow excitotoxicity, or a more general maturational deficit.  
 Crucially, the AMPAR is heavily implicated in iPSC-derived models of ALS 
(see Chapter 4). To re-iterate, the AMPAR is heavily implicated in ALS via a 
mechanism of “slow” excitotoxicity brought about by Ca
2+
-permeable AMPARs 
(Donnelly et al. 2013; Rothstein et al. 1995). Crucially, OLs may show similar 
responses to that of MNs, in that MNs are inherently more susceptible to glutamate-
mediated excitotoxicity as mediated by three factors; 1) increased AMPAR 
activation due to a reduced ability to clear excess glutamate at the synapse; 2) 
Increased expression of Ca
2+
-permeable AMPARs leading to increased/toxic levels 
of intracellular Ca
2+
; 3) a reduction in ability to buffer cytoplasmic Ca
2+ 
levels. This 
is of great relevance in light of seemingly conflicting findings in ALS, firstly that 
while iPSC-OLs harbouring the C9ORF72 (G4C2) mutation do not show persistent 
aberrant AMPAR Ca
2+
 permeability, iPSC-MNs with this mutation do. Thus, it is 
possible that tissue type-specific changes associated with different mutations may be 
convergent toward a common pathology as mediated by “slow” excitotoxicity via 
the AMPAR as described, ultimately leading to demyelination and neuronal death.  
In this chapter, OPCs and OLs derived from a patient without TDP-43 mutations 
will be referred to as “Control”. Cells harbouring the TDP-43 M337V mutation will 
be referred to as “T-1”, while those from two different patients harbouring the 
G298S mutation will be referred to as “T-2”, and “T-3”, respectively. iPSC-
OPCs/OLs derived from Case-3 with the G298S mutation corrected by 




6.2 Passive properties of iPSC-OPC/OLs. 
6.2.1 Input resistance, whole–cell capacitance, and resting membrane 
potential. 
 Initial electrophysiological characterisation of iPSC-OPC/OLs was conducted 
at 1 and 3 week time points (Figure.5.2) in order to observe potential alterations in 
development in lines harbouring ALS mutations (lines T1, T2, T-3) with respect to 
Control, and ∆T-3. Typical patterns of maturation investigated in terms of the 
intrinsic properties of iPSC-OPC/OLs between OPC at week 1, and mature OL at 
week 3 were observed. At any time point, lines harbouring TDP-43 mutations did 
not differ significantly from controls (typically p=>0.1), however, line T-2 showed a 
significantly decreased whole-cell capacitance (18.2 pF ± 1.7 pF, n = 5, N = 2; 
Control, 29.6 pF ± 3.7 pF, n = 12, N = 3; p=0.01398), as did line T-3 (19.2 pF ± 1.1 
pF, n = 8, N = 3; Control, as above. p=0.03887). 
 Between OPCs at week 1, to OL at week 3, mean input resistance 
measurements broadly decreased (Figure 6.2A), except line T-1, which showed a 
trend of decreasing input resistance across time in culture, but failed to reach 
significance (p=0.12668). The mean resting membrane potential (RMP) typically  
became more hyperpolarised with time in the majority of lines, however, line T02 
and line ∆T-3 showed a trend toward more hyperpolarised RMP which did not reach 
significance (Figure 6.2B; p=0.18836, and  p=0.43945 respectively). Additionally, 
whole-cell capacitance significantly increased (Student’s t-test; all p=<0.05) in all 
lines to similar levels (Figure. 5.2C). These data are generally consistent with the 
maturation of OPCs into OLs across development, showing trends where 
significance is not found; importantly, the mean values of passive properties 
obtained at all time points are not what are expected of adult OLs (Oswald et al. 
2013); input resistance measurements are somewhat higher, whole-cell capacitance 
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Figure. 6.2 Input resistance, resting membrane potential, and whole-cell capacitance 
of iPSC-OPCs/OLs. For all panels, n = 6 - 15, N = 1 - 3. Numbers on X axis indicate 
number of weeks in culture. Blue coloured symbols and text denotes OPCs, whereas black 
text and symbols indicate OLs at time in culture as labelled. A: Mean input resistances of 
iPSC-OPC/OLs. Input resistance was established from the mean passive membrane current 
amplitude generated from thirteen sequential -50 mV pulses. B: Mean resting membrane 
potential (RMP) of iPSC-OPC/OLs. C: Mean whole-cell capacitance of iPSC-OPC/OLs. * 










6.2.2 Rectifying membrane conductances in iPSC-OPC/OLs 
 Typically, OPCs display outwardly rectifying membrane currents in response 
to applied voltages, passing a much greater amount of current at membrane 
potentials that are positive to the reversal potential of the channel, and relatively 
little current at potentials more negative. OPC differentiation to OLs results in a 
linearisation of this relationship, resulting in a lack of rectification and a linear I-V 
plot. These properties have been widely described in rodent oligodendroglial 
counterparts, in vitro mouse PSC-derived OPCs and integrated mouse PSC-derived 
glial restricted progenitor cells that contain a proportion of OPCs indicating that 
comparable changes in ion channel expression occur throughout human 
oligodendrogenesis in vitro.  
 Figure 5.3 shows a typical pattern as described in previous literature on iPSC-
OPC/OLs. Similar to previous findings, membrane conductances in OPCs (see trace, 
Figure 6.3A) were highly non-linear, displaying strong outward rectification, 
whereas OLs typically displayed a more linear current response to applied voltage 
steps. Figure 6.3D shows an I-V plot normalised to the current passed at -64 mV, 
from an applied 20 mV step at a holding potential of -84 mV (See Chapter 2, 
Materials and methods), and displays a more linear I-V relationship in OLs than 
OPCs.  
 The rectification index, a measure used elsewhere in this thesis (See Materials 
and Methods, Chapter 2; Chapter 4), describes a ratio of the conductances at a 
positive holding potential (here, +16 mV) and a negative holding potential (here, -




6.3A,B for example traces). Across all lines, OPCs displayed a higher rectification 
index, which typically significantly dropped upon differentiation and maturation into 
OLs (P=<0.05; Figure 6.3C), however, this did not reach statistical significance for 
line T-2. Notably, there were no statistical differences between lines at any point, 
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Figure. 6.3 Rectification of membrane conductances in iPSC-OPC/OLs. For all panels, 
n = 7 - 12, N = 1 - 3. * indicates p=<0.05; ** indicates p=<0.01; *** indicates p=<0.001.  A: 
Example trace of membrane current responses to incremental 20 mV steps (shown below) 
at a holding potential of -84 mV in a control OPC at week 1 in culture. B: Example trace of 
current responses to incremental 20 mV steps (shown below) at a holding potential of -84 
mV in a control OL at week 3 in culture. C: Rectification index of membrane current 




coloured symbols and text denotes OPCs, whereas black text and symbols indicate OLs at 
time in culture as labelled. D: Mean normalised current-voltage plots for OPCs, and OLs at 
1, and 3, weeks in culture. Current amplitudes were measured 175 ms after the initiation of 
the voltage step and normalised to the current passed at -64 mV (See Chapter 2, Materials 






6.3 AMPAR subunit expression and Ca2+ -permeability in iPSC-
OPC/OLs 
 
6.3.1 Characterising the effects of TDP-43 mutations on AMPAR 
estimated mean single-channel conductance (γ). 
 It has been previously shown that iPSC-OPCs/OLs demonstrate a documented 
switch in AMPAR subunit expression that occurs upon the differentiation of OPCs 
into OLs. To re-iterate, the AMPAR has a tetrameric structure, potentially composed 
of 4 subunits (GluA1-4), with developmentally regulated subunit composition. In 
early development, AMPARs are typically assembled without the RNA edited (Q → 
R) GluA2 subunit, and are typically Ca
2+
 -permeable. Inclusion of the edited form of 
GluA2 renders the AMPAR impermeable to Ca
2+ 
(see Swanson et al. 1997), which 
is an isoform of the AMPAR associated with mature OLs .This switch occurs in 
much the manner described for hECNs, DISC1 iPSC-hECNs, and control iPSC-MNs 
with regard to time in culture, and is estimated using non-stationary noise analysis to 
determine the estimated mean single-channel conductance of the AMPAR. As 
described in previous chapters, the estimated mean single-channel conductance (γ) at 
the AMPAR increases markedly with the property of Ca
2+
 -permeability (Swanson et 
al. 1997; see Traynelis et al. 2012). Thus pervasive expression of Ca
2+
 -permeable 
AMPARs by altered subunit composition or inefficient RNA editing is prospectively 
detectable in iPSC-OPCs/OLs, and as a result may shed light on the viability of 
iPSC-OPC/OLs to model disease progression mediated by the TDP-43 mutation in 
ALS in a tissue-specific manner, much as that seen for the C9ORF72 (G4C2) 
mutation in iPSC-MNs.   
Previous chapters have explored the utility of examining the AMPAR 
estimated mean single-channel conductance (γ) as an indicator of developmental 
pathology in DISC1 iPSC-hECNs (Chapter 3), and iPSC-MNs (Chapter 4). Similarly 
as with MNs harbouring the C9ORF72 (G4C2) repeat expansion mutation, the 
AMPAR Ca
2+
 -permeability of iPSC-OLs is of particular relevance with regard to 
the above concerning the possibility of aberrant Ca
2+




Thus, it seems plausible that iPSC-OLs harbouring the TDP-43 mutation may show 
altered apparent Ca
2+
 -permeability at the AMPAR, using previously detailed 
methods of non-stationary noise analysis (See Methods; Chapter 3; Chapter 4) and 
subunit selective pharmacology (See AMPAR characterisation, Chapter 3; Chapter 
4).    
 


























C                                   D 

















































113 113 113 113
  
Figure. 6.4. Non-stationary noise analysis of AMPAR-mediated currents in iPSC-
OPC/OLs in whole-cell voltage-clamp at -60 mV (-74 mV). A: Traces from a week 3, 
Control iPSC-OL showing a slowly-rising and decaying  whole-cell response to AMPA (10 
µM); the upper trace shows the AC current recording and the lower shows the DC current 
recording. B: As in ‘A’ but for week 3, T-3, iPSC-OL. C: Example current-variance plot from 
week 3, Control iPSC-OL (black) and T3 iPSC-MN (red). The relationship yields a linear 
relationship to which a straight line was fitted. The slope of the plot gave the estimated 
AMPAR single-channel current. D: Mean estimated AMPAR single-channel conductance of 
AMPARs expressed on iPSC-OPC/OLs; n= 5 - 10, N = 1-3. Numbers on X axis indicate 
number of weeks in culture. Blue coloured symbols and text denotes OPCs, whereas black 




6.3.3 Characterising the effect of TDP-43 mutation on AMPAR blockade 
by NASPM. 
 Next, in order to confirm the observed persistent expression of Ca
2+
 -
permeable AMPARs, experiments were conducted to assess the sensitivity of 
AMPAR-mediated currents to the channel blocker 1-naphthyl acetyl spermine 
(NASPM, 3 µM; Koike et al. 1997), which is selective for AMPARs that lack the 
Ca
2+
 -impermeable, RNA-edited GluA2 subunit (for traces, see Fig 5.5A, B).  
At 5 weeks, Control, and isogenic control line ∆C9-2 showed low NASPM block 
(Fig 5.5C; 16.6% ± 2.2%; n=7, N=2, and 23.2% ± 2.1%; n=8, N=3, respectively; 
p=0.54 vs Control, Student’s t-test), indicating predominant expression of  the RNA 
edited (Q → R) GluA2 subunit, whereas in sharp contrast, both C9ORF72 (G4C2) -
harbouring lines, C9-2 and C9-1 showed consistently higher levels of NASPM 
blockade (Fig 5.5C; 38.6% ± 6.9%; n=9, N=3; p=0.0009 vs Control, Student’s t-test, 
and 44.3% ± 4.1%; n=9, N=2; p=0.0004 vs Control, Student’s t-test, respectively), 
thus demonstrating that the C9ORF72 (G4C2) mutation disrupts normal AMPAR 
development, maintaining an AMPAR conductance highly suggestive of Ca
2+
 -
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Figure. 6.5. NASPM blockade of AMPAR-mediated currents in iPSC-OPC/OLs. A: 
Traces from a week 3, Control iPSC-OL showing application of AMPA (blue bar) and 
NASPM (NAS; orange bar). B: As in ‘A’ but for T-3 iPSC-OL. C: Graph showing NASPM 
block across all iPSC-OPC/OLs. N = 5 - 10, N = 1 - 3. Numbers on X axis indicate number 
of weeks in culture. Blue coloured symbols and text denotes OPCs, whereas black text and 












 Here, the whole-cell patch-clamp technique was applied in order to examine 
ion channel expression as a measure of developmental maturity in iPSC-OPC/OLs, 
and to identify possible phenotypes imparted by TDP-43 mutations M337V, and 
G298S on known ion-channel expression across development in ALS. Control iPSC-
OPC/OLs used in this thesis have been studied elsewhere with highly similar results. 
iPSC-OPCs typically showed strong outward membrane conductances which 
linearised upon iPSC-OPC differentiation to OLs. Other passive properties such as 
whole-cell capacitance, RMP, and input resistance were also highly similar to 
previous work on iPSC-OPC/OLs (Livesey et al. 2015). This suggests that iPSC-
OPC/OLs are a fundamentally viable model for the study of human development in 
vitro, and additionally demonstrates a reliable benchmark for results obtained from 
iPSC-OPC/OLs harbouring mutations associated with disease states which implicate 
OPCs and OLs.  
 
6.4.1 General development in iPSC-OPC/OLs harbouring TDP-43 
mutations 
 Initial experiments examining the development of passive membrane 
properties showed that OLs harbouring ALS mutations were smaller, perhaps 
indicating a general maturational defect. This has been previously observed in rodent 
models of ALS such as SOD1 (G93A), where reduced size and altered morphology 
of OLs is observed (Zawadzka et al. 2010), which here may be reflected in a 
reduced whole-cell capacitance. Additionally, previous reports in SOD1 mutant mice 
indicate an increased level of OPC proliferation, and differentiation into OLs which 




and whole-cell capacitance. Mutations in ALS were not associated with changes to 
other passive properties and thus show normal ion channel development in this 
regard.  
 
6.4.2 Ca2+ -permeable AMPAR expression in iPSC-OPC/OLs 
harbouring ALS mutations 
 Here, findings using subunit-selective pharmacology and non-stationary noise 
analysis show that multiple iPSC-OPC/OL lines harbouring TDP-43 mutations 
(G298S; M337V)  do indeed exhibit persistent expression of Ca
2+
 -permeable 
AMPARs, a finding that is associated with ALS pathology and well supported by a 
large body of previous work (Donnelly et al. 2013; Rothstein et al. 1995; see 
Cleveland and Rothstein. 2001), inviting further study of iPSC-OPC/OLs capacity to 
model this described “slow” excitotoxicity in ALS as mediated by AMPARs (see 
Selvaraj et al. 2016, manuscript in review). Notably, and again, the observed 
AMPAR conductance measurements for iPSC-OPC/OLs with ALS mutations 
(G298S; M337V) were in line with previously reported values in recombinant and 
animal systems which predominantly express Ca
2+
-permeable AMPARs, typical of 
early development (Talos et al. 2006a, 2006b; Orlandi et al. 2011, see Traynelis et 
al. 2012). Interestingly, previous findings from iPSC OPC/OLs harbouring an ALS-
related mutation in C9ORF72 show no effect on AMPAR Ca
2+
 -permeability 
(Livesey et al. 2015), while MNs harbouring this mutation do indeed show persistent 
expression of Ca
2+
 -permeable AMPARs, as shown in the previous chapter of this 
thesis (Chapter 5) which is corrected by CRISPR/Cas9. This chapter has 
demonstrated that certain ALS mutations do, in fact, show increased expression of 
Ca
2+
 -permeable AMPARs, a phenotype which is absent in isogenic controls, 
suggesting that different ALS mutations may impart tissue-specific pathologies 
which are convergent on the AMPAR. Thus, iPSC-OPCs and OLs are viable when 
studying the pathology of highly developmentally regulated systems such as 
AMPAR Ca
2+









6.4.3 CRISPR/Cas9 and isogenic controls 
The ability of iPSC-OLs to undergo CRISPR/Cas9 gene editing was employed 
to produce isogenic controls (∆T-3) also derived from a patient line (T-3), with the 
point mutation G298S corrected. This was shown to rescue the observed persistent 
Ca
2+
 -permeable AMPAR expression found in the presence of TDP-43 (G298S), 
showing clear effects of TDP-43 mutations on Ca2+ -permeable AMPAR 
expression. As mentioned elsewhere, the utility of gene-editing platforms to alter 
gene sequences to rescue a disease phenotype is confluent with the goals of gene 
therapy; while not presently developed at a large-scale, validation of genetically 
engineered iPSC-derived tissue in the modelling of disease represents the solid 
foundations of a promising emergent health technology. 
6.4.4 What of iPSC-OPC/OLs in general? 
 Despite controversy surrounding the developmental origin, and possible 
functional specification, of OPC/OLs, the derivation of functional OPCs and OLs 
sufficient to re-myelinate CNS structures has been achieved in culture (Livesey et al 
2015, and implantation studies. Such validation of implanted ES-derived OPCs 
causing improvements in cognitive behavioural scores, and white matter structure is 
extremely promising given that cell identity is well established with expressed 
markers and functional properties. This suggests that iPSC-OPC/OLs represent a 
nascent technology with potential in CNS repair, as well as being representative of 
OPC/OLs in vitro. The latter provides a foundation for disease modelling, and the 




flexible model of human development and disease in vitro as suggested by study of 






















































The introduction of this thesis outlined several key research themes. Firstly, the 
over-arching research question concerns the validity of ESC and iPSC-derived 
neuronal, and oligodendrocyte, material in its recapitulation of development as 
recognised in animal models. This was conducted with the aim of establishing 
profiles of ion channel development which describe  ESC/iPSC derived neurones, 
oligodendrocyte precursor cells, and oligodendrocytes in terms of particular hallmark 
profiles of receptor expression and their associated ion channel properties. 
Collectively, this thesis supports a broader effort in neurobiology and associated 
fields which is currently seeking rigorously defined and reproducible, viable tissues 
for a variety of purposes using well defined protocols. This process is arguably 
fundamental to progress in the development of more representative tissues, and 
possibly thus a reliable in vitro platform for the development of models which 
require that certain physiological processes particular to a disease state are replicated 
in vitro. Thus, initially this thesis supports ideas about “what one might expect” 
when interpreting results concerning the typical phenotypes observed elsewhere 
using similar stem-cell derived neuronal tissues.   
The idea that human stem-cell cultures could become a useful companion of 
both rodent, and other systems such as recombinant expression systems, among 
many methods of exploring natural development, as well as examining disease 
pathology, is not a new one. Neither is the idea of seeking more specialised, or 
representative tissues with defined cellular lineages and phenotypes, or the potential 
utility of these systems in drug discovery. The emergent technology of CRISPR/Cas9 
for gene editing is novel in general terms, and was implemented by other members of 
the lab to excise nuclear repeat expansions in cell lines derived from patients with 
mutations in disease-related genes.  This being said, these things are not entirely 
novel in as much as they are experimentally verified. While cellular reprogramming 
and editing requires relatively painstaking and precise work even in terms of 
typically applied efforts, the successes in establishing Cas9/CRISPR indeed suggest 
work as is found in this thesis, namely utilising the technologies described to survey 





From this, the thesis then seeks to explore mechanisms of disease pathology 
using these established cellular phenotypes in terms of altered ion channel 
expression. Experiments in this thesis were broadly directed towards replicating 
previous electrophysiological findings which have used identical protocols to 
generate neuronal, and oligodendrocyte cultures. This initial step provides a 
reliability and replicability test for the basis of later questions concerning aberrant 
function. While it may seem to be stating the obvious, this is re-iterated in order to 
illustrate the broader effort, to relate this work directly what has been done 
previously in terms of making representative in vitro systems from human 
embryonic, and induced pluripotent stem cells that relaiably recapitulate the 
physiology of human development, and from this, the potential for mechanistic 
insights into disease states imparted by known mutations. 
 
7.2 GABAARs and GlyRs expressed by hECNs. 
 Initial experiments were conducted to establish the isoform(s) of GABAAR 
expressed on hECNs. Developmental regulation of the subunit composition of 
GABAARs is a well noted hallmark of neuronal development, along with changes in 
transporter proteins which govern the relative intra- and extra- cellular 
concentrations of Cl
-
, the primary ion species by which GABAARs (and indeed, 
GlyRs) exert their effect. As has been previously noted in rodent, and human, 
systems, typical GABAAR subunit composition in pre-natal mammalian cortical 
neurones follows a typical expression pattern of α2/3β2/3γ (though occasionally also  
δ). Upon birth, this expression pattern in the cortex diversifies massively, 
incorporating a wide array of GABAAR subunits into the receptor complex, though 
still with a very large population of α1β2γ2, the often-described typical adult 
GABAAR isoform.  
This thesis employs electrophysiology and pharmacology to identify the 
predominantly expressed subunit composition of GABAARs on hECNs. Primarily, 
the data show that the GABAAR α subunits expressed by hECNs at 35 DIV in culture 




predominantly found in embryonic rodent cortical neurones (Laurie et al. 1992; 
Fritschy et al. 1994). Given that GABA-evoked currents were not noticeably affected 
by furosemide, hECN GABAARs thus seemingly lack functional expression of α4 
and α6 subunits. Additionally, the lower than perhaps expected action of zolpidem 
suggests the absence of the α1 subunit. This may be expected in that this subunit is 
associated with a more mature-like, post-natal neuronal phenotype (Laurie et al. 
1992; Fritschy et al. 1994).  RNA-seq (conducted by O. Dando) also demonstrates 
relatively low expression of the α1 subunit, and negligible expression of α4 and α6 
subunits compared to abundantly expressed α2 and α3 subunit transcripts. Also, 
functional incorporation of the α5 subunit into GABAARs, which is associated with 
very high agonist potency comparable to α1, was unlikely given the relatively low 
levels of mRNA detected and the low agonist potencies of GABA and muscimol. 
Indeed, low potency typically indicates GABAARs that contain either α2 or α3 
subunits (Mortensen et al. 2011; Karim et al. 2013). High expression of the 
GABAAR β3 subunit has been associated with immature cortical neurones (Laurie et 
al. 1992), although the β2 subunit is often also reported to be heavily expressed in 
cortical neurones (Fritschy et al. 1994).  
Potentiation of GABA-evoked currents by the use of low concentrations of 
etomidate and propofol, a lack of SCS inhibition and a high level of mRNA 
expression for the β3 subunit all collectively demonstrate that hECNs are likely to 
predominantly express β3 subunit-containing GABAARs, although a contribution of 
β2 to GABAAR assemblies cannot be solidly doubted. Generally, the vast majority of 
GABAARs in the CNS contain a γ2 subunit.  (Olsen & Sieghart, 2009). RNA-seq 
data supporting the pharmacology in this thesis suggests that hECNs predominantly 
express γ2 subunits, in agreement with pharmacological results that GABA-evoked 
currents were potentiated by the γ subunit-selective agent diazepam. On occasion, δ 
subunit-containing GABAARs are selectively expressed by certain cortical adult 
neuronal phenotypes, and are typically described as being associated with GABAAR-
mediated tonic inhibition (Olsen & Sieghart, 2009). Here, the data show that hECNs 
lack δ subunit-containing GABAARs, as gaboxadol elicited small current ampitudes 




inhibit GABA-evoked currents is also in agreement with the absence of GABAARs 
composed of only α/β subunits. 
This thesis thus demonstrates that RNA-seq analysis and GABAAR 
pharmacology converge to indicate a predominant GABAAR composition of 
α2/3β3γ2. Such isoforms are observed in recombinant expression systems to have 
low agonist potency relative to other isoforms and again this thesis argues that 
GABAAR expressed upon hECNs exhibit relatively low agonist potency (Karim et 
al. 2013). This GABAAR isoform is seemingly the most likely to be widely 
expressed in the immature rodent cortex (Laurie et al. 1992; Olsen & Sieghart, 
2009).  
Nevertheless, our data cannot exclude the possibility of other GABAAR 
isoforms expressed at low levels. Additionally,  Brainspan (Atlas of the Developing 
Human Brain http://www.brainspan.org/rnaseq/search) indicates that the levels of 
mRNA observed in the RNA-seq analysis of hECNs (Conducted by O. Dando) 
appear similar to those seen in human cortical neurones between 12 and 21 weeks 
post-conception, i.e mid-to-late embryonic human development. As a result, it can be 
concluded that hECNs represent a viable platform to investigate the properties of 
human GABAAR pharmacology and GABAARs in maturing cortical neurones (see 
Wang & Kriegstein, 2009).  
Strong, yet transient GlyR expression is a typical feature of early neocortical 
development (see Avila et al. 2013). Indeed, hECNs cultured for 28–42 DIV give 
robust responses to glycine, which are blocked by GlyR antagonists such as 
picrotoxin and strychnine. Glycine concentration–response experiments give lower 
potency values than previously reported in other systems (Pribilla et al. 1992). 
Interestingly, glycine potency was observed to be higher than potencies typically 
observed in native cortical tissues (Okabe et al. 2004; Kilb et al. 2008). The reasons 
for these differences are essentially unknown, but may be due to differences in bath 
aCSF flow dynamics, where slower fluid exchange times are more likely to give 
shallower concentration–response curve observations. GlyRs expressed by rodent 
forebrain neurones have been described as progressing in development from an 




(Lynch, 2009). Pharmacological tools to conclusively identify the exact 
stoichiometry in heteromers are lacking (see Han et al. 2004); however, RNA-seq 
analysis in this thesis shows α2 subunit mRNA is heavily expressed. Similarly to 
GABAAR subunit expression, levels of mRNA expression for GlyRs in our RNA-seq 
analysis are consistent with a developmental age in humans of between 
approximately 12–21 weeks post-conception (Atlas of the Developing Human Brain 
http://www.brainspan.org/rnaseq/search). Finally, it is known that there is a transient 
expression of heteromeric α2/β GlyRs in rodent Cajal–Retzius cells early in post-
natal development (Okabe et al. 2004). This class of neurone is considered to form a 
significant population in hECN cultures (Bilican et al. 2014) and in this respect 
hECNs may well provide a useful human model of GlyR development. 
As activating both GlyRs and GABAARs typically gives anionic (typically Cl
-
 - 
based) currents, and that previous work in hECNs has shown intracellular [Cl
-
] to be 
approximate of human development as compared to other systems (Livesey et al. 
2014), these findings on ion channel and Cl
-
 -transporter expression form a 
functionally representative, and replicable model of GABAAR and GlyR expression 
and function along with their underlying primary physiological processes.  
Given previous exploration of other ion channels (e.g NMDAR, AMPAR 
development; Bilican et al 2014, Livesey et al 2014) in hECNs, this thesis 
contributes to, and is congruent with, an in vitro stem-cell derived model of human 
development which has been shown to be broadly representative of embryonic, and 
at most very early post-natal periods in human development. Given the arguable need 
for some kind of standardisation of comparability between protocols and systems, 
this work contributes to an ordered and rigorous view of stem cell protocol 
development, which suggests that the process can be scaled for a range of potential 
applications such as drug screening, or safety testing for compounds such as 
anaesthetics. Such a platform could be used to investigate the basic mechanisms of 
anaesthesia at the receptor level, and also may be useful for examining the safety of 
such compounds on immature human neurones found in vivo, i.e in a real child’s 
head. This is desirable, as anaesthetics and GABAAR-effective compounds are 




primary reason why drugs such as ketamine are used to anaesthatise neonatal 
humans. 
Human embryonic cortical neurones displayed highly similar properties to 
those reported elsewhere, and represent a stable model human GABAAR, and GlyR, 
and embryonic, and immediately postnatal periods, respectively. Interestingly, the 
DISC1 mutation studied did not show any suspected disease phenotypes in ion 
channel development, suggesting that the observed network pathologies in 
psychiatric disorders, particularly in terms of hypotheses describing balances 
between excitation and inhibition are not effected through a fundamental change in  
basic neuronal properties or basal ion channel expression/composition. 
In rodents, transient functional GlyR expression is a key feature of early 
neocortical development (Flint et al. 1998; Avila et al. 2013a). Indeed, hECNS 
maintained for 28–42 DIV exhibited strong responses to glycine that were blocked 
by the GlyR antagonist strychnine. Glycine concentration–response experiments 
indicated glycine potency was lower than previously reported recombinant values 
(Pribilla et al. 1992) but is generally higher than glycine potencies observed in native 
cortical preparations (Flint et al. 1998; Okabe et al. 2004; Kilb et al. 2008; but see 
Avila et al. 2013b). The reasons for these differences are unknown, but may be 
related to systematic differences in the solution exchange times of these studies, 
where slower exchange times are more likely to give shallower observed 
concentration–response curves. In this regard, the ability to examine deactivation 
kinetics of GlyRs expressed by hECNs in isolated patches using fast agonist 
application may yield further details of GlyR identity (Mangin et al. 2003; Pitt et al. 
2008; Krashia et al. 2011; Marabelli et al. 2013). GlyRs expressed by rodent 
forebrain neurones have been described as developing from an embryonic 
homomeric to postnatal heteromeric (β subunit-containing) composition (Lynch, 
2009). To investigate the functional GlyR composition we used the antagonist 
picrotoxin, which inhibits homomeric over heteromeric GlyRs (Lynch, 2009). Given 
the observed low sensitivity of GlyRs to picrotoxin, our results suggest that the 
principal GlyR identity of hECNs is likely to a heteromeric α/β assembly. 




the heteromer are lacking (but see Han et al. 2004); however, RNA seq analysis 
indicates that α2 subunit mRNA is the most abundantly expressed. As is the case for 
GABAAR subunit expression, levels of mRNA expression for GlyRs in our RNA-seq 
analysis are consistent with a development age of around 12–21 weeks post 
conception (Atlas of the Developing Human Brain 
http://www.brainspan.org/rnaseq/search). Finally, it is of interest to note that there is 
transient expression of heteromeric α2/β GlyRs by rodent Cajal–Retzius cells in early 
postnatal development (Okabe et al. 2004). This class of neurone is considered to 
form a significant population in our hECN cultures (Bilican et al. 2014) and in this 
respect hECNs may model this aspect of GlyR function in early postnatal human 
development 
Native cortical maturation is associated with a change in expression from 
GluA2(R)-lacking to GluA2(R)-containing AMPARs. Importantly, the presence of 
one or more GluA2(R) subunit in an AMPAR complex results in reduced single-
channel conductance, reduced sensitivity to channel-blocking polyamines and, 
crucially, reducedCa2+ permeability (Traynelis et al. 2010). Assessment ofthe 
functional AMPAR composition in hPSCC neuronesusing non-stationary fluctuation 
analysis to estimatemeanAMPAR single-channel conductance and their sensitivityto 
a GluA2(R)-lacking AMPAR channel blocker indicatesan activity-independent and 
native-like maturationfromGluA2(R)-lacking toGluA2(R)-
containingAMPARswithin 5 weeks of in vitro differentiation (Livesey et al.2014). 
GluA2 transcript expression also increases withtime in culture (Chander &Weick, 
2014; Stein et al. 2014;van de Leemput et al. 2014). Thus AMPAR expressionin 
hPSCC neurones appears to display properties that areobserved in native mature 
neuronal populations (Isaac et al. 2007). Both NMDARs and AMPARs are 
expectedto undergo maturational changes in composition in theearly postnatal weeks 
of cortical development in rodents(Traynelis et al. 2010) and in this regard the 
ontogeneticdevelopment of AMPARs in hPSCC neurones is muchmore rapid than 
expected. Interestingly, the GluA2 subunithas been shown to be rapidly edited and 
functionallyup-regulated 4 weeks after the in vitro differentiationof neurones from 




longerin vivo developmental time scales (Talos et al. 2006).These data suggest the 
rapid maturation of theAMPAR complex is a potential product of the in 
vitroenvironment. Nonetheless, this feature provides anopportunity to examine 
numerous scenarios in which abnormal regulation of theGluA2 subunit is prevalent 
in adult human disease (Wright & Vissel,2012). The breadth of possible GABAAR 
composition results in considerable functional and pharmacological diversity across 
brain regions and even cellular locations (Olsen & Sieghart, 2009).  
 
7.3 Surveying ion channels and neurodevelopment in hECNs with the 
DISC1 (1;11)(q42;q14.3) mutation.  
Human embryonic cortical neurones displayed highly similar properties to 
those reported elsewhere, and represent a stable model human GABAAR, and GlyR, 
and embryonic, and immediately postnatal periods, respectively. Interestingly, the 
DISC1 mutation studied did not show any suspected disease phenotypes in ion 
channel development, suggesting that the observed network pathologies in 
psychiatric disorders, particularly in terms of hypotheses describing balances 
between excitation and inhibition are not effected through a fundamental change in  
basic neuronal properties or basal ion channel expression/composition. 
Initially the intrinsic passive and firing properties of Case and Control hECNs were 
investigated across multiple time points in order to detect any potential 
developmental difference in excitability. The data in broad agreement with a 
developing neuronal phenotype (increasing whole-cell capacitance, increase in 
ability to fire and increase in amplitude and speed of action potentials) across all 
lines examined. The fact that no difference was found is consistent with a study 
where hippocampal CA1 neurones from a transgenic mouse expressing the 
equivalent truncated DISC1 protein also did not show any difference in the passive 
or intrinsic properties (Randall et al. 2014). Importantly, the properties of hECNs 
examined even at 35DIV are consistent with an immature neuronal profile; 
hyperpolarized RMP, high input resistance and low whole-cell capacitance, and are 
consistent with in vitro pluripotent stem cell derived neurones in general (see Kim et 
al. 2011; Pak et al. 2015; Scheglovitov et al. 2013). It maybe therefore plausible that 




phenotypes to emerge. Moreover, hECN culture composition may not be sufficiently 
representative to the possibility that specific neurones of the cortex may exhibit 
subtle differences in intrinsic excitability. For example, hECN cultures only contain 
nominal proportions of interneurones for which there is an important role in 
schizophrenia (Lewis et al. 2005). 
The properties of major neurotransmitter receptors, AMPARs, GABAARs and 
NMDARs, were then investigated. The expression of GABAARs upon Case and 
Control hECNs was found to be statistically equivalent indicating that mutant DISC1 
does not influence GABAAR expression in hECNs. This is in agreement with a 
recent study examining mutant DISC1 protein in rodent cortical neurones which 
expressed equivalent levels of GABAARs versus controls despite knock down and 
over expression of the full DISC1 protein having opposing effects upon GABAAR 
expression (Wei et al. 2015). The previous results chapter determined that the 
composition of GABAARs was representative of the major immature GABAAR 
expressed in the immature cortex. Selected pharmacological analyses demonstrated 
that it is unlikely that GABAAR composition in Case and Control hECNs was 
different. Similarly, the NMDAR receptor expression in Case hECNs was not 
different from Control hECNs and the composition was pharmacologically 
determined using ifenprodil to be representative of a predominantly immature 
NMDAR cortical profile, i.e., GluN1/GluN2B-containing. Recently, Wen et al. 
(2014) describe a small increase in the GluN2B mRNA level, but not GluN1 protein 
levels, in hECNs derived from mutant DISC1 patients. Data presented here suggests 
that this disparity does not manifest at the functional level.  
 The finding that GABAAR and NMDAR compositions are consistent with 
immature neuronal profiles clearly restricts conclusions to the subunits expressed. 
Mutant DISC1 patients have a late juvenile/young adult symptomatic onset 
(Thomson et al. 2013) and maturation of cortical GABAAR and NMDAR 
composition is expected to have taken place. For example, the findings that mutant 
DISC1 affects GluN2A NMDAR subunit expression (Wei et al. 2013) and 
potentially reduces functional NMDAR expression to slow NMDAR maturation in 




system. This highlights the value of thorough characterisation like that performed in 
this study and that it is absolutely required if the field is to interpret findings from 
stem cell-derived neurone technology for disease-modelling studies.  
 AMPAR expression was observed to be equivalent between Case and Control 
hECNs at 35 DIV indicating that mutant DISC1 has no apparent effect. AMPAR 
composition was then determined using non-stationary fluctuation analysis and the 
sensitivity of AMPAR-mediated currents to NASPM. This data was directly 
equivalent to that of rodent cortical neurones that had undergone a period of post 
natal development in which edited GluA2 is upregulated (Brill and Hugenuard. 
2008) and also recombinantly expressed AMPARs containing edited GluA2 subunts. 
(Swanson et al. 1997). Both strategies clearly converged on the predominant 
AMPAR composition at 35 DIV as being edited GluA2-containing for both Case and 
Control hECNs. Contrary to the GABAAR and NMDAR, AMPAR expressed on 
hECNs have a composition that is expected of neurone that has undergone a period 
of maturation (Orlandi et al. 2011; Talos et al. 2006). A rapid upregulation of GluA2 
AMPAR subunit transcripts has also been reported in other similar systems (Stein et 
al. 2014; van de Leemput et al. 2014). Wen et al. (2014) recently reported an increase 
in the mRNA level of GluA2 in hECNs generated from mutant DISC1 patient-
derived iPSCs over control and isogenic, gene-corrected mutant DISC1 hECNs, 
though data obtained in this study indicates this transcriptional difference may not 
translate to a functional difference. It appears that the functional upregulation of the 
GluA2 subunit is much faster than expected from what is expected in vivo (Orlandi 
et al. 2011; Talos et al. 2006). Of note, Whitney et al. (2008) report that the GluA2 is 
rapidly edited and functionally upregulated within 4 weeks in in vitro neurones 











7.4 Observing a possible mechanism of AMPAR pathology in MNs and 
OLs  harbouring multiple  ALS-related mutations. 
The data presented in this thesis, alongside that which has been presented from 
elsewhere, collectively demonstrate that advances in protocols which aim to generate 
more homogenous, defined populations of neuronal and ologodendroglial celll 
lineages have led to a reliable, scaleable in vitro platform suitable for the modelling 
of basic, fundamental physiological processes in normal human development, and 
disease, with the limitations of such advances detailed previously. This is to say that 
thus far, the capacity to generate tissue “on-demand” which will have a defined 
identity (here, embryonic cortical neurones, OPCs, and oligodendrocytes) and a set 
of physiological properties not only representative of a moderately specific 
developmental period – that of reaching late pre-natal maturity after 35 DIV in 
culture in the case of hECNs, but also capable of demonstrating subtleties predicted 
by animal models, and indeed human findings in key disease theories of conditions 
such as ALS.  
This thesis shows maturation-dependent changes in membrane conductances, 
occurring in human oligodendrocytes as they differentiate from OPCs which 
recapitulate many of the changes in ion channel expression previously observed in 
rodent-based systems. OPCs displayed outwardly rectifying membrane currents and 
differentiation to oligodendrocytes results in a linearization of the membrane 
currents. These properties have been widely described in rodent oligodendroglial 
counterparts, in vitro mouse PSC-derived OPCs and integrated mouse PSC-derived 
material. These data indicate that comparable shifts in ion channel expression are 
occurring throughout human oligodendrogenesis in vitro.  Such data are in 
accordance with previously observed developmental shifts in IA and IK channel 
expression in rodent oligodendroglial cells and also prominent expression of these 
membrane conductances in in vitro mouse PSC-derived OPCs. Oligodendrocytes did 
not show any spiking activity, in agreement with reports from rodent 
oligodendroglial cells. It is important to highlight that numerous reports describe 
native OPCs being heterogeneous in their ability to display either spiking or non-




status of the OPC rather than developmentally independent subclasses of OPC. The 
data in this thesis are consistent with numerous studies reporting an increase in 
functional expression of the GluA2(R) subunit in AMPARs expressed in rodent 
oligodendrocytes upon differentiation and maturation from OPCs in the case of 
control tissues, but not in one ALS model.  
This developmental variability in AMPAR composition (and Ca
2+
permeability) 
is disease-relevant and confers vulnerability of immature oligodendroglial cells to 
excitotoxic conditions. Taken together these findings show species conservation of 
the defining physiological properties of oligodendrocyte lineage cells, and crucially 
establish a platform to investigate possible disease-related changes.  The precise 
function of the C9ORF72 protein itself remains largely unknown although 
accumulating evidence implicates a gain of function mediated toxicity in ALS. 
In exploring the “slow excitotoxicity model” of ALS, the suggested mechanism 
of which being suggested is that aberrant Ca
2+
 - entry into cells is a cause of motor 
neurone degradation seen in ALS (via an increase in the relative expression of 
calcium-permeable CP-AMPARs which may pervade into adulthood). This thesis 
has demonstrated that in lower motor neurone tissue, the typical expression pattern of 
AMPAR expression, which terminates in a “mature-like” predominant expression of 
Ca2+ impermeable CI-AMPARs, is disrupted in cells harbouring the C9ORF72 
(G4C2) NRE, which, unlike their “control” counterparts without said mutation, 
results in a relative increase in the expression of AMPARs permeable to calcium 
ions,  CP-AMPARs.  
This suspected mechanism of ALS progression, ‘slow’ excitotoxicity, as 
mediated by AMPARs was also observed in OPC/OLs harbouring known mutations 
strongly associated with ALS, though in the case of OPC/OLs in this thesis, it is 
TDP-43 mutation which is associated with increased relative CP-AMPAR 
expression. Interestingly, it has been shown that OPC/OLs harbouring the C9ORF72 
mutation are not affected by this pervasive increase in relative CP-AMPAR 
expression (Livesey et al 2016).  
Critically, the phenotype of aberrant Ca
2+ 
-permeable AMPARs was replicated 




convergent on a phenotype across different tissue types, providing potentially  
valuable insights for further research. Motor neurone, and oligodendrocyte 
populations used in this thesis broadly recapitulated pathologies observed in animal 
models of heritable ALS imparted by mutations in novel candidate genes, and more 
classically studied mutations. Ultimately, this thesis argues that ESC and iPSC-
derived neuronal cultures represent a stable and scaleable system for the modelling 
of disease, and also as potential drug screening and development platforms. Material 
produced in vitro often faithfully recapitulates ion channel development as described 
in rodent models and elsewhere, and is highly amenable to the study of ion-channel 
related diseases. 
Synaptic events are often described in two general forms; phasic and tonic, and 
are both essential to the normal function of the CNS. Synaptic connectivity between 
cortical neurones is key to cortical network development and function (Spitzer,2006). 
It is therefore critical to the development of in vitro hPSCC-derived neurones to 
recapitulate native synaptic properties. The co-localization of pre- and post-synaptic 
membrane-associated scaffold proteins such as synaptophysin and PSD-95, however, 
it is largely accepted that many standard in vitro hPSC protocols do not generate 
cultures that exhibit robust synaptic activity (Bardy et al. 2015). 
Many groups co-culture neurones with primary rodent astrocytes, which also 
promote synapse activity (Johnson et al. 2007; Kim et al. 2011;Shcheglovitov et al. 
2013; Wen et al. 2014; Park et al .2015). Analysis of the field-evoked postsynaptic 
events in co-cultured neurones has shown that glutamate activates both fast AMPAR-
mediated, and also slower GluN1/GluN2B-like NMDAR-mediated events in control 
neurones (Shcheglovitov et al. 2013). Pre-synaptic neurotransmitter-release related 
pathophysiology has been modelled in neurones derived from schizophrenia (DISC1; 
Wen et al. 2014) and autism (NRXN1;Pak et al. 2015) patients.  
Also, inhibitory GABA-ergic interneurones are essential for maintaining the 
balanced activity of cortical neural circuits. GABA-ergic synaptic activity has been 
detected within hPSCC cultures in the form of spontaneous postsynaptic currents 
(Johnsonet al. 2007; Wu et al. 2007; Shcheglovitov et al. 2013).However, a recent 




that resembles that of early-stage cortical development and which occurs in cultures 
that contain a low percentageof interneurones and is insensitive to pharmacological 
blockade of GABAARs (Kirwan et al. 2015). A key studyin the near future will 
therefore be the culture of defined mixtures of hPSCC neurones and defined 
populations of GABA-ergic interneurones. Notably, it has been demonstrated human 
pluripotent stem-cell-derived neurones can be integrated into neural networks in 
mice, (Weick et al.2011).  Espuny-Camucho et al. (2013) successfully demonstrated 
differentiation and functional integration of stem-cell derived neurones into rodent 
cortex. Several months after transplantation into the developing cortex, neurones 
exhibited intrinsic membrane properties consistent with adult mature cortical 
neurones, in contrast to the more immature properties of in vitro differentiated 
pluripotent stem cell-derived neurones. While there is still much to learn in order to 
achieve fully developed functional integration, this thesis suggests that stem-cell 
derived tissues have the inherent potential to integrate into networks. In conclusion, a 
major challenge is to generate neuronal populations that exhibit maturation profiles 
thatmore closely reflect those seen in vivo. Co-culture with astrocytes and mixed 
neuronal populations, together with the maintenance of cells in media that promotes 
increased synaptic activity, indicates that such strategies are likely required to 
















7.5 Opportunities for further research 
 
7.5.1 Developing networks in vitro 
Here, the development of in vitro techniques which produce cells with a 
definitive neuronal or oligodendroglial identity is a double-edged sword. As the 
composition of hECNs is typically above 90% for cortical excitatory neurones, and 
that normal development of the nervous system is conducted by a vast network of 
interconnected molecular mechanisms which rely on interactions between the 
elements in order to produce the organism in vivo, it could be argued that the purity 
of the cultures allows the study of very specific neuronal phenotypes, though reaches 
its limit when examining whole networks as found in vivo. This presents a barrier in 
studying phenomena important for mechanisms thought to underlie learning and 
memory, as typically these phenomena are much easier to observe when anatomical 
organisation and stimulus pathways are known (e.g LTP in linear pathways in the 
hippocampus) in order to elicit a response that can be measured and altered by 
electrical or chemical stimulation. In the case of hECNs, these anatomically 
organised pathways are not a feature of the culture, nor ar predictable inputs and 
outputs between neurones. Additionally, there seems to be little basal synaptic 
activity in hECNs to begin with. Thus, before networks can be studied, they must be 
formed. One could study synaptic potentiation, and thus potentially the basic 
mechanisms of learning and memory in hECNs without this problem. 
One immediate answer would be to use cultures of tissues which combine 
these elements to explore the possibility of the development of functional synapses. 
The initial problem of being unable, as yet, to produce truly functional, 
representative networks in vitro (a humongous task that no doubt will take much 
work), could be approached from the perspective of attempting to produce not only 
pure excitatory contrical neurones in culture, but to attempt to extend their lifespan, 









This initial suggestion is complemented by a divergent approach which is less 
concerned with the purity of cultures, and more focused on combining tissue types. 
While this type of experimentation typically involves a high failure rate, the 
possibility of producing a co-culture with excitatory and inhibitory cortical 
neurones, oligodendrocytes, and other glial cell types epitomises this idea in terms of 
combining specifically derived tissues, and grafting them in co-culture at various 
stages of neuronal development. Thus, by composition, events associated with the 
early stages of development of the nervous system such as early ripples of excitation 
spreading through the cortex, or the change in expression of chloride co-transporter 
proteins could be studied, along with the potential for examining network pathology 
within a more nuanced in vitro culture model that may accommodate such 
phenotypes as found in the study of complex neurobiological disorders. One 
example would be the study of DISC1, in this thesis the (1;11)(q42;q14.3). It is still 
highly possible that the properties which are sought of the disease model, such as 
some form of chloride transporter dysfunction, or alteration in excitability and ion 
channel function, are not produced until some developmental criteria is met that 
cannot be replicated in a pure culture in 35 DIV. From this, it seems immediately 
apparent that the first suggestion would be to attempt to introduce complex 
compositions from the starting point of purity of culture. 
This stand in a similar perspective to previous work using human stem cell 
derived neuronal cultures which utilise mixed tissue types using more general 
protocols to generate neurones and glial cells of varying lineages. These cultures are 
then examined in light of disease-associated mutations such as those found in DISC1 
One potential pitfall of examining neuronal function in this way is that one cannot be 
sure of the exact nature of any cellular type within that culture – though it is an 
exceptional finding in itself that there may be phenotypes which indeed could be 
explored by more developed mixed culture populations. From this, an addition of the 
more specific approach, to the approach found in previous work of human stem-cell 
derived cultured neurones seems appropriate. Grafting populations of cells while 
maintaining their cellular identity along with integrating various cell types in this 




iPSC derived neuronal material is expensive and fragile. Conducting this type of 
experimentation then would likely involve taking “lifted” populations of cells and 
grafting them manually at certain times in development e.g by grafting 21 DIV 
hECNs onto a comparably mature layer of astrocytes. One could combine these in 
any fashion, though this in itself could be guided by attempting to “line up” findings 
with developmental periods, and attempting to transplant tissues accordingly to 
prepare for certain events such as the change in intracellular Cl
-
 concentration in 
neurodevelopment, or AMPAR/NMDAR subunit switching. Interneurones could 
also be amenable to this line of enquiry, in that DISC1 has been found to localise to 
inhibitory synapses and could be used to explore excitation-inhibition models, and 
cell-cycle exit theories in neuropsychiatric conditions associated with genetic 
mutations found to affect neuronal populations in some way in other models. 
Another suggestion for the progression of the technology is to explore the 
potential of applying developmentally selected “cues” in the form of hormones 
which are active on neuronal tissues. As development is associated with changes in 
the levels of hormones at key developmental times, e.g birth, and that the pre- to 
post- natal period marks many changes in ion channel composition and function, it 
may be possible to approach the problem from a more artificial framework. This 
approach tackles the problem by attempting to replace some aspect of unsupplied 
external cue that is not found in more pure culture systems. In this way, it can be 
considered an extension of the development of protocol, with the caveat that it seeks 
to “trigger” some aspect of development which may yield the properties that are 
required for representative in vitro networks. This would take the form of 
introducing hormones that replace physiological events in line with the findings of 
reproductive biology. While currently a flight of fancy, this progresses to a very 
primitive model of an artificial womb in some senses. While this may initially seem 
grandiose, it is not intended to suggest that these experiments would engineer a 
revolution in reproductive technology, but merely that the attempt to replace external 
cues typically supplied by the organism at large to neurones in vivo in a culture 
model is akin to attempting to replicate, in some fashion, the operations of 
reproductive biology. As such, this indicates the potential for this type of 




neurobiological development, but also suggests a wider context that disease models 
could be studied within, again by attempting to replicate the influence of “the rest of 
the human” around neurones in stem cell derived culture.  
 
 
7.5.2 Further work in disease modelling with stem cells 
One key finding of this thesis, when taken in light of other work, is that there 
appears to be a neuronal phenotype of increased Calcium permeability, mediated by 
AMPARs, in motor neurones derived from iPSCs which harbour ALS mutations in 
C9orf72. This recapitulates aspects of the disease found elsewhere and in other 
models – moreover the AMPAR pathology is not found when the nuclear repeat 
expansion in C9orf72 is excised by CRISPR/Cas9. Interestingly, oligodendroctyes 
which express nuclear repeat expansions in C9orf72 do not show this phenotype, 
indicating the effect is tissue specific. 
Of great interest, however, is the finding that mutations in other ALS-associated 
genes such as TARDBP, which are associated with disease markers in ALS and 
pathophysiology associated with expression of the misfolded protein product TDP-
43, do not show this aberrant increase in AMPAR-mediated Calcium permeability in 
MNs. This demonstrates something perhaps of interest when examined in light of 
the finding that oligodendroglial lineages, themselves also suspected in ALS 
progression, aberrantly express calcium permeable AMPARs when derived from 
patients with mutations which are associated with TDP-43 production. Thus, 
mutations in C9ofr72 seem to predominantly affect motor neurone AMPAR 
expression, while mutations which are associated with TDP-43 pathophysiology 
appear to predominantly affect oligodendroglial AMPAR expression. Indeed, both 




The next step is to directly test the prospect of calcium-mediated 
excitotoxicity, perhaps by linking excitotoxicity to mRNA expression which 
describes proteins associated with AMPAR editing and trafficking, along with 
assaying cell death or otherwise noticeable ALS-related neuropathology in cultured 




which control AMPAR trafficking and disease are suggested as a core target for 
further research, perhaps by examining various protein interactions with AMPARs, 
as the commonalities between different mutations in different tissues suggest the 
potential for an up-stream intervention between direct receptor modulation, and gene 
editing which is nascent and not yet capable of intervening directly –though in future 
indeed it may in some form. Here, enzymes which control the RNA editing of 
GluA2, such as ADAR2, represent a possible link between observed 
neurophysiological phenotypes, the potential for observed excitotoxic cell death in 
vitro, and the observed mutations which link these processes to disease states in 
vivo. Indeed, other mutations have been studied in ALS in this manner with similar 
implications. The ALS2 gene, which is involved in early-onset ALS and affects 
AMPAR trafficking by interfering with GRIP1, a glutamate receptor interacting 
protein necessary for AMPAR trafficking, shows alterations in AMPAR expression 
in line with observed findings in this thesis. It may also then be of interest to 
examine co-culture of tissues to explore how one particular mutation exerts an effect 
on the whole, e.g to co-culture oligodendrogilial and neuronal cells derived from cell 
lines which harbour certain mutations associated with ALS.   
 
 
7.6 Concluding statement 
This thesis has aimed to demonstrate the viability of stem-cell derived 
neuronal, and oligodendroglial cells, in generating a stable, scaleable, reliable 
platform to examine human physiology in normal development and disease via ion 
channel dysfunction as a potential mechanism. With the caveats supplied 
concerning limited capacity for network-focused study, and thus potentially the 
study of some disorders and mutations, stem-cell derived tissues of this nature do 
indeed replicate key, well defined hallmarks of normal development, and in some 
specific cases support models of disease states and their attendant neuropathological 
observations. Interestingly in the case of ALS, this thesis demonstrates the practical 
utility of stem-cell derived neuronal tissue and genetic modification techniques in 
studying disease pathology at the receptor level by elucidating potentially 
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